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8 | Chapter 1
In 2004, a study on the relationship between gastrointestinal symptoms and the Helicobacter 
bacterium in alcohol dependent patients, reported as a secondary finding that 54% of the 
patients were alexithymic (van Rossum, Laheij, de Doelder, de Jong & Jansen, 2004). Because 
these patients were hospitalized in the detoxification units of addiction centers affiliated with 
the Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA), the study constituted the 
start of a research project with the aims of replicating these findings and investigating the clinical 
consequences of this high prevalence of alexithymia.
This chapter begins with a definition of substance use disorders (SUDs). Thereafter, I will 
successively discuss epidemiological issues, the risks factors for SUDs, affect regulation and SUDs, 
and alexithymia and SUDs. The chapter ends with an overview of the aims and the structure of 
this thesis.
Definition and characteristics o f SUD and addiction
In the DSM-IV (Diagnostic and StatisticaI Manual of Mental Disorders), substance use disorders 
were formally classified into substance abuse or substance dependence. In the DSM-5, a 
combination of the two conditions has been proposed as a single condition, called substance-use 
disorder (SUD). SUD is characterized by a pattern of continued pathological use of a psycho- 
active substance, which results in repeated adverse social consequences related to the use of this 
substance, such as failure to meet work, family, or school obligations; interpersonal conflicts; and 
legal problems. Substance abuse is particularly related to the social consequences of psychoactive 
substance use. Substance dependence is a more severe form of SUD and is, in addition to social 
consequences, primarily defined in terms of physiological (tolerance and withdrawal symptoms) 
and behavioral symptoms.
Substance abuse and particular substance dependence are often classified under the term 
"addiction", which has, over the past two decades, been increasingly regarded as a brain disease 
(Leshner, 1997). However, addiction is not a disorder or classification according to the DSM- 
IV classification, and there has been debate regarding whether the concept should be limited 
to the use of psycho-active substances or broadened to include behavioral addictions, such as 
(pathological) gambling, sex and food intake, as well as some eating disorders. Addiction is 
characterized by a loss of control over substance intake (or behavior) and compulsive behavior 
in seeking and taking substances (or performing the pathological behavior), even in the face of 
dire consequences.
The recently introduced DSM-5 criteria recognize that mental and behavioral aspects of SUDs 
are more specific to SUDs than the physical domains of tolerance and withdrawal, which are not 
unique to addiction. However, because all the studies of this thesis have been conducted with the 
DSM IV as classification model, I will not elaborate on the changes, that have been established 
by the introduction of DSM-5.
The risk of developing SUDs is determined by the individua! genetic constitution, including 
gene-environment interaction (main genetic and Gene x Environment factors), with an estimated 
contribution of 40% - 60% and by shared (familial factors) and non-shared environment (such 
as access to substances and stress) (Kendler, Myers & Prescott, 2007; Volkow & Li, 2005). It is 
believed that for many SUD patients, the vulnerability of their disorder persists for a lifetime, with 
recurring periods of craving or relapse even after long intervals of abstinence. This substantial 
proportion of SUD patients suffers from a chronic disease course (McLellan, Lewis, O'Brien & 
Kleber, 2000). These insights motivated the American Society of Addiction Medicine (ASAM) to 
release a new definition of addiction in 2010: "Addiction is a primary, chronic disease of brain 
reward, motivation, memory and related circuitry". This definition emphasizes that addiction is 
a chronic brain disorder and not simply a behavioral problem involving alcohol, drugs, gambling 
or sex to excess (American Society of Addiction Medicine, 2010). However, in this document, 
the ASAM mentions five features of addiction that are not intended to be used as "diagnostic 
criteria": 1) inability to abstain consistently; 2) impairment of behavioral control; 3) craving or 
increased "hunger" for drugs or rewarding experiences; 4) diminished recognition of significant 
problems with one's behaviors and interpersonal relationships; and 5) dysfunctional emotional 
responses. However, each feature is not equally prominent in every case of addiction. The 
diagnosis of addiction requires a comprehensive biological, psychological, and social assessment 
by a trained and certified professional (American Society of Addiction Medicine, 2010).
Epidemiology o f SUDs: prevalence and costs
In the United States (U.S.), approximately 12.5% of men and 5% of women meet the criteria for 
an alcohol use disorder (AUD, abuse or dependence) during the previous year, and an estimated 
42% of men and 20% of women will experience AUD during their lifetimes (Hasin, Stinson, 
Ogburn, & Grant, 2007). In 2010, 22.6 million Americans (8.9%) 12 years old or older were 
current (past month) illicit drug users, and 22.1 million individuals 12 years old or older were 
classified as having SUD in the past year (8.7%). Of these individuals, 2.9 million were classified 
as having dependence or abuse of both alcohol and illicit drugs, 4.2 million had dependence 
or abuse of illicit drugs but not alcohol, and 15.0 million had dependence or abuse of alcohol 
but not illicit drugs (Substance Abuse and Mental Health Services Administration, 2011) In the 
Netherlands, the percentages are slightly lower, with 19.1 % experiencing a SUD in their lifetime 
(male: 27.7%; female: 10.3%) and 5.6% (male: 7.6%; female: 3.6%) over the past year (de 
Graaf, ten Have & van Dorsselaer, 2010).
SUDs, including both AUD and nicotine use disorders, are a cause of extreme human 
suffering, with societal costs estimated at more than $600 billion dollars annually in the United 
States, consisting of health- and crime-related costs and losses in productivity, not to mention 
incalculable personal and social devastation (Harwood, 2000; Office of National Drug Policy, 
2004). Alcohol-related costs exceed 1 % of the gross national product in high-income and middle-
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income countries, and tobacco use alone is the leading cause of preventable death in the United 
States and is responsible for more than 400,000 deaths peryear (Rehm et al., 2009). The societal 
costs of SUD in the Netheriands have never systematically been investigated. In 2001, the costs 
of treatment for AUD, together with losses in productivity and traffic accident- and crime-related 
consequences, were estimated at 2.6 billion euros annually (KPMG Bureau voor Economische 
Argumentatie, 2001).
Another way of looking at the global burden of psychoactive substance use is to calculate 
Disability Adjusted Life Years (DALY). They are computed by adding the years of life lost due to 
premature mortality and to living with disability. The latter are determined from morbidity. Each 
disease has been given a certain disability weight, which is multiplied with the time spent with 
that disease, to arrive at the years of life lost due to disability.
An initial estimate of factors responsible for the global burden of disease found that tobacco, 
alcohol and illicit drugs contributed together to 12.4% of all deaths worldwide in the year 2000. 
Looking at the DALY's or percentage of total years of life lost due to these substances, it has been 
estimated that they account for 8.9%, more specifically tobacco 4.1%, alcohol 4.0% and illicit 
drugs 0.8% (WHO, 2002).
The high prevalence and costs of SUDs warrant research into the risk factors of SUDs to 
optimize prevention, as well as research into predictors of SUD treatment outcomes to improve 
these outcomes and thereby reduce societal costs related to SUDs.
Risk factors o f SUDs
Although many individuals are exposed to alcohol and drugs, only a small number becomes 
addicted or develops a SUD. To determine more effective approaches to the prevention and 
treatment of SUDs, understanding of the sources of individual differences regarding risk is 
important. These risk factors will be presented based on a biopsychosocial approach. However, 
research has indicated that in most cases, a combination of genetic and environmental risk factors 
contributes to developing SUDs (Kendler et al., 2012)
From a biological perspective, the genetic risk factors for SUDs are not very substance- 
specific in their effects but rather general. In other words, these risk factors index the liability 
for abuse of various substances (Campbell & Oei, 2010). The genetic and environmental risks 
for SUDs do not only add together, but they also interact with one another (Schellekens et al., 
2012). The impact of genetic variants on SUDs risk is individually small (Kendler et al., 2012). 
In the case of AUD, most genetic influences also appear to impact intermediate characteristics 
that interact with environmental events: a flushing or low-level response to alcohol; personality 
characteristics, including impulsivity, sensation seeking, and neuronal and behavioral disinhibition; 
and psychiatric symptoms (Schuckit, 2009). From a more psychological point of view, Carroll, 
Anker and Perry (2009) identified risk factors from preclinical models of nicotine and other drug 
abuse: age (adolescence); sex and hormonal effects; impulsivity (impulsive choice and impaired
inhibition); dietary preferences (liking sugary foods); novelty reactivity; avidity for exercise; and 
impoverished vs. enriched environments. Other individual risk factors include depression and 
aggression, (early life) stress, relief of withdrawal symptoms (Enoch, 2011; Goeders, 2003) and 
affective dysregulation (Cheetam, 2010). Sociodemographic predictors of alcohol abuse and 
dependence incidence include younger age, male sex, and never having been married or being 
separated, divorced or widowed. Among African Americans, the risk of incident alcohol abuse is 
lower. The risk of incident drug dependence is greater for men, for people of younger ages and 
for separated, divorced or widowed people. Having a lower socioeconomic status is also more 
likely to be correlated with incident drug abuse and dependence (Compton, Thomas, Stinson & 
Grant, 2007; Grant et al., 2009)
Research into predictors of the course of substance use disorders has revealed relevant 
sociodemographic variables, such as age, relationship (cohabiting/married) and work, as well as 
substance disorder-related variables. Severity of dependence, poly-drug use, the number and 
duration of previous treatments, age of onset, motivation, positive family history of alcohol or 
drugs, comorbid psychopathology, treatment drop-out, female gender and the sum of positive 
and negative/stressful life events could be predictive for subsequent relapses (Bottlender & Soyka, 
2005; Keyes, Hatzenbuehler & Hasin, 2011, McLellan et al., 1994; Moos, McCoy & Moos, 2000; 
Rounsaville, Dolinsky, Babor & Meyer, 1987)
The next chapter will focus on affect (dys)regulation as one of the psychological risk factors 
for SUDs (Cheetam, 2010).
Affect (or emotion) regulation and SUDs
Affect, or emotions, usually refers to the relatively brief feelings that are experienced in response 
to a particular stimulus or situation. Affect has been regarded as an adaptive tendency that is the 
direct result of situations that hold some evolutionary significance, and it thus plays an important 
role in facilitating decision-making (Cheetham, Allen, Yuecel & Lubman, 2010). Affective 
experience can be conceptualized in terms of a trait, a personality characteristic or a temperament 
with a stable and enduring pattern of affective response or in terms of a state phenomenon, which 
is a more transient fluctuation in emotional experience (Cheetam et al., 2010). Affect regulation 
deficits are a putative maintaining factor and a promising treatment target in SUDs. Traits related 
to disinhibition have been shown to predict alcoholism prospectively, and personality traits related 
to reward seeking (positive affect) are strongly associated with alcohol use (Sher et al, 2000). A 
prominent clinical factor in SUDs is difficulty coping with negative affect as a consequence of 
SUDs. However, to the extent that SUD is also partially conceptualized as an effort to regulate 
or avoid negative emotions, it is often associated with withdrawal symptoms. AUDs are highly 
comorbid with anxiety and mood disorders (Grant et al., 2004; Kessler et al.,1997), and they have 
also been associated with negative affectivity (Caspi et al., 1997). Previous research has supported 
a causal relationship between negative affect and SUDs (Kassei et al., 2007). The combination of
negative affect and deficits in the ability to regulate affect has implications for the development 
and maintenance of, as well as recovery from, SUDs. Coping skills moderate the relationship 
between negative emotions and alcohol use (Holahan, Moos, Holahan, Cronkite, & Randall, 
2001), and poor affect regulation skills predict posttreatment levels of alcohol use (Berking 
et al., 2011) and could increase relapses in situations involving negative emotions (Bandura, 
Caprara, Barbaranelli, Gerbino, & Pastorelli, 2003). Effective emotion regulation skills include the 
abilities to be aware, identify and label emotions; to interpret emotion-related bodily sensations 
correctly; and to accept and tolerate negative emotions (Berking et al., 2011; Gratz & Roemer,
2004). Berking et al. (2011) integrated previous findings to argue for the role of specific emotion 
regulation deficits in harmful dysregulated behaviors, while also providing evidence that severe 
behavioral dysregulation can be reduced by therapy that primarily targets the emotion regulation 
skills of tolerance and acceptance.
One of the major problems regarding addictive disorders is that more than 80% of SUD 
patients fail to seek treatment (SAMHSA, 2007). It has been suggested that this failure could 
reflect impairments in recognition of the severity of the disorder, often referred to as "denial" 
(Goldstein et al., 2009). Denial could also be interpreted as a primitive psychological defense 
mechanism, i.e., a characteristic of higher-order cognitive dysfunction that can be a part of 
serious psychopathology (Finzi-Dottan & Karu, 2006) and perhaps also pathophysiology. From a 
neurobiological perspective, recent research has suggested that dysfunctional neuronal networks 
associated with insight and self-awareness could be responsible (Naqvi & Bechara, 2010). In 
these neuronal networks, relationships have been suggested between conscious interoception, 
emotional experience and decision-making as potentially important roles in addiction. Research 
has also suggested that empathy deficits, which are associated with a lack of emotion perception, 
are a function of interoceptive deficits related to alexithymia (Bird et al., 2010). In the context of 
this thesis, the relationship between emotion perception and addiction is important.
A better understanding of the role of affective dysregulation in addiction will aid in clarifying 
how addictive behaviors originate and are maintained, thereby facilitating the development 
of preventative strategies and novel treatments. Future studies should continue to identify the 
affective characteristics that predispose high-risk individuals to later substance use problems 
(Cheetam et al., 2010). In the next part of this chapter, we will therefore focus on alexithymia as 
one of the main concepts of affect dysregulation.
Alexithymia
Definition and general characteristics
Alexithymia, literally meaning "no words for emotions", refers to difficulty in identifying and 
describing feelings, the inability to discriminate between feelings and physical sensations, 
possessing a limited fantasy life and the inclination toward an externally oriented way of thinking 
(Sifneos, 1973; Taylor & Bagby, 2004). The prevalence of alexithymia in population-based studies
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has varied between 8% and 15%, with most studies showing a slightly higher prevalence in men 
than in women (Salminen, Saarijarvi, Aarela, Toikka & Kauhanen, 1999). Alexithymia has been 
associated with increasing age, low educational level, poor perceived health,1 and depression 
(Franz et al., 2008; Mattila, Salminen, Nummi & Joukamaa, 2006). In several studies, alexithymic 
features have been associated with an enhanced risk for a broad spectrum of somatic and 
psychiatric disorders, especially somatoform, mood, anxiety (PTSD), eating and substance-related 
disorders (Taylor, Bagby & Parker, 1997).
Alexithymia and response to psychotherapy
Alexithymia is purported to be a negative prognostic factor for psychological treatments, especially 
with regard to insight/cognitions, emotional awareness and therapeutic alliance. However, when 
dealing with highly structured behavioral interventions, alexithymic patients seem to perform 
as well as, or sometimes even better than, non-alexithymic patients (Lumley, Neely, & Burger,
2007). If alexithymia is an (independent) negative predictor of the efficacy of cognitive-behavioral 
treatment (CBT) for SUD patients, it could be considerably important to adjust CBT interventions, 
especially the cognitive components, for alexithymic (SUD) patients. Expecting these patients to 
differentiate, name, and describe difficult experiences, such as craving, withdrawal symptoms, 
and anxiety and mood states, would be difficult, given the concept of alexithymia but reflects the 
daily routine of CBT.
Little research has been conducted on the effects of psychotherapy on alexithymia, and the 
available results have been mixed. Some studies have reported no changes (lancu, Cohen, Ben 
Yehuda, & Kotler, 2006), whereas other studies have found a decrease in alexithymia during 
treatment (Lumley et al., 2007). The interventions in these studies were not specifically aimed at 
reducing alexithymia; thus, the changes observed could have reflected a reduction in associated 
symptoms, such as depression, anxiety or psychological stress (Stingl et al., 2008). Only two 
studies were specifically aimed at reducing alexithymic characteristics (Beresnevaite, 2000; Gay, 
Hanin & Luminet, 2008). Group psychotherapy in post Myocard Infarct patients, was associated 
with a decrease in the mean levels of alexithymia, with a resulting favorable influence on the 
clinical course of these patients with coronary heart disease (Beresnevaite, 2000). The group 
psychotherapy comprised 3 components: teaching relaxation and increasing motivation to 
reduce alexithymia; promoting nonverbal expressions of emotion; gestalt techniques and other 
interventions tofacilitate verbal emotional expression (Beresnevaite, 2000). In addition, a decrease 
in alexithymic scores was obtained in female students with hypnosis, with no correlation with 
changes in mood state (Gay et al., 2008). In conclusion, there is still little known about which 
psychotherapeutic interventions are effective in reducing alexithymia in the general and most 
patiënt populations. Since no research has been done to reduce alexithymia in SUD patients, a 
similar lack of knowledge exists about effective psychotherapeutic interventions in these patients.
Alexithymia and interpersonal style
As a consequence of their emotional deficits, alexithymic individuals have problems with 
interpersonal relationships. It is difficult for them to understand and relate to the emotions of 
others in addition to their own; thus, they typically exhibit an impaired capacity for empathy 
(Taylor et al., 1997). Moreover, absent or minimal expression of positive emotions by a patiënt can 
trigger negative reactions from therapists. Such negative reactions have been found to contribute 
to the poor treatment outcomes in highly alexithymic patients (Ogrodniczuk, Piper, & Joyce, 
2008). The interpersonal style of alexithymic patients has been characterized by cold, socially 
avoidant and non-assertive behavior (Spitzer, Siebel-Jurges, Barnow, Grabe, & Freyberger, 2005; 
Vanheule, Desmet, Meganck, & Bogaerts, 2007; Vanheule, Vandenbergen, Verhaeghe & Desmet, 
2010). Little research has been conducted into the relationship between interpersonal styles and 
alexithymia in SUD patients.
Instruments measuring alexithymia
The Toronto Alexithymia Scale (TAS-20) is the most frequently used assessment instrument for 
alexithymia, and it includes three factors: (1) difficulty in identifying feelings (DIF); (2) difficulty 
in describing feelings (DDF); and (3) externally oriented thinking (EOT) (Bagby, Parker, & Taylor, 
1994). The TAS-20 can be analyzed in its entirety, or its three components — DIF, DDF, and 
EOT — can be analyzed separately. As suggested by Taylor et al. (1997), a total score of 61 and 
above indicates alexithymia, and scores of 51 and below indicate low or absent alexithymia. A 
score from 52 to 60 represents a moderate degree of alexithymia. Alexithymia might be better 
conceptualized as a continuous, rather than a categorical variable (Parker, Keefer, Taylor, & Bagby,
2008). However, to provide clinical impressions of the differences in alexithymia in patients, data 
are often presented for patients with low, moderate and high alexithymia (Taylor et al, 1997).
Another less frequently used self-report scale is the Bermond Vorst Alexithymia Questionnaire 
(BVAQ) (Vorst & Bermond, 2001). The BVAQ consists of five subscales, each consisting of eight 
items. This scale is meant to have a two-factor structure, with an affective alexithymia dimension 
(Emotionalizing, Fantasizing) and a cognitive alexithymia dimension (Identifying, Verbalizing and 
Analyzing). The TAS-20 and the BVAQ have been criticized for being self-report scales. Many 
researchers have questioned whether self-report instruments can adequately assess deficits of 
which alexithymic individuals may not be aware (Kooiman, Spinhoven & Trijsburg, 2002).
To overcome this problem, performing multimethod alexithymia assessments, with a structured 
interview and an observer scale induded, is advised (Dorard et al., 2008). The Toronto Structured 
Interview for Alexithymia (TSIA) is composed of a 24-item set with 4 lower-order facet scales: DIF, 
DDF, EOT and imaginal processes (IMP). The 2 lower-order facet scales, DIF and DDF, constitute a 
single higher-order domain scale, labeled affect awareness (AA), and the other 2 lower-order facet 
scales, EOT and IMP, constitute a second higher-order domain scale, labeled operative thinking 
(OT) (Bagby, Taylor, Parker & Dickens, 2006). The Observer Alexithymia Scale (OAS) consists of
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five alexithymic features: (1) distant (unskilled in interpersonal matters and relationships); (2) 
uninsightful (lacking sufficiënt stress tolerance and insight or self-understanding); (3) somatizing 
(having health worries and physical problems); (4) humorless (colorlessness and lack of interest), 
and (5) rigid (being too self-controlled) (Haviland, Warren, Riggs & Gallacher, 2001).
Other, older, instrumentsto measure alexithymia, such as the Beth Israël Hospital Questionnaire 
(BIQ) and the Schalling-Sifneos Personality Scale remain undiscussed in this thesis, due to 
insufficiënt psychometric properties (Taylor et al., 1997).
Because the TAS-20 is the most frequently used instrument worldwide, and research into 
alexithymia within SUD populations has predominantly been undertaken using the TAS-20, the 
research in this thesis was conducted with the (Dutch) TAS-20. The Dutch TAS-20 showed good 
internal consistency in student and outpatient psychiatric populations, with a Cronbach's a 
varying between 0.79 and 0.82. The internal consistency for the DIF factor was good, that of the 
DDF factor was moderate to good, and that of the EOT factor was unsatisfactory (Cronbach's cc:
0.52-0.66) (Kooiman et al., 2002).
Previous research on SUDs has shown conflicting results regarding the state or trait 
characteristics of alexithymia. This issue is related to the stability of the concept of alexithymia, 
especially as measured with the TAS-20, and which will be discussed in the next subsection.
Alexithymia as a trait or state: the absolute and relative stability of alexithymia 
In the literature, there has been an extensive debate on whether alexithymia is conceptualized 
best as a state or as a trait characteristic. The concept of alexithymia as an enduring trait has been 
supported by longitudinal studies on clinical populations, but not SUD populations (Tolmunen 
et al., 2011). However, it has also been suggested that alexithymia could be a temporary or 
concomitant state reaction to emotional stress resulting from illness, anxiety, and depression 
(Taylor & Bagby, 2004). This distinction is of clinical importance because if alexithymia were mainly 
a state-dependent phenomenon, for instance, in response to stress, illness, anxiety, or depression, 
the need to address alexithymia in the treatment of SUD patients would decrease. Then, the 
treatment could be focused specifically on the stress, illness, anxiety, and depression components.
The research on alexithymia as a trait or a personality characteristic has focused on the 
concept of the absolute and relative stability of alexithymia. Previous research has shown that 
the stability status can change according to the population that is studied (de Timary, Luts, Hers 
& Luminet, 2008; Honkalampi et al., 2001; Luminet, Rokbani, Ogez & Jadoulle, 2007; Pinard, 
Negrete, Annable & Audet,1996; Rufer et al., 2004; Saarijarvi, Salminen & Toikka, 2006; Stingl 
et al., 2008).
This means that the stability shows considerable differences between the diverse populations, 
which have been examined on the stability of alexithymia.
Absolute stability refers to the extent to which the average personality scores or trait levels of 
a population change. This stability is assessed based on mean level differences over time. These 
differences indicate whether and in which direction the population as a whole is changing (Caspi, 
Roberts, & Shiner, 2005). A systematic review or meta-analysis of the stability of alexithymia as 
a personality trait does not exist, but a meta-analysis of longitudinal studies of personality traits, 
according to the five-factor model, provided evidence for continued plasticity, which refers to 
change in personality, beyond the age of 30 years old (Roberts, Walton & Viechtbauer, 2006).
Relative, or rank-order, stability indicates the extent to which the relative differences among 
individuals remain the same over time and is assessed by test-retest correlations (Caspi et al.,
2005). In a meta-analysis of the relative stability of personality, also based on the five-Factor model, 
test-retest correlations were moderate in magnitude over time (Roberts & DelVecchio, 2000). 
Stability was higher at older age, and lower with increasing intervals between the observations. 
Roberts and DelVecchio (2000) found that trait consistency was .31 in childhood and increased 
to .54 during the college years and to .64 at age 30, reaching a plateau of approximately .74 
between the ages of 50 and 70 years old, indicating that personality traits continue to change 
throughout adulthood. Both meta-analyses demonstrated that personality trait development is 
not only a phenomenon of childhood or adolescence, but continues during adulthood (Roberts & 
DelVecchio, 2000, Roberts et al., 2006).
A high relative stability of alexithymia in SUD patients is strong evidence for alexithymia being 
a stable trait or personality characteristic. This evidence could be important in addressing whether 
the degree of alexithymia is related to the outcomes of therapeutic interventions in SUD patients. 
A strong relationship between alexithymia and state factors, such as anxiety or depression, and 
a low relative stability of alexithymia would support a more state-dependent phenomenon. This 
categorization would argue against alexithymia being an autonomous trait-like SUD vulnerability 
factor (de Timary et al., 2008). Addressing the other state factors, such as anxiety or depression, 
would automatically change alexithymia, with less of a need to address alexithymia in SUD 
patients.
However, if alexithymia is a state-dependent feature, not related to stress, illness, anxiety or 
depression, the reason to address it in the treatment of SUD patients depends on the relationship 
with treatment outcome and attrition. When no relationship is found between alexithymia, as a 
state-dependent phenomenon, and attrition in SUD or treatment outcomes, such as the reduction 
in substance use or the degree of abstinence, then no specific intervention for alexithymia in the 
treatment of SUD-patients is needed.




Prevalence and characteristics of alexithymia in SUD patients
Van Rossum et al. (2004) reported that 54% of the patients with alcohol-related disorders 
referred to inpatient detoxification units, affiliated with NISPA (Nijmegen Institute for Scientist- 
Practitioners in Addiction), in the eastern and Southern parts of the Netherlands were alexithymic, 
according to the Toronto Alexithymia Scale (TAS-20). However, since an unusual cut-off score for 
identifying alexithymia (> 56) was used, whereas the conventional cut-off score for alexithymia 
on the TAS-20 is higher (> 60) (Taylor et al., 1997), this did result in overestimating the number 
of alexithymic patients. In SUD patients, alexithymia rates of up to 67% have been reported 
(Thorberg, Young, Sullivan & Lyvers, 2009); however, research on this subject has mainly been 
based on AUD patients.
Associations were found in a cross-sectional Egyptian study between the degree of 
alexithymia and the degree of opiate, benzodiazepine and polysubstance use (El Rasheed, 2001). 
The evidence regarding the associations among alexithymia, alcohol consumption and severity 
of alcohol dependence is limited, as is the support for alexithymia as a direct risk factor for AUD 
(Al Birt et al., 2008; Cleland, Magura, Foote, Rosenblum, & Kosanke, 2005; Junghanns et al., 
2005; Loas et al., 1997; Thorberg et al., 2009; Ziolkowski et al. 1995). Evaluations of therapy 
in alexithymic SUD patients have been scarce, but the limited available findings have shown a 
negative association between alexithymia and treatment-related outcomes, particularly in AUD 
patients (Cleland et al., 2005; Loas, Fremaux, Otmani, Lecercle, & Delahousse, 1997; Ziolkowski, 
Gruss, & Rybakowski, 1995).
Rosenblum et al. (2005) demonstrated less substance abuse in high-scoring alexithymic SUD- 
patients as a result of group cognitive behavior therapy (CBT), compared to a group receiving 
motivational intervention (GMI). In contrast, low-scoring alexithymic patients performed better 
with GMI. However, in the total study population, alexithymia was associated with a lower number 
of treatment sessions attended and with a higher ASI alcohol composite score at follow-up, i.e., 
a worse outcome (Cleland et al., 2005). Cocaine-abusing alexithymic outpatients showed better 
outcomes when treated with clinical management, compared to cognitive-behavioral relapse 
prevention (Keiler, Carroll, Nich & Rounsaville, 1995). I have already described that a lack of 
knowledge exists about effective psychotherapeutic interventions specifically aimed at reducing 
alexithymia in general and in particular in SUD patients. Based on the limited available research, it 
is as well hardly possible to indicate which form of therapy focusing on SUDs and not specifically 
aimed at reducing alexithymia, would be more successful in alexithymic SUD patients.
Stability of alexithymia in SUD
Studies of the stability of alexithymia have only been conducted in detoxifying or recently 
detoxified SUD populations (de Timary et al., 2008; Haviland, Macmurray & Cummings, 1988; 
Pinard et al., 1996) and thus have been conflicting. One study indicated a change in alexithymia
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during detoxification, with the suggestion that alexithymia is a state phenomenon resulting from 
anxiety and depression (Haviland, Macmurray, & Cummings, 1988). Another study showed no 
changes in mean levels after detoxification, concluding that alexithymia is a stable trait (Pinard, 
Negrete, Annable, & Audet, 1996). These studies did not examine both absolute and relative 
stability at the same time. More recently, an absolute reduction in alexithymia was found in AUD 
patients during withdrawal, with high relative stability over a short time period (de Timary, Luts, 
Hers, & Luminet, 2008). Alexithymia was defined as a stable personality trait, rather than a state- 
dependent phenomenon, because of the limited influence of anxiety and depression and because 
of high relative stability (de Timary et al., 2008).
Biological, familial and genetic aspects of alexithymia in SUD
A substantial genetic influence of alexithymia was demonstrated in an extensive Danish twin 
pair study, and this result was replicated, controlling for depressive symptoms, in an Italian twin 
pair study (Jorgensen, Zachariae, Skytthe & Kyvik, 2007; Picardi et al., 2011). Based on this 
genetic influence, a higher percentage of alexithymia is to be expected in parents and other 
family members of alexithymic patients. This relationship could also explain a family history 
of alcoholism (FHA) in these parents and other family members, because of the relationship 
between alexithymia and alcohol use disorders (Thorberg et al., 2009; Lyvers, Onuoha, Thorberg 
& Samios, 2012). However, apart from a genetic mechanism, problems with alcohol in parents 
could also cause parents to neglect their children's emotional states during child rearing, leading 
to emotional self-regulation deficits, such as alexithymia. The latter was shown in a recent meta- 
analysis on parental bonding and alexithymia (Thorberg, Young, Sullivan & Lyvers, 2011). A lack 
of maternal care, but also maternal and paternal overprotection, was correlated with alexithymia 
(Thorberg et al., 2011). In line with this finding, disturbed family functioning was correlated with 
the development of alexithymic characteristics (Lumley, Mader, Gramzow & Papineau, 1996). This 
finding was also demonstrated for a history of neglect or (sexual) abuse, independent of whether 
the abuse occurred within the family (Berenbaum, 1996; Bermond, Moormann, Albach & van 
Dijke, 2008; Evren, Evren, Dalbudak, Ozcelik & Oncu, 2009).
As one of the neurobiological explanatory models, alexithymia has been correlated with 
dysfunction in interhemispheric transfer (Larsen, Brand, Bermond & Hijman, 2003; Paul et al., 
2007). In fetal alcohol syndrome (FAS), agenesis, malformations and hypoplasia of the corpus 
callosum are common (Swayze et al., 1997; Roebuck, T.M., Mattson, S.N. & Riley, 1998), and 
these issues could form an argument for a more general interhemispheric transfer problem in 
children of mothers with alcohol abuse problems, thus accounting for higher scores of alexithymia 
(Romei et al., 2008). However, corpus callosum abnormalities were also present in young, alcohol- 
naïve male subjects at high risk for alcoholism because of alcohol-dependent fathers, with their 
mothers not having lifetime diagnoses of alcohol dependency and not having used alcohol 
during pregnancy (Venkatasubramanian, Anthony, Reddy, Reddy, Jayakumar & Benegal, 2007).
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In addition, the toxic effects of alcohol exposure on the corpus callosum have been reported as 
resulting in a reduction in thickness and therefore in a loss of transfer function (Pfefferbaum, Lim, 
Desmond & Sullivan, 1996; Rohlfing, Sullivan & Pfefferbaum, 2006).
Three previous studies examined the impact of a FHA on alexithymia (Finn, Martin & Pihl, 1987; 
Rybakowski &Ziolkowski, 1991; Lyvers et al., 2012). One study found strong alexithymic features 
in non-alcoholic sons with an extensive male-limited generational family history of alcoholism, but 
not in non-alcoholic sons without any family history or with alcoholic fathers without an extensive 
family history (Finn et al., 1987). In the second study, no relationship was found between a FHA 
and alexithymia (Rybakowski & Ziolkowski, 1991). However, both studies used the Schalling- 
Sifneos Personality Scale for the assessment of alexithymia, which lacks sufficiënt validity and 
internal reliability (Taylor et al., 1997). In a recent study in a non-clinical population, an association 
was found between the TAS-20 and being the offspring of an alcoholic parent, as defined by the 
Children of Alcoholics Screening Test (Lyvers et al., 2012)
Aims, research questions, and cutline of the thesis
The main aim of this thesis is to examine the prevalence, the stability, the familial-history correlates 
and the clinical implications (of high levels) of alexithymia in SUD patients.
The specific research questions are as follows.
1. What is the prevalence of alexithymia in three different SUD populations: heterogeneous 
abstinent SUD patients, homogeneous abstinent AUD patients and heterogeneous SUD 
patients during detoxification?
2. Does alexithymia predict therapy-related outcomes in heterogeneous SUD patients after 
CBT, and is there a moderation of these results as a result of adding shared decision- 
making (SDM) as a structured therapeutic intervention?
3. Does alexithymia predict therapy-related outcomes in more homogeneous AUD patients 
after completing an inpatient treatment program based on CBT?
4. Is alexithymia a state or trait phenomenon in heterogeneous SUD patients, based on 
the absolute and relative stability of alexithymia after an inpatient CBT treatment, when 
controlling for anxiety, depression and therapy-specific variables?
5. Is alexithymia a state or trait phenomenon in heterogeneous SUD patients during 
detoxification, based on the absolute and relative stability of alexithymia in an SUD
population, when controlling for withdrawal symptoms, induding anxiety and 
depression?
6. Does a family history of alcoholism (FHA) predict higher levels of alexithymia in SUD 
patients when controlling fordisturbed family functioning?
In Chapter 2, a heterogeneous group of SUD inpatients is assessed for the prevalence of 
alexithymia and the relationship of alexithymia with SUD characteristics at baseline and with 
3-month follow-up results after inpatient cognitive behavioral therapy (CBT) as usual (TAU group) 
or CBT with an SDM (shared decision-making) intervention (SDM group), as part of a RCT of 
SDM. Research question 2 is addressed in this chapter.
Chapter 3 covers research question 3. Homogeneous AUD inpatients are assessed for the 
prevalence of alexithymia and the relationships of alexithymia with AUD characteristics at baseline 
and with one-year follow-up results after CBT.
Chapter 4 presents the data on the absolute and relative stability of the TAS-20 over a period of 
6 months in the same heterogeneous SUD inpatients described in Chapter 2 in a pre-post design, 
as part of a RCT of SDM. Research question 4, on the state or trait construct of alexithymia, is the 
main topic of this chapter.
In Chapter 5, the state or trait auestion of alexithymia, research question 5, is addressed 
by examining the absolute and relative stability among heterogeneous SUD patients at two 
time points during a 3-week inpatient detoxification period, while controlling for withdrawal 
symptoms and for personality disorder traits.
In Chapter 6, whether familial vulnerability to alcoholism is correlated with the presence and 
severity of alexithymia in SUD patients, research question 6, is examined.
Finally, in Chapter 7, the research questions are answered with an overview of the prevalence 
of alexithymia in the different populations (research question 1), and a summary and general 
discussion of the main findings are presented, as well as the scientific and clinical relevance of 
this thesis.
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Abstract
Background: About 40% of all patients with substance use disorders (SUD) are considered to 
be alexithymic. It is hypothesized that alexithymia is negatively associated with outcome results.
Methods: 187 SUD inpatients were assessed at baseline and 3-month follow-up with the Dutch 
version of the TAS-20 and EuropASI after an inpatient cognitive behavioural therapy (CBT) as 
usual (TAU-group) or CBT with a SDM (Shared Decision Making) intervention (SDM-group).
Results: Thirty-seven percent of the patients were alexithymic (TAS-20 è 61). Baseline alexithymics 
showed higher severity-scores on the EuropASI "work, education and income" [ t(129) = 2.1, p 
= 0.04] and psychiatric severity [ t(129) = 5.2, p < 0.001] domains. Alexithymia did not predict 
abstinence at follow-up. Alexithymic male patients improved more on the domains "work, 
income and education" [ t(79) = 2.7, p < 0.01] than non-alexithymic men. Alexithymic patients in 
the TAU-group improved more on the domains "drugs" [ t(55) = 2.2, p = 0.04] and "family and 
social relations" [ t(55) = 2.2, p = 0.03] than non-alexithymics.
Conclusion: Alexithymic SUD patients at baseline showed more addiction related problems. 
Baseline alexithymia was predominantly positively associated with outcome results. Alexithymic 
SUD-patients profit very well from structured CBT-interventions. Based on these results assessing 
alexithymia in SUD-patients at baseline for treatment adjustments in CBT is not necessary.
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Introduction
Alexithymia refers to the difficulty in identifying and describing feelings, the inability to discriminate 
between feelings and physical sensations, having a limited fantasy life and the inciination to 
an externally oriented way of thinking [1, 2].The prevalence of alexithymia in population-based 
studies varies between 8% and 15% with most studies showing a slightly higher prevalence in 
men than in women[3], Alexithymia has been associated with increasing age, low educational 
level, poor perceived health, and depression[4, 5], In substance related disorders alexithymia rates 
till 67% have been reported[6, 7]. In 2004 van Rossum et al.[8] reported 54% of the patients 
with alcohol related disorders to be alexithymic with a mean score of 56 on the TAS-20. The 
patients were recruited in 4 of our inpatient detoxification units in the East and South part of the 
Netherlands.
In a mixed population of psychoactive substance dependent patients state-anxiety, depression 
and alexithymia were related. Women's average alexithymia scores were higher than for men [9]. 
Regarding alexithymia only the total TAS-20 and the subscale "difficulty identifying feelings" (DIF) 
showed significant differences between men and women.
In several studies alexithymic features have shown an enhanced risk for a broad spectre 
of somatic and psychiatric disorders, especially somatoform, mood, anxiety (PTSD), eating 
and substance-related disorders[10, 11], Yet the evidence regarding the association between 
alexithymia, alcohol consumption and severity of alcohol dependence is still limited as is the 
support for alexithymia as a direct risk factor for alcohol related disorders [7, 10, 12-15]. 
Associations were found in a cross-sectional Egyptian study between alexithymia and opiate, 
benzodiazepine and polysubstance use and lower numbers of reported relapses, but also with 
non-persistence in treatment [16].
Alexithymia is supposed to be a negative prognostic factor for many psychological treatments, 
especially when aimed at insight, emotional awareness or therapeutic alliance. Butwhen dealing 
with highly structured cognitive behavioural interventions alexithymic patients seem to perform 
as well as or sometimes even better than non-alexithymic patients [17].
Therapy evaluations for alexithymic patients with substance related disorders are scarce. 
Rosenblum et al.[18] demonstrated less substance abuse in high alexithymic SUD patients 
as a result of group cognitive behaviour therapy (CBT) compared to a group of motivational 
intervention (GMI). The other way around, low alexithymics did better on GMI. But for the total 
study population alexithymia was related to less treatment sessions attended and to a larger 
follow-up ASI alcohol composite score[10], Outpatient cocaine abusing alexithymic patients 
showed better outcomes when treated with clinical management over cognitive-behavioural 
relapse prevention[19], There is limited empirical evidence for an influence of alexithymia on 
attrition rates in the treatment of alcohol related disorders [7, 10].
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Despite limited indications that alexithymic SUD patients can profit from CBT we still have 
our concerns about the suitability of the regular CBT programs, in which alexithymic patients are 
asked many times a day to describe their feelings and cravings.
This study examines a) the prevalence of alexithymia in SUD-patients after detoxification, b) 
the difference in addiction severity between alexithymic and non-alexithymic SUD patients and c) 
the predictive value of alexithymia at baseline on recovery as the result of an inpatient cognitive 
behavioural therapy program for SUD-patients. Outcome results for recovery were dropping- 
out, time in treatment, abstinence at follow-up and improvement in EuropASI scores between 
baseline and follow-up. We hypothesized that alexithymic SUD-patients showed a larger score 
on addiction severity at baseline and would profit less from cognitive behavioural treatment 
than non-alexithymic patients, because the program is not designed for alexithymic patients: 
alexithymic patients are accounted for capabilities they do not have, such as showing and working 
on emotions and cravings.
Methods
Subjects
Subjects were 220 inpatients recruited from three addiction treatment centres in the East and 
South part of the Netherlands: GGZ Noord- & Midden-Limburg, department Addiction Treatment, 
Novadic-Kentron and Tactus Addiction Treatment. This study was part of a randomized controlled 
trial investigating a Shared Decision Making Intervention (SDMI) in addiction health care that was 
carried out between January 2005 to December 2006 and published in 2009[20, 21]. Compared 
with a well established 3-month inpatient treatment program alone, addition of SDMI showed 
significant benefits on drug use and psychiatric problems.
All 261 inpatients hospitalized during the study period were assessed for eligibility. No 
distinction was made for the kind of substance(s) used. Due to exclusion criteria (being under 
the age of 18, insufficiënt knowledge of the Dutch language, severe psychiatric co-morbidity 
precluding to take part in the SDM-intervention or no signed informed consent), refusing or early 
leaving 227 patients were randomized. Because 7 patients refused to participate later on and 8 
patients could not start because of an untimely stop at one location, 107 patients started the 
SDM-intervention and 105 patients started in the control group: decision making as usual, i.e. 
treatment as usual (TAU). All patients have been diagnosed according to DSM-IV-TR as having 
one or more substance related disorders.
At follow-up evaluation, three months after discharge from inpatient treatment, patients 
received a voucher for EUR 20. The study was approved by the Dutch Ethical Assessment 
Committee for Experimental Investigations on People (No. 4.108).
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Interventions
The participating treatment units had a comparable 3-month inpatient cognitive behavioural 
approach with elements of motivational interviewing (Ml), relapse prevention, social skills training 
and both individual and group components. SDM is a structured approach to reach a treatment 
agreement during 5 sessions and is also partly based on Ml-techniques[22],
In the Netherlands Ml is widely known and used to motivate patients with substance use 
disorders to start and stay in treatment. So, therapists in the control (TAU) group, mostly nurses 
or social workers as in the SDM intervention, also use Ml but not in a structured way. In the SDM 
group Ml was applied by protocol to explore, compare and evaluate indicated treatment goals. 
In this condition both therapists and patients completed the Goals of Treatment Questionnaire, 
based on the Camberwell Assessment of Needs (CAN)[23, 24], In the control intervention all 
participating centres used comparable, unstructured, procedures to reach treatment agreement 
with patients. For a detailed explanation of the SDM intervention is referred to Joosten et al.[21].
Instruments
Alexithymia was assessed at baseline and 3-month follow-up with the Dutch version of the TAS- 
20[25, 26] comprising three dimensions: (1) difficulty in identifying feelings (DIF), (2) difficulty in 
describing feelings (DDF) and (3) externally oriented thinking (EOT). Each item consists of a five- 
point Likert scale ranging from "completely disagree" to "completely agree". The TAS-20 can 
be analyzed in its entirety or the three components can be analyzed separately. The TAS-20 total 
scores were categorized according to the empirically derived cut-off points suggested by Taylor et 
al.[27]: a total score of 61 and above indicates alexithymia, and scores of 51 and below indicate 
no alexithymia. A score from 52 to 60 represents a mild degree of alexithymia.
Type of substance use disorder was assessed by using the Composite International Diagnostic 
Interview, Substance Abuse Module (CIDI-SAM) at baseline[28], The CIDI-SAM is an expanded and 
more detailed version of the substance use sections of the CIDI. The interview questions address 
the diagnostic criteria of DSM-IV-TR and ICD-10 psychoactive substance use disorders. Severity of 
substance use was established on the basis of the European Addiction Severity Index (EuropASI) 
at baseline and 3-month follow-up[29, 30], The EuropASI is a clinical research interview designed 
to assess problem severity in 7 areas of functioning: physical health, employment, alcohol and/or 
drug use, legal, family/social and psychiatric. The Dutch version of EuropASI used in the present 
study also includes gambling. Eight severity scores that could range from 0 (no problem) to 9 
(extremely serious problem) were derived from this interview. Data used in this part of the study 
were collected at baseline and at three-month follow-up. Independent interviewers carried out 
the 3-month follow-up measurements.
StatisticaI analysis
The prevalence of alexithymia is presented in percentages. For the comparison of the baseline 
characteristics (table 1), time in treatment, dropping-out of alexithymic (TAS-20 > 60) and non- 
alexithymic patients (TAS-20 < 52) Chi-square or Fisher's exact tests were used for dichotomous 
data and independent t-tests for continuous data.
"Change scores" of the EuropASI severity scores were computed by subtracting the follow-up 
scores from the baseline scores of the 8 domains of the EuropASI. Independent t-tests were used 
to show differences in means for EuropASI "change scores" on domain level between baseline 
alexithymics and non-alexithymics. To estimate the effect size of the changes in the EuropASI 
severity scores, Cohen's d (p1 -  p2) / a l was calculated between baseline and follow-up. Cohen 
defines d of 0.2, 0.5 and 0.8 as small, medium and large effects, respectively.
Multivariate logistic and linear regression models were performed with abstinence and the 
EuropASI "change scores", respectively, as the dependent variables. The predictor variables were 
age, gender, intervention type (SDM or TAU), based on previous research[4, 9, 18, 21], and the 
total baseline (TAS-20) alexithymia score. Variables with a p<0.15 in univariate analyses, were 
entered in a full multivariate model. Subsequently, non-significant variables were removed, one 
by one, until -2 log likelihood deteriorated significantly (logistic regression) or R-squared changed 
by more than 10% (linear regression). Based on previous research effect modification by gender 
and type of intervention was expected in the relationship between alexithymia and abstinence, 
respectively EuropASI "change scores. Therefore, interaction terms for a(exithymia*gender and 
alexithymia*intervention were brought into the models to formally test for significant interaction. 
Flowever, regardless of significance, stratified analyses were also performed. We included all 
patients with a baseline alexithymia assessment.
Finally, all statistical tests were 2-sided, with a p value < 0.05 considered to be significant, and 
performed using SPSS for Windows (release 16.0).
Table 1. Baseline characteristics of the study population by alexithymia
High alexithymic Low alexithymic
(TAS-20 > 60) (TAS-20 < 52)
Patiënt characteristics n = 69(36.9%) n = 62(33.2%) P
Gender % (n) 0.34
Male 40.0(56) 32.9(46)
Female 27.7(13) 34.0(16)
Condition % (n) 0.95
SDM 52.4(33) 47.6(30)
TAU 52.9(36) 47.1(32)
Age (years) Mean(SD) 39.6(10.6) 42.1(10.3) 0.16
Country of birth % (n) 0.23
Netherlands 54.1(66) 45.9(56)
Other 33.3(3) 66.7(6)
Relationship % (n) 0.87
Married 50.0(11) 50.0(11)
Divorced/widowed 53.1(26) 46.9(23)
Never married 56.1(32) 43.9(25)
Employment % (n) 0.05
Employed 46.3(31) 53.7(36)
Unemployed 62.8(37) 36.2(21)
Education (years) Mean(SD) 11.0(2.8) 12.0(3.0) 0.05
Type of substance dependence % 0.72
Only alcohol dependent 47.8(32) 52.2(35)
Only drug dependent 51.9(14) 48.1(13)
Years alcohol use > 5 U Mean(SD) 14.0(11.1) 10.8(10.8) 0.10
Years drug use Mean(SD) 8.6(6.6) 8.1(7.5) 0.75




Poly substance 61.9(26) 38.1(16)
Other 33.3(1) 67.7(3)
EuropASI-scores Mean(SD)
Physical health 2.9(2.0) 2.7(22) 0.67
Work, education and income 4.0(1.8) 3.3(1.9) 0.04
Alcohol 5.4(2.4) 5.0(2.6) 0.38
Drugs 3.9(3.2) 3.0(3.3) 0.10
Legal 1.6(2.0) 1.3(1.8) 0.27
Family/social relations 4.5(1.3) 4.0(1.6) 0.07
Psychiatric 6.8(1.2) 5.1 (2.4) <0.001
Gambling 0.4(1.2) 0.2(0.7) 0.43
Notes: SDM = Shared Decision Making; TAU = Treatment As Usual
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Results
Prevalence o f alexithymia
TAS-20 baseline data were available for 187 patients. According to the cut-off score 36.9% 
(n = 69) was alexithymic, 29,9% (n = 56) had an intermediate or moderate position and 33.2% 
(n = 62) scored beneath the cut-off point and did not meet the criteria for alexithymia. The mean 
score of the TAS-20 on baseline was 55.7 (SD = 11.3) The mean scores of the factors DIF, DDF and 
EOT were respectively 19.1 (SD = 6.4), 16.2 (SD = 4.3) and 20.3 (SD = 4.2).
Baseline differences between (high) alexithymic and non-alexithymic patients
Table 1 shows the baseline characteristics for the alexithymic (TAS-20 > 61) and the non-alexithymic 
(TAS-20 < 51) patients. Alexithymic patients had less years of education and were more often 
unemployed than non-alexithymics. On the EuropASI alexithymics showed more problems on the 
"work, income and education" and the "psychiatry" scales.
Predictive value o f baseline alexithymia on recovery
Follow-up data
The outcome results at 3-month follow-up were based on 166 (78%) of the 212 participating 
patients. Hundred fifty and two (81.3%) of the 187 patients with baseline alexithymia scores 
participated at the follow-up interviews, but from 16 of these patients follow-up data for 
abstinence were missing. The availability of follow-up data did not differ between baseline 
alexithymics (78.3%; n = 54) and non-alexithymics (83.9%; n =52) (x2 (1) = 0.67, p = 0.42).
Time in treatment
The mean time in treatment (days) for alexithymic patients (M = 116.0, SD = 58.9) was not 
different from patients without alexithymia (M = 105.1, SD = 48.6) [t(129) = 1.14, p = 0.26],
Drop-out
Completers versus drop-outs did not differ between alexithymics (50,7% completers) and non- 
alexithymics (43,5% completers) [x2 (1) = 0.68, p = 0.41].
Abstinence
Fifty-four percent (54.0%) of the baseline alexithymics were abstinent at follow-up and 45.7% 
of the non-alexithymics [x2 (1) = 0.67, p = 0.41]. At univariate analysis none of the predictor 
variables (age, gender, condition, TAS-20 and factors) showed significance at a p-value <0.15 
(table 2), so logistic regression models were not performed. Baseline alexithymia or factors (DIF, 
DDF and EOT) did not predict abstinence at follow-up.
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Table 2. Characteristics of abstinent versus non-abstinent patients at follow-up: independent t- tests for 








TAS-20: Mean(SD) 55.4(10.1) 55.3(12.8) -0.0(- 4.0 -  3.9) 0.98
DDF: Mean(SD) 16.3(4.1) 16.0(4.6) -0.3(- 1 .8 - 1.1) 0.65
EOT: Mean(SD) 20.2(4.3) 20.4(4.2) 0.2(- 1.3-1.6) 0.84
Age: Mean(SD) 42.0(10.0) 41.4(12.4) - 0.6(- 4.4 -  3.2) 0.76
Gender: % (n) 0.30
Male 52.0(51) 48.0(47)
Female 42.1(16) 57.9(22)
Condition: % (n) 0.62
SDM 51.6(32) 48.4(30)
TAU 47.3(35) 52.7(39)
Notes: FU = Follow-up; TAS-20 = "Toronto Alexithymia Scale"; DIF = "Difficulty Identifying Feelings"; 
DDF = "Difficulty Describing Feelings"; EOT = "Externally Oriented Thinking". SDM = Shared Decision 
Making; TAU = Treatment As Usual.
Changes in EuropASI domains
The effect sizes for the changes in EuropASI severity scores varied from small (Cohen's d of 
alexithymic patients for gambling = 0.11) to large (Cohen's d of alexithymic patients for psychiatric 
severity = 2.55). Effect sizes were predominantly larger for alexithymic than for non-alexithymic 
patients. However, independent t-tests between baseline alexithymic and non-alexithymic 
patients on the "change scores" of the EuropASI showed only significant differences for men in 
the "work, income and education" and for the TAU-group in the "family and social relations" 
and "psychiatry" sections (table 3).
Changes in "physical health", "drugs", "family and social relations" and "psychiatry" domains 
Based on an a priori expected interaction between alexithymia and type of intervention, stratified 
analyses for type of intervention were performed. SDM showed on the "physical health" domain 
better outcomes for higher scores on alexithymia (p = 0.06) and treatment as usual (TAU) was 
negatively associated with alexithymia. In the TAU group men did better than women. Alexithymia 
explained 7% of change in R2 (table 4a). Exploring the alexithymia factors that contributed to 
the change, we found the DDF factor to be responsible for the change of "physical health" in 
the SDM condition and EOT in the TAU condition (table 4b). On the "drugs" domain none of the 
variables in the SDM group delivered a relevant contribution. In the TAU group age was negatively 
related to improvement. Alexithymia was positively related and explained 5% of the variance 
(table 4a). On factor level EOT accomplished the improvement (table 4b). Also for the changes 
on the "family and social relations" and "psychiatry" domains no significant predictor could be 
found in the SDM intervention. Improvement in the "family/social relations" domain in TAU was 
only related to baseline alexithymia (table 4a). When converting the total alexithymia score in
the factor scores, the EOT factor was responsible (table 4b). On the change in the "psychiatry" 
domain alexithymia contributed in the TAU group significantly to the variance besides gender 
(table 4a). DIF was the responsible factor (table 4b).
Table 3. EuropASI severity "change scores" (baseline minus follow-up) for baseline high alexithymic and low 
alexithymic patients; independent t-tests with Cohen's d for change between baseline and follow-up for high 
alexithymics(A+) and low alexithymics(A-). Stratified analyses for type of intervention or gender are shown 
when interaction effects with alexithymia are present.
Addiction severity Alexithymics Non-alexithymics P d(A+) d(A-)



















0.6(1.9) 0.33 0.52 0.30
1.5(2.3) 0.10 0.29 0.66
0.2(1.8) 0.009 0.75 0.10
0.9(2.1) 0.56 1.11 0.62
1.7(2.2) 0.33 0.91 0.66
2.0(2.4) 0.86 0.57 0.58
0.5(1.1) 0.04 0.41 0.15
0.9(1.6) 0.79 0.55 0.50
1.8(2.5) 0.48 1.68 1.01
1.1(2.2) 0.03 1.66 0.73
3.1(2.7) 0.99 2.55 1.54
1.1(2.6) 0.07 2.34 0.46
0.2(0.8) 0.57 0.11 0.29
Note: SDM = Shared Decision Making; TAU = Treatment As Usual.
Table 4a. Multivariate linear regression analyses predicting change in EuropASI domains "physical health", 
"drugs", "family and social relations", and “psychiatry" from baseline to follow-up from gender, age and 
baseline total TAS-20, stratified by intervention type. Non-significant variables were removed until R-squared 
changed by more than 10%.
P P R2 Fchange P
"physical health"
SDM (n = 69)
TAS-20 at baseline .23 0.06 .05 3.76 0.06
TAU (n = 83)
Gender -.21 0.05 .12 5.32 0.007
TAS-20 at baseline -.27 0.01
"drugs"
TAU
Age -.21 0.06 .10 4.36 0.02
TAS-20 at baseline .22 0.04
"family and social relations"
TAU
TAS-20 at baseline .26 0.02 .07 5.79 0.02
"psychiatry"
TAU
TAS-20 at baseline .24 0.03 .06 4.69 0.03
Notes: SDM = "Shared Decision Making"; TAU = "Therapy As Usual'
Table 4b. Multivariate linear regression analyses predicting change in EuropASI domains “physical health”,
"drugs", “family and social relations" and "psychiatry" from baseline to follow-up from gender, age,baseline
total TAS-20 factor scores, stratified by intervention type. Non-significant variables were removed until
R-squared changed by more than 7 0%.
P P R* Fchange P
"physical health"
SDM (n = 69)
DDF at baseline .23 0.06 .05 3.73 0.06
TAU (n = 83)
Gender -.26 0.02 .12 5.35 0.007
EOT at baseline -.28 0.01
"drugs"
TAU
Age -.21 0.05 .11 4.90 0.01
EOT at baseline .24 0.03
“family and social relations"
TAU
EOT at baseline .24 0.03 .06 4.98 0.03
"psychiatry"
TAU
DIF at baseline .27 0.01 .08 6.44 0.01
Notes: DIF = "Difficulty Identifying Feelings" ;DDF = "Difficulty Describing Feelings"; EOT = "Externally 
Oriented Thinking"; SDM = "Shared Decision Making"; TAU = "Therapy As Usual".
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Change in the "work, income and education" domain
Based on an a priori expected interaction between alexithymia and gender a stratified analysis 
was performed. For women baseline alexithymia had no explanatory power in the change scores 
beyond age and type of intervention. Age and SDM as treatment intervention predicted both 
better change scores for women. On the contrary age and condition had no part in the change 
scores for men, but baseline alexithymia did, although for a small part (R2 = 0.03). By importing 
the alexithymia factors in stead of the total alexithymia score only the DIF factor contributed to 
the model (table 5).
Tabie 5. Multivariatel linear regression analysis predicting change in EuropASI "work, income and education " 
domain from baseline to follow-up from age, type of intervention and baseline total TAS-20 and factor scores, 
stratified by gender. Non-significant variables are removed until R-squared changed by more than 7 0%.
P P R2 Fchange P
Men (n =113) 
TAS-20 at baseline .18 0.05 .03 3.82 0.05
DIF at baseline .20 0.03 .04 4.66 0.03
Women ( n = 39) 
Age .25 0.12 .17 3.69 0.04
Intervention .28 0.08
Changes in the "alcohol", "legal" and "gambling" domains
The change in the "alcohol" severity score (R2 = .08; Fchange = 6.03, p = 0.003) was predicted 
by age (p = .23, p = 0.004) and type of intervention (p = .13, p = 0.09). Higher age and SDM in 
comparison with TAU predicted better change scores. On the "legal" domain (R2 = .15; Fchange 
= 12.87, p < 0.001) age (p = -.30, p < 0.001) and female gender (p = -.21, p = 0.006) were both 
negatively related to improvement. No significant predictors for the change in the "gambling" 
domain were found. Baseline alexithymia did not reach significance in these 3 domains.
Discussion
We replicated, conform previous studies[6-9], a relative high prevalence (37%) of alexithymia in 
our detoxified inpatient SUD-population. Our baseline data showed limited evidence regarding 
the association between alexithymia and severity of SUD, in line with the review of Thorberg 
et al. for alcohol dependence[7], The lower scores for alexithymic patients on work, income 
and education are in accordance with population-based studies[4, 5]. In recent detoxified SUD- 
patients symptoms of depression and anxiety are relatively high and because of the strong relation 
between these symptoms and alexithymia, a part of the high baseline alexithymia score could be 
interpreted as a state phenomenon[9, 31]. The psychiatric severity rating scale of the Dutch ASI is 
moderately correlated with the Beek Depression Inventory (BDI) and the SCL-90 mean score[30],
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so higher scores of our baseline alexithymics on the psychiatry scale partly represent these anxiety 
and depression symptoms.
Thus our first hypothesis that alexithymic SUD patients show a higher rate of addiction severity 
has partly been confirmed, although the relationship did not concern direct addiction measures, 
but substance use related aspects.
Against expectations alexithymia did not have a negative influence on abstinence at follow- 
up, time in treatment and dropping-out. These outcomes are contrary to previous research [12, 
13].
We also expected worse therapeutic outcome results for alexithymic SUD-patients on the 
EuropASI change scores in comparison with non-alexithymic patients. But overall, alexithymics 
did just as well as non-alexithymics or even better. Male alexithymic patients managed to improve 
their social circumstances (EuropASI "work, education and income" domain) better than non- 
alexithymic male patients. But these social circumstances were at baseline worse for alexithymic 
patients, so there was more to improve for them. Only the DIF-factor in alexithymia was related 
to the improvement. DIF is also the factor that is most sensitive for change in mood and anxiety 
[31], Reducing depression and anxiety, as was the case owing to the improvement of the 
EuropASI "psychiatry" domain, could have stimulated patients to improve social circumstances 
and therefore be an explanation for the relation between the DIF-factor and the improvement 
of the "work, income and education" domain. In line with this argument, the changes in the 
EuropASI domains "work, education and income" and "psychiatry" were also related (r = .30; 
p < 0.001). Not only male but also female alexithymic patients improved more on this domain 
than non-alexithymic women. This improvement was relatively less because non-alexithymic 
female patients showed a larger improvement than male non-alexithymic patients. In addition 
older age and participating in the SDM-group were for women related to a better outcome on 
this domain.
Alexithymic patients in the TAU-group improved also better than non-alexithymics on the 
"drugs" and "family and social relations" domains. This difference was not found in the SDM- 
group, but alexithymics and non-alexithymics improved both very well on these domains. Again 
the baseline scores in both domains were larger for the alexithymic patients. Externally oriented 
thinking (EOT) was the responsible alexithymia factor that predicted the change in these domains. 
In previous research this factor was not related to improvement in outcome results[10, 32]. The 
part in the variance that was explained by EOT is relatively small (6% in both domains), so we are 
curious if this finding could be replicated in future studies.
Looking at the regression analyses we found that alexithymia was also positively related to the 
change of the "physical health" domain in the SDM-group (p = 0.06) and "psychiatry" domain in 
the TAU-group, but negatively to the change of the "physical health" domain in the TAU-group. 
Alexithymics did just like non-alexithymics very well in the SDM group regarding the "psychiatry" 
domain. On factor level DDF and EOT were involved in the change in the "physical health"
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domain and DIF in the "psychiatry" domain, but only small parts (5% - 8%) of the variances were 
explained by these factors. A shared decision making intervention makes it easier for patients with 
difficulty in describing feelings (DDF) to improve their physical complaints. However an externally 
oriented way of thinking (EOT) in SUD-patients makes it in regular CBT more difficult to improve 
physical health problems. The relation between the DIF factor and the change in the "psychiatry" 
domain, including aspects of anxiety and depression, is in line with previous remarks on this 
subject[31], Older age and participating in the SDM intervention, but not alexithymia predicted a 
worse outcome of the "alcohol" change score, unlike the results of a previously done study[10]. 
Alexithymia was also not related to the changes in the "legal" and "gambling" domains.
In contrast to our expectations, alexithymics performed just as well or even better than non- 
alexithymics on outcome results and therefore our second hypothesis was not confirmed.
In accordance with the findings of Rosenblum et al.[18] we also found that alexithymia can 
be a moderator in a more motivational enhancement like intervention (SDM) in comparison with 
a cognitive behavioural treatment as usual (TAU) intervention. But in our study alexithymia was 
not negatively associated with SDM. Alexithymics did just as good as or even better in the SDM 
group than in the TAU group. In our study SDM was a very structured add-on intervention, unlike 
the motivational enhancement versus the cognitive behavioural intervention in Rosenblum's et 
al. study. Perhaps our TAU had more unstructured motivational interventions in comparison with 
the intervention of Rosenblum et al. In addition our alexithymic patients could have experienced 
more support from the structural part of the SDM intervention than from the motivational 
enhancement therapy in the Rosenblum et al. study. This is in line with the findings of Lumley et 
al.[17] that interventions that are externally focused or are structured may be better suited for 
alexithymic patients.
Gender and age played ambivalent roles as predictors in the change of the EuropASI domains. 
In the TAU-group men performed better on the "physical health" domain and there was a trend 
forwomen to perform better on the "psychiatry" domain. For men there was more change in the 
"legal" domain, but their baseline score was much higher than for women (Mmen = 1.8, SD = 
2.0; Mwomen = 0.7, SD = 1.1; p < 0.001). Age was positively related with the change in alcohol 
severity and only for women with the change in the "work, education and income" domain, but 
negatively with the change in the legal section and for the TAU-group with the change in severity 
of the drugs domain.
Lumley et al. [17] and others [33-37] showed that in general alexithymia is related to negative 
treatment outcomes, but sometimes alexithymia did not interfere with the outcome results [38, 
39] and in 3 studies alexithymia was associated to some positive results [17], One of the latter 
is the study of Rosenblum et al [18], so our results confirm that alexithymic SUD patients can 
profit from a structured cognitive behaviour therapy and even more when structured motivational 
aspects in the form of shared decision making are added.
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Limitations of our study were the absence of systematic urine or blood samples to confirm 
abstinence and not measuring depression and anxiety with better equipped instruments. The 
TAS-20, although the most commonly used measure of alexithymia, could be criticized for being 
a self-report scale. Many researchers have questioned if a self-report instrument can adequately 
assess deficits that alexithymics may not be aware of [26, 40]. To overcome this problem it is 
advised to perform multimethod alexithymia assessment with an observer scale included [6], SUD 
patients could have the wrong self-image. They can believe to be more alexithymic, but do not 
always have to perform in that way[41].
We conclude, based on our results, that there is no need to assess alexithymia at baseline. 
Alexithymic SUD-patients do not profit less from regular cognitive behavioural therapy than 
non-alexithymic SUD patients. Adding a structured motivational intervention as shared decision 
making improves outcome results for alexithymic SUD-patients, but predominantiy also for non- 
alexithymic SUD-patients. Thus the predictive value of measuring baseline alexithymia before an 
inpatient CBT-intervention for SUD-patients is of no clinical or therapeutical importance.
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Alexithymia is purported to be a negative prognostic factor for many psychological treatments 
[1]. In substance use disorders (SUD) alexithymia rates of up to 67% have been reported [2-4], 
but evaluations of therapy in alexithymic SUD patients are scarce. Group cognitive behaviour 
therapy (CBT) was relative successful in high-scoring alexithymic SUD patients [5], but alexithymia 
was associated with a lower attrition rate and with a larger Addiction Severity Index (ASI) alcohol 
composite score at follow-up [6].
From a clinical point of view we were interested in the predictive value of alexithymia at 
baseline on recovery. We hypothesized a negative relation of alexithymia with outcomes, which 
would be a strong argument for addressing alexithymia at intake and adjusting therapy for high 
alexithymic patients.
This study was part of a trial investigating a Shared Decision Making Intervention (SDMI) in 
addiction health care [7, 8], The main study indicated that compared with a 3-month inpatient 
treatment, addition of SDMI was associated with benefits in drug use and psychiatric problems 
[8].
A total of 187 abstinent SUD inpatients were assessed at baseline with the Dutch version of 
the Toronto Alexithymia Scale (TAS-20) [9, 10] and the European ASI (EuropASI) at baseline and 
3-month follow-up [11, 12] after an inpatient CBT as usual (CBT-TAU-group) or CBT with SDMI 
(CBT-SDMI-group). The TAS-20 is the most widely used measure of alexithymia [1], Although 
predominantly seen as a dimensional construct [13], a total score of 61 and above indicates a high 
alexithymia score, and scores of 51 and below indicate a low alexithymia score [14]. The EuropASI 
is a clinical research interview assessing problem severity in: physical health, employment, alcohol 
and/or drug use, legal, family/social and psychiatric. All patients have been diagnosed according 
to DSM-IV-TR as having 1 or more substance-related disorders.
In all, 152 (81.3%) of the patients had follow-up interviews. Follow-up data for abstinence 
from 16 patients were missing. The availability of follow-up data did not differ between baseline 
high-scoring (78.3%; n = 54) and low-scoring alexithymics (83.9%; n =52) (x2 (1) = 0.67, p = 
0.42).
The mean score of the TAS-20 at baseline was 55.7 (SD = 11.3). According to the cut-off 
score 36.9% (n = 69) were highly alexithymic and 33.2% (n = 62) were low-scoring alexithymics. 
Highly alexithymic patients had fewer years of education [ t(129) = 2.0, p = 0.05] and were more 
often unemployed [x2(1) = 3.8, p = 0.05] than low-scoring alexithymics. High-scoring alexithymics 
showed more problems in the "work, income and education" [ t(129) = 2.1, p = 0.04] and 
"psychiatry" domains [ t(129) = 5.2, p < 0.001]. In recently detoxified SUD patients, the incidence 
of symptoms of depression and anxiety is high and because of their relationship with alexithymia, 
a part of the high baseline alexithymia score could be interpreted as a state phenomenon [15, 
16]. The "psychiatric severity" rating scale of the Dutch EuropASI is correlated with depressive 
and anxiety symptoms [12], thus the higher scores of highly alexithymic patients in the psychiatry 
domain reflect these symptoms.
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The mean time of treatment (in days) for highly alexithymic patients (M = 116.0, SD = 
58.9) was not different from low-scoring alexithymics [M = 105.1, SD = 48.6; t(129) = 1.14, 
p = 0.26], and also the rate of completers was similar between high- (50,7%) and low-scoring 
alexithymics [43,5%; %2 (1) = 0.68, p = 0.41]. Fifty-four percent of the high-scoring and 45.7% 
of the low-scoring alexithymics were abstinent at follow-up [%2 (1) = 0.67, p = 0.41 ]. Alexithymia 
measured as a continuous variable was not related to abstinence [MTas = 55.4 (SD = 10.1) 
for abstinent patients; MTas = 55.3 (SD = 12.8) for non-abstinent patients, t(134) = 0.02, p = 
0.98], So alexithymia did not, contrary to previous research reports, have a negative influence on 
abstinence at follow-up, time of treatment and dropping-out [17, 18].
The study population improved on all EuropASI domain scores (Cohen's d between 0.33 
for "physical health" and 1.27 for "family and social relations", all p < 0.001). We stratified 
EuropASI change scores (baseline minus follow-up) for intervention type (CBT-SDMI versus CBT- 
TAU) because of interaction effects between intervention type and alexithymia. Differences 
between baseline high- and low-scoring alexithymic patients were found for the "work, income 
and education" domain in the CBT-SDMI group and for the "family and social relations" and 
"drugs" domains in the CBT-TAU-group (table 1).
Because of a strong support for alexithymia as a dimensional score [13] we also performed 
linear regression analyses with TAS-20 score as a continuous independent variable. In the CBT- 
TAU group, TAS-20 score was negatively associated with change in the "physical health" domain 
(P = -.27, p = 0.01), but positively with changes in the "drugs" (|3 = .22, p = 0.04), "family and 
social relations" (p = .26, p = 0.02), and "psychiatry" (f5 = .24, p = 0.03) domains.
Overall, highly alexithymic patients improved on the EuropASI change scores at least equally 
well as low-scoring alexithymic patients and alexithymia as a continuous score was predominantly 
positively associated with these change scores. However, statistically significant differences should 
be interpreted with caution because of the many tests that were performed.
Our results show that highly alexithymic SUD patients can profit from CBT with or without 
SDMI, and that the degree of alexithymia is not negatively related with resulting outcomes.
Limitations of our study were the absence of systematic urine or blood samples to confirm 
abstinence, and not having performed multi-method alexithymia assessments with an observer 
scale included [2]. There is critique of alexithymia as a categorical construct and the stability of 
alexithymia is under debate [13]. However, in answering our clinical question on whether a highly 
alexithymic SUD patiënt should be treated differently at the beginning of treatment, we made use 
of the two extremes of the categorical classification of alexithymia.
As highly alexithymic SUD patients performed very well and alexithymia was associated with 
the treatment outcomes, CBT may be used in this population even if patients present alexithymic 
features at intervention entry.
Multivariate linear regression analyses predicting change (baseline -  follow-up) in EuropASI domains "physical 
health", "work, income and education", “alcohol", "drugs" Z'legal", "family and social relations", and 
"psychiatry" from baseline high-scoring alexithymic patients (TAS-20 > 60) versus low-scoring alexithymic 
patients (TAS-20 < 52), stratified by intervention type and all controlled for gender and age (not shown). 
Age and gender were, if non-significant, removed unless R-squared changed by >10%. CBT-SDMI: n = 49; 
CBT-TAU: n = 57.
"physical health" P* P R2
CBT-SDMI .14 0.33 .02
CBT-TAU -.22 0.10 .05
“work, income and education"
CBT-SDMI .29 0.04 .15
CBT-TAU .23 0.08 .05
“alcohol"
CBT-SDMI .25 0.09 .11
CBT-TAU .17 0.89 .17
"drugs"
CBT-SDMI -.03 0.86 .01
CBT-TAU .27 0.04 .13
“legal"
CBT-SDMI -.16 0.24 .22
CBT-TAU .15 0.24 .09
"family and social relations"
CBT-SDMI .10 0.48 .01
CBT-TAU 28 0.03 .08
"psychiatry"
CBT-SDMI .02 0.89 .08
CBT-TAU .25 0.06 .10
Note: CBT-SDMI = Cognitive Behavioral Therapy- Shared Decision Making Intervention ; CBT-TAU = Cognitive 
Behavioral Therapy -  Treatment As Usual; p* : High- versus low-scoring alexithymic patients.
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Abstract
Background: The inability of individuals with Alcohol Use Disorders (AUD) to recognize and 
describe their feelings and cravings may be due to alexithymia. Previous researches have shown 
evidence for a negative influence of alexithymia on treatment outcomes in patients with AUD. 
Therefore, it was hypothesized that high alexithymic patients with AUD would benefit less from 
cognitive behavioral therapy (CBT) treatment compared with low alexithymic patients.
Methods: One hundred alcohol-dependent inpatients (DSM IV) were assessed with the Mini 
International Neuropsychiatric Interview for psychiatrie disorders, the Toronto Alexithymia Scale 
(TAS-20), and the European Addiction Severity Index (EuropASI). Baseline alexithymia, as a 
categorical and continuous variable, was used to compare or relate baseline demographic and 
addiction characteristics, time in treatment, abstinence, and differences in addiction severity at 
1-year follow-up. Analyses were performed using Chi-square, analysis of variance or Kruskal- 
Wallis, paired t-tests or Wilcoxon's signed rank tests, multivariate logistic, and linear regression 
models, as appropriate.
Results: The prevalence of high alexithymia (TAS-20 > 60) was 45%. The total TAS-20 score 
correlated negatively with years of education (r =-.21; p = .04) and positively with the psychiatry 
domain of the EuropASI (r = 23; p = .04). Alexithymia showed no relation to abstinence, time in 
treatment, or change in severity of alcohol-related problems on the EuropASI.
Conclusion: High alexithymic patients with AUD do benefit equally from inpatient CBT-like
treatment as low alexithymic patients with AUD.
Scientific significance: Multimethod alexithymia assessments with an observer scale have been 
advised to judge the relationship with resulting outcome in CBT.
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Introduction
Alexithymia is predominantly seen as a personality construct that is characterized by a difficulty 
in identifying and describing feelings, inability to discriminate between feelings and physical 
sensations, limited fantasy life, and an externally oriented way of thinking (1). The prevalence 
of alexithymia in population-based studies varies between 8% and 15% (2). Some researchers 
have reported the prevalence of alexithymia up to 67% (3) in patients with alcohol use disorders 
(AUDs). In the general population, alexithymia has been associated with increasing age, low 
educational level, poor perceived health, and depression (4, 5). Additionally, in substance use 
disorders (SUDs), alexithymia was related to state of anxiety and depression (6).
Alexithymia has also been related to several somatic and psychiatric disorders, especially 
somatoform, mood, anxiety (PTSD), eating, and SUD (7). However, the support for alexithymia as 
a risk factor for AUD is present, but limited (3, 7-11).
Alexithymia is a negative prognostic factor for psychological treatments regarding insight, 
emotional awareness, or therapeutic alliance (12). However, in highly structured cognitive 
behavioral interventions, alexithymic patients seem to perform equally well as non-alexithymic 
patients (12).
There is a lack of therapeutic evaluations for alexithymia in SUDs, including AUD. Evidence 
for a negative influence of alexithymia on attrition rates, abstinence, and other treatment 
outcomes is available for AUD (3, 7-9, 11); however, less or not at all for patients with drug-only 
or a combination of alcohol and drug use disorders (7, 13). Rosenblum et al. (14) demonstrated 
less substance abuse in high-scoring alexithymic patients with SUD following group cognitive 
behavior therapy (CBT) compared with a group motivational intervention. In a recent study from 
our research group, CBT showed to be as effective in high versus low alexithymic patients with 
SUD, independent of a structured motivational intervention add-on treatment (13).
Because of the high prevalence of alexithymia in patients with AUD and the indication that 
alexithymic patients with AUD benefit less from addiction treatments, we were concerned about 
the suitability of our regular addiction therapy programs for patients with AUD. Most of these 
programs are CBT-oriented and administered in combination with some form of motivational 
interviewing (Ml) (15). Patients are often asked to describe their feelings and cravings as part 
of these CBT interventions, and not properly responding to these questions can hinder the 
therapeutic relationship and, accordingly, have a negative influence on outcome results.
This study examined the following in patients with AUD: (a) the prevalence of alexithymia 
after successful detoxification; (b) the relationship between alcohol dependence severity and 
alexithymia (a positive correlation would support alexithymia as a risk factor for AUD); and (c) the 
predictive value of alexithymia on recovery after an inpatient treatment program based on CBT 
and motivational interviewing (Ml).
Method
Study sample
Alcohol-dependent male patients with AUD (DSM IV) were recruited consecutively from Novadic- 
Kentron, an addiction treatment center in the south of the Netherlands, and were tested after 1 
month of controlled abstinence. All patients were born in the Netherlands. This study was part of 
a research project that investigated the effects of the dopamine receptor agonist apomorphine on 
cognitive performance in male patients with AUD (16). After written informed consent, patients 
were screened for medical illness and axis I psychiatric disorders. Patients who required treatment 
for serious psychiatric disorders, such as psychotic or psycho-organic disorders, were excluded.
In this study, 100 alcohol-dependent inpatients, hospitalized between 2004 and 2007, 
participated and were assessed with the Toronto Alexithymia Scale (TAS-20) and the European 
Addiction Severity Index (EuropASI). The regional medical ethical assessment board approved this 
study (METiGG, protocol no.271).
Measures and procedures
Alexithymia was assessed at baseline with the Dutch version of the TAS-20 (17), which comprises 
three factors: (1) difficulty in identifying feelings (DIF), (2) difficulty in describing feelings (DDF), 
and (3) externally-oriented thinking (EOT). Each item consists of a five-point Likert scale that 
ranges from "completely disagree" to "completely agree." The TAS-20 provides a total score 
and three dimensional factor scores. We used the empirically derived cut-off points suggested 
by Taylor et al. (18); a total score of 61 and above indicates a high alexithymia score and scores 
of 51 and below indicate a low alexithymia score. A score from 52 to 60 represents a moderate 
degree of alexithymia.
Severity of substance use was established based on the EuropASI at baseline and at 1-year 
follow-up with the "alcohol," "drugs," and "psychiatry" domains of the EuropASI (19). The 
EuropASI is a clinical research interview tool designed to assess problem severity in seven areas 
of functioning; physical health, employment, alcohol and drug use, legal, family, social, and 
psychiatry. The seven severity domains, with scores that range from 0 (no problem) to 9 (extremely 
serious problem), were derived from this interview. The Dutch version of the Mini International 
Neuropsychiatric Interview (MINI) for psychiatric disorders version 2.1 (20) was used for detecting 
psychiatric, especially anxiety and depressive, disorders.
The participating treatment center used an inpatient cognitive behavioral approach with 
elements of Ml, relapse prevention, and social skills training. Interventions were primarily groups, 
but they also implemented individual components. In the Netherlands, Ml is widely known and 
used to motivate patients with SUD to start and stay in treatment (20).
The primary outcome parameter for recovery was abstinence at follow-up during the previous 
30 days. Secondary outcome parameters included alcohol use (less than 5 units per day in the
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previous year), time in treatment, and improvement between baseline and follow-up on the 
EuropASI domains "alcohol," "psychiatry," and "drugs," in case of comorbid drug abuse.
Data analysis
The prevalence of alexithymia is presented in percentages. Group comparisons of the baseline 
characteristics (Table 1); time in treatment; and abstinence of high, moderate, and low alexithymic 
patients were conducted using Chi-square for categorical data and analysis of variance (ANOVA) 
or the Kruskal-Wallis test for continuous data. Because of the critical discussion on alexithymia 
as a categorical variable (21), we also tested the relation of alexithymia as a continuous variable.
Changes between baseline and follow-up on the EuropASI severity scores were analyzed 
using paired Mest or Wilcoxon's signed rank test, as appropriate. Subsequently, "change scores" 
on the EuropASI severity scores were computed by subtracting the follow-up scores from the 
baseline scores. An ANOVA or the Kruskal-Wallis test was used to analyze differences in EuropASI 
"change scores" on domain level between baseline high, moderate, and low alexithymic patients. 
To estimate the effect size of changes on the EuropASI severity scores, Cohen's d ((jjl - p2) / o 1) 
was calculated between baseline and follow-up.
Multivariate logistic and linear regression models were performed with abstinence and the 
EuropASI "change scores," respectively, as the dependent variables. The predictor variables, 
based on previous studies (2, 3, 6), included age, presence of anxiety or mood disorders, time 
in treatment, and the total baseline or factor (TAS-20) alexithymia score. Factor scores were also 
used as independent predictor variables, apart from the total TAS-20 scores, because of the 
multi-faceted construct of alexithymia and the differences in validity and reliability of the different 
TAS-20 factor scores (22). Variables with a p-value of less than .2 in the univariate analyses 
were entered in a full multivariate model. Subsequently, non-significant variables, except the 
alexithymia scores, were removed, one by one, until -2 log likelihood deteriorated significantly 
(logistic regression) or R2 changed by more than 10% (linear regression). We included all patients 
with a baseline alexithymia assessment. Finally, all statistical tests were 2-sided, with p-values of 
less than or equal to .05 considered significant, and were performed using SPSS (IBM Corporation, 
Armonk, USA) for Windows (release 16.0).
Results
Prevalence of alexithymia
According to the cut-off score, 45% (N = 45) of patients had a high degree of alexithymia, 
24% (N = 24) had a moderate degree of alexithymia, and 31% (N = 31) had a low degree of 
alexithymia. The mean (SD) score of the TAS-20 at baseline was 58.0 (10.7). The mean (SD) scores 
of the factors DIF, DDF, and EOT were 20.2 (6.0), 16.4 (4.1) and 21.5 (4.8), respectively.
Baseline differences between high, moderate, and low alexithymic patients
Table 1 shows the baseline characteristics for the high, moderate, and low alexithymic patients. 
High alexithymic patients had obtained fewer years of education compared with moderate and 
low alexithymic patients. As a continuous variable, the total TAS-20 score correlated negatively 
with years of education (r=-.21; p = .04) and positively with the "psychiatry" domain (r=.23; p = 
.04). However, the prevalence of anxiety or depressive disorders did not differ for low, moderate 
or high alexithymic patients.
All (n = 100) patients were alcohol dependent, but only for 83 patients EuropASI data were 
available on their co-morbid drug abuse. No difference in degree of alexithymia was found 
between the only alcohol dependent (n = 50) or comorbid drug abuse patients (n = 33; Table 1).








(51 < TAS <61) (TAS >60) 
(n=24) (n=45)
X2 F P
Age (years) Mean (S.D.) (n=91) 44.2(9.2) 44.7(8.3) 40.8(9.7) 1.81 0.17
Relationship %  (n=92) 5.74 0.22
Married 30.8(4) 42.6(6) 23.1(3)
Divorced/widowed 27.3(9) 21.2(7) 51.5(17)
Never married 32.6(15) 17.4(8) 50.0(23)
Employment %  (n=87) 1.84 0.40
Employed 29.4(10) 17.6(6) 52.9(18)
Unemployed 32.1(17) 28.3(15) 39.6(21)
Education (years) Mean (S.D.) (n = 93) 13.2(3.7) 13.4(3.1) 11.6(3.1) 3.12 0.05
Co-morbid drug abuse %  (n=83) 3.95 0.14
Only alcohol dependent 30.0(15) 32.0(16) 38.0(19)
Alcohol and drug abuse 27.3(9) 15.2(5) 57.6(19)
Years alcohol use > 5 U Mean (S.D.) (n=93) 15.7(11.2) 19.9(9.9) 18.4(10.2) 1.02 0.37
Any anxiety disorder %  (n=90) 19.2(5) 4.5(1) 23.8(10) 3.72 0.16
Any depressive disorder %  (n=91) 29.6(8) 40.9(9) 26.2(11) 1.49 0.47
EuropASI-scores Mean (S.D.)(n=84)
Physical health 2.4(2.5) 2.8(2.5) 2.7(1.9) 0.25 0.78
Work, education and income 3.2(2.0) 4.6(1.8) 4.0(2.3) 2.90 0.06
Alcohol 6.0(1.1) 6.1(0.9) 6.3(1.3) 0.46 0.64
Drugs'(n=33) 4.2(1.9) 3.0(1.6) 4.7(1.4) 2.48 0.10
Legal 1.4(1.6) 1.3(1.6) 1.3(1.8) 0.00 1.00
Family/social relations 4.2(1.9) 4.6(1.6) 4.0(2.1) 0.75 0.48
Psychiatric 4.5(1.9) 4.6(2.1) 4.9(1.6) 0.45 0.64
Notes: SD = Standard Deviation;
1 Only patients with alcohol dependence and drug abuse
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Predictive value of baseline alexithymia on recovery
Time in treatment
Data were missing for 14 patients. The mean (SD) time in (inpatient) treatment (days) for high 
(N = 40), moderate (N = 20), and low (N = 26) alexithymic patients did not differ significantly 
[131 (94); 176 (125); 128 (109), F=1.46 (2,83), p = .24, respectively]. In addition, as a continuous 
variable, alexithymia (total TAS-20) was not related to time in treatment (r =-.02, p = .88).
Abstinence at follow-up
For 93 (93.0%) patients, follow-up data for relapse of alcohol use were available. Fifty (53.8%) 
patients were abstinent for alcohol during the previous 30 days at the 1-year follow-up. Twenty- 
two (53.7%) of the baseline high alexithymics were abstinent for alcohol, 15 (65.2%) of the 
moderate, and 13 (44.8%) of the low alexithymics [x2 (2) = 2.15, p = .34], For 6 of the 33 patients 
with comorbid drug abuse, data on abstinence at follow-up were missing. Seven (46.7%) of the 
baseline high alexithymic patients were abstinent for all substances at follow-up, two (50%) of 
the moderate and three (37.5%) of the low alexithymics [x2 (2) = 0.24, p = .89]. Total mean 
(SD) TAS-20 or factor (data not shown) scores did not differ between abstinent patients for 
alcohol (N = 50) and patients who had relapsed with alcohol (N = 43) [57.7 (10.0) and 57.7 
(10.8), t (91) = .00, p = 1.00, respectively] or between abstinent patients with comorbid drug 
abuse for all substances (N = 12) or with any type of relapse (N = 15) [57.3 (9.6) and 59.7 
(12.4), t (25) = .57, p = .58, respectively]. Based on these findings, logistic regression models with 
abstinence as the dependent variable were not performed. Baseline TAS-20 or factors did not 
predict abstinence at follow-up.
Alcohol abuse (greater than five units per day)
The median (Interquartile range, IQR: 25th to 75* percentile) number of months of more than five 
units of alcohol use per day during the past year was not significantly different between high | (N 
= 41), moderate (N = 23) and low alexithymic patients (N = 29; missing values: n = 7) [.0 (.0-3.0); 
.0 (.0-4.0); and 2.0 (.0-5.0), 1-1(2) = 2.60, p = .27, respectively]. TAS-20 total, as a continuous 
variable, was not related to the average number of months of more than five units of alcohol use 
per day during the past year (rs = .04, p = .70).
Changes in EuropASI domains
The outcome results at the 12-month follow-up consisted of the following: 65 (77%) of the 84 
patients on the EuropASI "alcohol" domain, 22 (67%) of the 33 mixed alcohol- and drug-using 
patients on the "drugs" domain, and 64 (75%) of the 84 patients on the "psychiatry" domain. 
The availability of follow-up data did not differ between baseline high, moderate, and low 
alexithymic patients [x2 (2) = .55, p = .76, %2 (2) = 4.08, p = .13, x2 (2) = .96, p = .62, respectively].
Alexithymia in aitohoklependent pstiai not relattd to ii
Patients improved on the EuropASI "alcohol" domain from a mean (SD) score of 6.3 (1.1) to a 
mean score of 3.3 (2.8) at follow-up [t (64) = 8.16, p < .0001] with a large effect size (Cohen's d 
= 2.7). In addition, the "psychiatry" domain showed a large improvement from a mean (SD) score 
of 4.7 (1.9) to 2.1 (2.7) [f (63) = 7.70, p <  .0001] (Cohen's d =  1.4). Patients with co-morbid drug 
abuse (A/= 22) improved on the "drugs" domain from a median (IQR: 25th to 75th percentile) of
5.0 (3.0-5.0) to .0 (.0-4.3) [z = -3.23, p = .001, r = -.51 ]. However, Kruskal-Wallis tests between 
baseline high, moderate, and low alexithymic patients on the "change score" of the EuropASI 
showed no significant differences for the "alcohol" and "psychiatry" domains. In patients with 
comorbid drug abuse, high alexithymic patients improved more so than low alexithymic patients 
(Table 2).
Table 2. EuropASI severity "change scores" (baseline minus follow-up) for baseline high alexithymic, moderate 












EuropASI-scores (n) Median (Interquartile Range)
Alcohol (n=19) 3.0 (4.5) (n=17) 3.0 (4.5) (n=29) 3.0 (5.0) 1.29 0.53
Drugs1 (n=8) 1.5 (5.3) (n=4) 1.5 (4.0) (n=10)5.0 (3.3) 6.79 0.03
Psychiatric (n=18)3.5(3.5) (n=17) 2.0 (4.0) (/i=29) 3.0 (3.5) 2.67 0.26
Note:1 only patients with alcohol dependence and drug abuse
Additionally, in multivariate linear regression models with EuropASI scores as dependent variables, 
baseline alexithymia, as a continuous variable, was only related to the change in the "drugs" 
domain in patients with co-morbid drug abuse (N = 22; Table 3). On the TAS-20 factor level, the 
DDF-factor was responsible (p = .46, p = .03; R2 = .21; Fchange = 5.28, p = .03).
Table 3. Multivariate linear regression analyses predicting change in EuropASI domains "alcohol", "drugs" 
and "psychiatry" from baseline to follow-up from baseline total TAS-20, age, time in treatment, change in the 
"psychiatry" domain* andpresence ofan anxiety or mood disorder. Non-significant variables, except TAS-20, 
were removed until R2 changed by more than 7 0%.
P P /?* Fchange P
"alcohol" (n = 60) 
Anxiety disorder -.23 0.07 .18 3.94 0.01
"Psychiatry" change .33 0.01
TAS-20 at baseline .15 0.24
"druas" (n = 22)
TAS-20 at baseline .43 0.04 .19 4.56 0.04
"Dsvchiatrv" (n = 64)
TAS-20 at baseline .07 0.56 .01 0.34 0.56
Note: * the "psychiatry" domain was only used as an independent variable in the regression analyses on the 
"alcohol" and "drugs" domains.
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Disciission
This study showed that the level of alexithymia had no relation to abstinence, time in treatment, 
or change in severity of alcohol-related problems after an inpatient CBT-oriented treatment in 
patients with AUD. Therefore, alexithymia is unlikely to be a negative prognostic factor in the 
CBT-treatment of patients with AUD.
Specifically, we found a high prevalence (45%) of (high) alexithymia in the abstinent inpatient 
AUD population, which is in line with previous studies (3). Our baseline data also showed limited 
evidence for associations between alexithymia and severity of AUD. This supports a review on 
this topic (3), which reported mixed evidence to suggest an association between alexithymia and 
severity of alcohol dependence. Worse scores for high alexithymic patients regarding years of 
education are in accordance with population-based studies (4, 5) and inpatient SUD-populations 
(18) but not found in a Turkish study (23). Our results should be interpreted with caution because 
of the many statistical tests performed.
The "psychiatry" domain of the Dutch EuropASI is moderately correlated with anxiety and 
depression symptoms (19). These symptoms are common in newly detoxified patients with AUD 
and are related to alexithymia (6). In the current data, as in our previous research on an inpatient 
SUD-population (13), alexithymia as a continuous variable was related to the "psychiatry" 
domain. Therefore, we cannot exdude that a part of higher baseline alexithymia scores could be 
interpreted as a state phenomenon that reflects momentary anxiety and depression symptoms 
(6, 24). However, for alexithymia as a categorical variable no difference on the "psychiatry" 
domain was found, nor differences in the prevalence of anxiety and depressive disorders, as 
measured with the MINI. Perhaps these anxiety and depression symptoms are more characteristic 
of addiction-related symptoms, for instance of delayed withdrawal, than specific for anxiety or 
depressive disorders.
Contrary to expectations and previous reports, yet conformed in another small study (10), 
alexithymia did not have any influence on abstinence at follow-up in patients with AUD (8, 9). 
We also did not find a relation between alexithymia and treatment attendance, in line with an 
outpatient treatment for patients with SUD, including patients with AUD (7). In our previous 
study of an inpatient SUD population, findings confirmed this lack of a relationship between 
alexithymia and abstinence, time in treatment, and drop-out at follow-up (13). We expected 
worse therapeutic outcomes for high alexithymic patients with AUD on the EuropASI change 
scores in comparison to low alexithymic patients. However, overall, high alexithymics did equally 
well as low alexithymics on the "alcohol" and "psychiatry" domains and alexithymia, as a 
continuous variable, was not related to change in these domains.
Regarding the "alcohol" domain, thisfinding is in line with our research on a SUD population 
(13); however, contrary to an outpatient AUD population with a much shorter follow-up (7). The 
mean (SD) total TAS-score in this population was 48.3 (12.7), which was considerably lower than
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58.0 (10.7) in the current study. This finding could hinder a proper comparison between these 
studies.
High alexithymics in the patients with AUD with drug abuse performed even better on 
the "drugs" domain than did low alexithymics as confirmed by the regression analysis with 
alexithymia as a continuous independent variable (Table 3). This finding could not be explained by 
an improvement in anxiety or depressive symptoms as measured by the change in the "psychiatry" 
domain of the EuropASI. The DDF-factor was the responsible alexithymia factor; however, this 
result was based on a very small sample (N = 22) and should be interpreted with caution. In a 
previous study (7), alexithymia variables were not related to a change on the "drugs" domain. 
However, in our study on an inpatient SUD population (13), a positive relation between the total 
TAS-20 and the "drugs" domain was found. Of note, the EOT-factor was responsible in the later 
study. As DDF and EOT are very different factors of the alexithymia concept, these outcomes are 
not consistent and therefore probably the result of chance findings.
However, based on these findings, alexithymia, as measured with the TAS-20, is unlikely to be 
a negative prognostic factor in the treatment of drug or combined drug-alcohol related disorders.
Previous research has shown that, in general, alexithymia is related to negative treatment 
outcomes. However, sometimes alexithymia does not interfere with the outcome results; in three 
studies alexithymia was associated with some positive results (12,14). Our current results confirm 
that inpatient alexithymic patients with AUD, as we already found for a mixed drug and alcohol 
inpatient SUD population (13), can benefit from a CBT-oriented treatment.
Limitations of this study included the absence of systematic urine or blood samples to confirm 
abstinence and not measuring the change in depression and anxiety symptoms with more sensitive 
instruments. Our treatment interventions were also primarily group based and we did not check 
how much time was spent on individual interventions and coaching, neither did we record the 
differences in outpatient (after inpatient) treatment. Therefore, more individual attention for high 
alexithymic patients cannot be ruled out. The TAS-20, the most widely used measure of alexithymia, 
could also be criticized for being a self-report scale and for its psychometric shortcomings in 
alcohol-dependent populations (22). Some researchers have questioned whether a self-report 
instrument can adequately assess deficits that alexithymic patients may not be aware of (17). As 
a result, multimethod alexithymia assessments with an observer scale have been advised (25).
In conclusion we found that high alexithymic patients with AUD do benefit equally from 
inpatient CBT-like treatment compared to this treatment with low alexithymic patients with AUD. 
Thus, in contrast to the outcomes of previous studies (7,12,13,15), we did not find an argument 
for measuring baseline alexithymia before an inpatient CBT-like intervention for patients with 
AUD or making therapeutic adjustments for high alexithymic patients with AUD.
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Abstract
The construct of alexithymia as a vulnerability factor for Substance Use Disorders (SUD) is 
under debate, because of conflicting research results regarding alexithymia as a state or trait 
phenomenon. The absolute and relative stability of alexithymia were evaluated in a pre-post 
design as part of a randomised controlled trial, controlling for several co-variates. Assessments 
were done with the Toronto Alexithymia Scale (TAS-20) and Addiction Severity Index (EuropASI) 
at baseline and follow-up of a 3-month trial of inpatient Cognitive Behavioural Therapy (CBT) 
with or without a Shared Decision Making intervention for 187 SUD patients. Paired sample 
t-tests and analyses of variance were performed to assess absolute stability, intra class correlations 
coefficients were calculated for relative stability and multivariate linear regression models were 
used to evaluate the relation between co-variates and change in alexithymia. Mean level 
reduction of total TAS-20 and two subfactors demonstrated no absolute stability, but change in 
alexithymia differed for low, moderate and high alexithymics. Relative stability of alexithymia was 
moderate to high for the total population, but differed for patients with low, moderate and high 
alexithymia scores. The EuropASI "psychiatry" domain, covering anxiety and depression, was 
related to alexithymia, but CBT-related variables were not. In conclusion, alexithymia is partly a 
state-dependent phenomenon, but not a stable personality trait in this SUD-population.
Introduction
Alexithymia refers to the difficulty in identifying and describing feelings, the inability to discriminate 
between feelings and physical sensations, having a limited fantasy life and the inclination to an 
externally oriented way of thinking (Sifneos, 1973). The Toronto Alexithymia Scale (TAS-20) is 
worldwide the most frequently used assessment instrument for alexithymia and includes three 
factors: (1) difficulty in identifying feelings (DIF), (2) difficulty in describing feelings (DDF) and (3) 
externally oriented thinking (EOT) (Bagby et al., 1994).
A Dutch study (van Rossum et al., 2004) reported 54% of alcohol use disorder (AUD) patients 
to be alexithymic with a mean score of 56 on the TAS-20, a finding that is in accord with research 
on alcohol related disorders in other studies (Thorberg et al., 2009). In other substance use 
disorder (SUD) populations alexithymia rates up to 67% have been found (Taylor et al., 1997; El 
Rasheed AH, 2001; Dorard et al., 2008).
Based on a reduction in alexithymia scores after detoxification in a homogeneous AUD 
population, it is suggested that alexithymia is a state-related phenomenon resulting from 
anxiety and depression (Haviland et al., 1988). In a comparable study with a heterogeneous 
SUD population (Pinard et al., 1996), however, no change in alexithymia scores was found and 
alexithymia appeared to be a stable trait. In a recent study in homogeneous AUD-patients the 
absolute and relative stability of alexithymia was evaluated during alcohol withdrawal; an absolute 
reduction ( i.e. no absolute stability) of alexithymia scores was found (de Timary et al., 2008). The 
observed high relative stability over three time points, as well as the restricted influence of anxiety 
and depression, supported the view that alexithymia is a stable personality trait rather than a 
state-dependent phenomenon. The absolute decrease in alexithymia mean level score was in this 
study completely explained by a decrease of the DIF-factor.
In the literature there is an extensive debate on the state versus trait concept of alexithymia 
that focuses on the concept of absolute and relative stability of alexithymia as a personality 
characteristic. Previous research showed that stability status may change according to the 
population that is studied (Pinard et al., 1996; Honkalampi et al., 2001; Luminet et al, 2001; 
Rufer et al., 2004; Saarijarvi et al., 2006; Luminet et al., 2007; Stingl et al., 2008; de Timary et 
al., 2008).
Absolute stability refers to the extent to which average personality scores or trait levels of a 
population change. It is assessed by mean-level differences over time. These indicate if and in 
which direction the population as a whole is changing (Caspi et al. 2005). A systematic review 
or meta-analysis on the stability of alexithymia as a personality trait does not exist, but a meta- 
analysis of longitudinal studies of personality traits, according to the Five-Factor Model provided 
evidence for the continued plasticity beyond age 30 (Roberts et al., 2006).
Relative or rank-order stability indicates the extent to which the relative differences among 
individuals remain the same over time and is assessed by test-retest correlations (Caspi et al.
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2005). From a meta-analysis of the rank-order stability of personality, also based on the Five- 
Factor Model, test-retest correlations were moderate in magnitude over time (Roberts and 
DelVecchio, 2000). There was an increase with age and a decrease with increasing intervals 
between the observations. Rank-order stability peaked sometime after age 50, at a level below 
unity, thus also indicating that personality traits continue to change throughout adulthood. Both 
meta-analyses (Roberts and DelVecchio, 2000, Roberts et al., 2006) demonstrate that personality 
trait development is not just a phenomenon of childhood or adolescence but continues during 
adulthood.
Alexithymia has been associated with negative treatment outcomes in different SUD 
populations (Loas et al., 1997; Ziolkowski et al., 1995; Cleland et al., 2005), which could be a 
rationale for addressing alexithymia in treating SUD patients. However, only as a stable personality 
trait alexithymia can be an autonomous vulnerability factor for SUD, as has also been suggested 
by de Timary et al. (2008). As a state phenomenon alexithymia is not an autonomous vulnerability 
factor, because, as has been shown, it is highly related to anxiety and depression in different 
populations (Haviland et al., 1988; Honkolampi et al., 2000). Anxiety and mood disorders both 
have a high co-morbidity with SUD and are predictors themselves for SUD (Compton et al., 2007; 
Grant et al., 2009).
The stability of alexithymia during or after treatment was investigated in several studies with 
conflicting results with regard to absolute stability. Most studies, however, supported the relative 
stability of alexithymia (Porcelli et al., 2003; Rufer et al., 2004; Micolajczak et al., 2006; Rufer 
et al., 2006; Saarijarvi et al., 2006; Luminet et al., 2007; Spek et al., 2008; Stingl et al., 2008). 
Depression was as a co-variable related to change in mean level alexithymia scores, especially in 
the DIF factor, but there was little or no relation to the EOT factor (Luminet et al., 2001).
There has been little research into the effects of psychotherapy on alexithymia and the available 
results are ambiguous. Some studies reported no change (lancu et al., 2006), whereas others 
found a decrease in alexithymia during treatment (Lumley et al., 2007). In all these studies, the 
interventions were not specifically aimed at reducing alexithymia; thus, the changes seen could 
have reflected a reduction in associated symptoms such as depression, anxiety or psychological 
stress (Stingl et al., 2008).
Only a few reported studies (Beresnevaite, 2000; Gay et al., 2008) were specifically aimed at 
reducing alexithymic characteristics. In one of the studies group psychotherapy was associated 
with a decrease in mean levels of alexithymia with a resulting favourable influence on the clinical 
course of patients with Coronary Heart Disease. But the relative stability was still high 2 years 
after therapy (Beresnevaite, 2000).
Evaluations of alexithymia in homogeneous and heterogeneous SUD (Keiler et al., 1995; 
Rosenblum et al., 2005) did not showa specific impact of various therapies on alexithymia scores. 
However, in one study (Rosenblum et al., 2005) alexithymic SUD patients profited more from a 
cognitive behavioural treatment (CBT) than from a motivational enhancement intervention.
Given the conflicting results concerning the stability of alexithymia in detoxifying or recently 
detoxified homogeneous AUD and heterogeneous SUD populations (Haviland et al., 1988; 
Pinard et al., 1996; de Timary et al., 2008) and the assumption that alexithymia only as a stable 
personality trait is a vulnerability factor for SUD, we were interested in evaluating the stability 
of alexithymia in a detoxified heterogeneous SUD-population after an inpatient treatment 
intervention. If alexithymia were not a stable personality trait and therefore not a vulnerability 
trait for SUD, there would be no need to assess and address alexithymia in SUD patients. Because 
the therapy was not specifically aimed at reducing alexithymic characteristics, we hypothesized 
that a) a mean level reduction of alexithymia and factor scores relates to a reduction in anxiety 
and/or depression, b) no differences in change of mean level alexithymia scores will be observed 
between "low", "moderate" and "high" alexithymic patients, when controlled for anxiety 
and depression c) there is a moderate to high relative stability of alexithymia and d) there is 
no difference in relative stability between "low", "moderate" and "high" alexithymic patients. 
In addition if it is shown that variance in follow-up alexithymia could be better predicted by 
baseline alexithymia than "state" conditions, like anxiety and depression, this would support the 
argument for the relative stability of alexithymia.
Msthods
Subjects
Subjects were inpatients recruited from three addiction treatment centres in the East and South 
part of the Netherlands: Vincent van Gogh Institute, department Addiction Treatment, Novadic- 
Kentron and Tactus Addiction Treatment. The main study comprised a randomized controlled trial 
of Shared Decision Making (SDM) that was carried out from January 2005 to December 2006.
All 261 inpatients hospitalized during the study period with different forms of SUD were 
assessed for eligibility. Due to exclusion criteria (being under the age of 18, insufficiënt knowledge 
of the Dutch language, severe psychiatric co-morbidity precluding to take part in the study or no 
signed informed consent), refusing or early withdrawal, a total of 227 patients were randomised. 
Because seven patients later refused to participate and eight patients could not start because 
of an untimely stop at one study location, 107 patients started the SDM-intervention (SDM- 
CBT) and 105 patients started in the control group: decision making as usual, i.e. treatment 
as usual (TAU-CBT). However, TAS-20 baseline data were only available for 187 patients and 
complete TAS-20 follow-up data for 140 and incomplete (i.e. not all TAS-20 dimensions) for 
151 patients. All patients had been diagnosed according to DSM-IV-TR as having one or more 
substance related disorders. At follow-up evaluation, patients received a voucher for EUR 20. The 
study was approved by the Dutch Ethical Assessment Committee for Experimental Investigations 
on People (No. 4.108).
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Interventions
SDM-CBT was an add-on intervention on a standardised 3-month inpatient course of CBT with 
elements of motivational interviewing (Ml), relapse prevention, social skills training and both 
individual and group components. SDM-CBT was a structured approach to reach a treatment 
agreement over five sessions and was also partly based on Ml-techniques (Miller, 1996). TAU-CBT 
group received the same standardised 3-month inpatient CBT without the SDM-intervention. In 
the Netherlands Ml is well known and used to motivate SUD patients to participate in treatment. 
In the SDM-CBT group Ml was applied by protocol to evaluate indicated treatment goals. In the 
TAU-CBT group Ml was also used but in an unstructured way and all participating centres used 
similar, unstructured, procedures to reach treatment agreement with patients. For a detailed 
explanation of the interventions, see Joosten et al. (2009).
For the alexithymia study we pooled the two groups (SDM-CBT and TAU-CBT) and controlled 
in the analyses for intervention.
Instruments
Alexithymia was assessed at baseline and at 3-month follow-up after a 3-month inpatient 
treatment using the Dutch version of the TAS-20 comprising three dimensions: (1) difficulty in 
identifying feelings (DIF), (2) difficulty in describing feelings (DDF) and (3) externally oriented 
thinking (EOT). Each item consists of a five-point Likert scale ranging from "completely disagree" 
to "completely agree". The TAS-20 can be analysed in its entirety or the three components can 
be analysed separately (Kooiman et al., 2002, Taylor et al., 1997). The TAS-20 total scores were 
categorised according to the empirically derived cut-off points suggested by Taylor et al. (Taylor 
et al., 1997): scores of 61 and above represent a "high" degree of alexithymia; scores of 51 or 
below indicate a "low" degree and from 52 to 60 a "moderate" degree of alexithymia. The 
Dutch total TAS-20 showed a good internal consistency in student and outpatient psychiatric 
populations with Cronbach's a varying between 0.79 and 0.82. The internal consistency for the 
DIF-factor was good, for the DDF-factor moderate to good and for the EOT-factor unsatisfactory 
(Cronbach's a: 0.52 - 0.66). (Kooiman et al., 2002)
The substance disorder was assessed and typified by using the Composite International 
Diagnostic Interview, Substance Abuse Module (CIDI-SAM) at baseline (Compton et al., 1996). 
The CIDI-SAM is an expanded and more detailed version of the substance use sections of the 
CIDI. The interview questions address the diagnostic criteria of DSM-IV (American Psychiatric 
Association, 1994) and ICD-10 (World Health Organization, 1992) psychoactive substance use 
disorders.
Severity of substance use was established on the basis of the European Addiction Severity 
Index (EuropASI) at baseline and at 3-month follow-up , that is, 3 months after finishing the 
3-month inpatient treatment (McLellan et al., 1980; Hendriks et al., 1989). The EuropASI is 
a clinical research interview designed to assess problem severity in 7 domains of functioning:
physical health, employment, alcohol and/or drug use, legal, family/social and psychiatric. The 
Dutch version of EuropASI used in the present study also indudes gambling. Eight severity scores 
that could range from 0 (no problem) to 9 (extremely serious problem) were derived from this 
interview. The psychiatric severity rating of the Dutch ASI is moderately correlated with the 
Beek Depression Inventory (BDI) (Beek et al., 1961) and the Symptom Check List - 90 (SCL-90) 
(Derogatis et al. 1973) mean score. Subscales of the SCL-90 also show moderate correlations with 
the psychiatric severity rating, with coefficients ranging from 0.48 for "depression" to 0.52 for 
"anxiety" (Hendriks et al., 1989).
Independent interviewers, not related to the treatment of patients, with a bachelor's or 
master's degree in psychology carried out the 3-month follow-up measurements.
Statistical analysis
The absolute stability of the TAS-20, factor scores and EuropASI severity domains between 
baseline and 3-month follow-up were tested with paired f-tests. Cohen's d = (p1 - p2) / o1 
was calculated to determine the effect sizes for significant variables. Cohen defines d of 0.2, 
0.5 and 0.8 as small, medium and large effects, respectively (Cohen, 1988). The differences in 
absolute stability between "low", "moderate" and "high" alexithymia scores were also tested 
by comparing the difference scores (subtracting baseline from follow-up alexithymia scores) with 
analysis of variance. Intraclass correlations were used to assess the relative stability of TAS-20 and 
factor scores between baseline and follow-up.
Multivariate linear regression models were performed with total alexithymia and factor scores 
at follow-up as the dependent variables. The predictor variables, partly based on previous research 
(Haviland et al., 1994, Rosenblum et al., 2005, Mattila et al., 2006, Joosten et al., 2009) were 
the EuropASI baseline and follow-up scores, age, gender, time in treatment, type of intervention 
(SDM-CBT or TAU-CBT) and baseline total alexithymia or factor scores. Effect modification was 
formally assessed by interaction terms between intervention type and baseline total alexithymia 
or factor scores. Variables with a p <0.15 in univariate analyses (correlations between predictors 
and the different dependent variables) were entered in a full multivariate model. Subsequently, 
non-significant variables were removed, one by one, until /?-squared changed by more than 10%.
To assess to what extent changes in alexithymia can be accounted for by therapy related 
variables, multivariate linear regression models were performed with TAS-20 and factor "change 
scores" (baseline minus follow-up scores) as the dependent variables and the EuropASI "change 
scores", age, gender, time in treatment, type of intervention (SDM-CBT versus TAU-CBT) and 
degree of baseline alexithymia as the predictor variables. Effect modification was formally 
assessed by interaction terms between intervention type and degree of baseline total alexithymia 
or factor scores. Variables with a p <0.15 in univariate analyses (correlations between predictors 
and the different dependent variables) were entered in a full multivariate model. Subsequently, 
non-significant variables were removed, one by one, until ft-squared changed by more than 10%.
All statistical tests were 2-sided, with a p-value < 0.05 considered to indicate statistical 
significance and performed using SPSS for Windows (release 16.0).
Results
Baseline characteristics
TAS-20 baseline data were available for 187 patients, with no specific cause for this loss of data. 
No differences in baseline characteristics were found between these 187 patients and the (212 - 
187) 25 other patients of theSDM-CBT andTAU-CBT groups (data not shown). Sixty-nine patients 
(36.9%) scored as "high" alexithymic, 29,4% (n = 56) "moderate" and 33.2% (n = 62) as "low" 
alexithymic. The mean baseline TAS-20 score for all patients was 55.9 (SD = 11.1). One hundred 
forty (75%) were male patients. Mean age was 40.7 (SD = 10.9) and mean years of education 
11.4 (SD = 3.0). Forty-four percent had never been married, 39% were divorced or widowed and 
17% were still married. Forty-four percent had no work and 94% were born in the Netherlands. 
In 54% alcohol was the substance of preference, cocaine or other stimulants in 11 % , cannabis in 
4%, polydrug use in 29% and other substances in 2%. There were no differences between men 
and women in substance use preference. To give insight in the most prominent differences of 
the degree of alexithymia on baseline characteristics, we compared the high and low alexithymia 
groups and left the moderate group out. "High" alexithymic patients did not differ from "low" 
alexithymic patients in gender, age, country of birth, relationship, type of substance dependence, 
substance preference, but fewer were employed [x2(1) =3.9, p = 0.05] and "high" alexithymics 
had fewer years of education [t<129) =2.0, p = 0.05]. On the EuropASI-scores they differed only 
on the "work, education and income" domain [M "high" alexithymics = 4.0 (SD = 1.8); M "low" 
alexithymics = 3.3 (SD = 1.9); t{ 129) = 2.1, p = 0.04] and the "psychiatry" domain [M "high" 
alexithymics = 6.8 (SD = 1.2); M "low"-alexithymics = 5.1 (SD = 2.4); f(129) = 5.23, p < 0.001)]. 
Alexithymia measured as a continuous variable was also related to years of education (r = -0.19, 
p = 0.01) and the EuropASI "psychiatry" section (r = 0.31, p < 0.001), but not to the "work, 
education and income" section (r = 0.12, p = 0.11).
No differences were found in percentages between high, moderate and low alexithymic 
patients regarding type of intervention [x2(2) =0.0, p = 0.99]. In the SDM-group 36.7% were 
high, 30.0% moderate and 33.3% low alexithymic. In the TAU-group 37.1 %  were high, 29.9% 
moderate and 30.0% low alexithymic.
Baseline characteristics showed no significant differences between completers and drop-outs 
for EuropASI-, TAS-20- and factor scores, age, gender and type of intervention (data not shown). 
No differences were found in total TAS-20 scores between the four main addiction types in our 
sample, based on the primary addiction of the patients, i.e. alcohol, poly drug, stimulants and 
other substances (data not shown)
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Follow-up data
Because of differences in missing values between the factor scores of alexithymia, complete 
TAS-20 scores for baseline and follow-up were availabie for 140 patients, DIF-scores for 148, 
DDF-scores for 151 and EOT-scores for 143 patients. Abstinence, drop-out and time in treatment 
were not different for baseline "low", "moderate" and "high" alexithymic patients (table 1). 
To be sure that we could pool the four main addiction types together we did an ANOVA on the 
difference scores for the total TAS-20 between baseline and follow-up and found no significant 
differences (data not shown). As part of the drop-out analyses we compared the 140 patients 
with complete TAS-20 follow-up scores with the 72 of the 212 baseline participants without 
these scores. Both groups differed on type of substance preference[x2(3) =8.8, p = 0.03] with 
55.8% of the TAS-20 FU-group showing a preference for alcohol, 6.5% for stimulants, 31.9% 
for poly drug use and 5.8% for other substances. For the group without TAS-20 FU scores the 
percentages were respectively 47.9%, 18.3%, 23.9% and 9.9%. Next, in the SDM-CBT group 
57.9% had TAS-20 FU scores and in the TAU-CBT group 74.3% [x2(1) =6.3, p = 0.01], Time in 
treatment was also different. The mean of the group with TAS-20 FU scores was 115.1 days (SD 
= 56.2) and for the group without, the mean was 92.9 days (SD = 40.4) [((210) =3.0, p = 0.003], 
No other differences were found (data not shown).













45.7% 50.0% 52.0% 0.40 0.82
Mean (SD) 105.1 (48.6) 106.2 (53.0) 116.0 (58.9) 0.81 0.45
Drop-out (%) 56.5 58.9 49.3 1.30 0.52
Absolute stability
The paired sample t-tests showed significant reductions in total TAS-20-, DIF- and DDF-scores 
from baseline to follow-up with small effect sizes. For the EuropASI domains the reductions at 
follow-up were all significant and effect sizes varied from small (d = 0.20: gambling) to large (d 
=1.27: family/social relations) (table 2).
Table 2. TAS-20 total and factor scores and EuropASI scores from baseline to follow-up: paired sample t-tests
Severity-scores 
Mean (SD)
Baseline Follow-up T P d (Cohen)
TAS-20 (n=140) 55.9 (11.1) 53.8(11.8) 2.3 0.02 0.19
DIF (n=148) 19.1 (6.0) 18.0(6.5) 2.1 0.04 0.18
DDF (n=151) 16.3 (4.3) 15.0(4.0) 3.8 <0.001 0.31
EOT (n= 143) 20.4(4.1) 20.6 (3.9) -0.4 0.67 -0.04
EuropASI scores (n=152)
Physical health 2.6 (2.1) 1.9 (2.0) 5.0 < 0.001 0.33
Work, education and Income 3.5 (1.8) 2.7 (2.0) 5.1 <0.001 0.39
Alcohol 5.3 (2.5) 3.4 (2.4) 9.6 < 0.001 0.72
Drugs 3.2 (3.2) 2.0 (2.6) 8.0 <0.001 0.34
Legal 1.5 (1.8) 0.4(1.1) 8.5 <0.001 0.58
Family/social relations 4.3 (1.5) 2.4 (2.1) 9.5 <0.001 1.27
Psychiatric 5.7 (2.0) 3.6 (2.4) 9.8 <0.001 1.10
Gambling 0.3 (1.0) 0.1 (0.6) 3.2 0.001 0.20
Note: TAS-20 = "Toronto Alexithymia Scale"; DIF = "Difficulty Identifying Feelings"; DDF = "Difficulty 
Describing Feelings"; EOT = "Externally Oriented Thinking"
The mean change scores (baseline minus follow-up) for the TAS-20 and the different factors 
between "low", "moderate" and "high" alexithymic patients were highly significant (table 3). 
Post-hoc analyses showed that the changes for the "high" alexithymics differed from the "low" 
alexithymics and, except for the DDF factor, also from the "moderate" alexithymics. "Low" 
alexithymics differed on the total TAS-20 and the DDF factor from the "moderate" alexithymics. 
The total and factor TAS-20 scores for "low" alexithymic patients were larger at follow-up 
compared with baseline, while the scores for "moderate" and "high" alexithymic patients were 
lower (the reduction was greatest in "high" alexithymics). ANOVA on the mean change scores 
of the EuropASI psychiatry domain, measuring also depression and anxiety, for baseline "low" 
(.M = 2.0, SD = 2.8), "moderate" (M = 1 6, SD = 2.6) and "high" (,M = 2.7, SD = 2.5) alexithymic 
patients indicated no significant differences [F(2,130) = 2.12, p = 0.12],
Table 3. Mean difference score tor TAS-20 and factor scores (baseline -  follow-up) for low (TAS-20 < 52), 












Total TAS-20 -3.8 (11.2) (52) 1.5 (9.8) (43) 7.9 (9.0) (52) 16.74 <0.001 3 > 2 >1
DIF -1.9 (6.1) (46) 0.8 (6.2) (45) 3.8 (6.0) (53) 10.79 <0.001 3 > 1,2
DDF -0.9 (4.3) (47) 1.7 (4.2) (46) 2.6 (3.4) (53) 10.20 <0.001 3,2 > 1
EOT -1.2 (4.8) (46) -0.8 (4.0) (44) 1.5 (3.8) (52) 5.91 0.003 3 > 1,2
Note: TAS-20 = "Toronto Alexithymia Scale"; DIF = "Difficulty Identifying Feelings"; DDF = "Difficulty 
Describing Feelings"; EOT = "Externally Oriented Thinking"
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Relative stability
Intraclass correlation (ICC) for the total TAS-20 between baseline and follow-up was 0.52, for 
DIF 0.45, DDF 0.44, and EOT 0.42 (all p < 0.001). This means that effect sizesfor relative stability 
were all on a moderate to high level. ICC's for patients with a baseline "low", "moderate" 
and "high" alexithymic score differed considerably, especially on the total TAS-20. Baseline 
"moderate" alexithymic patients had non-significant low ICC's (except for EOT) and "low" and 
"high" alexithymic patients had nearly all significant lowto moderate ICC's. Only the EOT factor 
demonstrated significant ICC's for all patients (table 4).
Table 4. Intra class correlations (ICCs) for TAS-20 and factors between baseline and follow-up for low, 
moderate and high baseline alexithymic patients





.30 (p = 0.02) (n = 45) 
.26 (p = 0.04) (n = 46) 
.33 (p = 0.01) (n = 47) 
.37 (p = 0.005) (n = 46)
-.06 (p = 0.67) (n = 43) 
.15 (p = 0.17) (n = 45) 
.09 (p = 0.26) (n = 46) 
.33 (p = 0.01) (n = 44)
.20 (p = 0.08) (n = 52) 
.22 (p = 0.05) (n = 53) 
.28 (p = 0.02) (n = 53) 
.23 (p = 0.05) (n = 52)
Note: TAS-20 = "Toronto Alexithymia Scale"; DIF = "Difficulty Identifying Feelings"; DDF = "Difficulty 
Describing Feelings"; EOT = "Externally Oriented Thinking"; ICC = Intra Class Correlation
In predicting TAS-20 at follow-up the EuropASI factor "psychiatry" at follow-up (p = 0.22) 
contributed a small part compared with the TAS-20 at baseline (p = 0.50) (table 5). Regarding the 
prediction of the DIF factor at follow-up baseline DIF contributed just a little more (p = 0.44) to 
the variance than "psychiatry" at follow-up (p = 0.29), age (p = 0.21) and the baseline EuropASI 
"alcohol" domain (p = -0.16). In predicting the DDF-factor at follow-up, the "drugs" domain at 
baseline contributed a smaller part to the variance (p = 0.20) than baseline DDF (p = 0.47). The 
"legal" domain at follow-up contributed to the variance (p = 0.19) of the EOT-factor at follow-up, 
but less than the baseline EOT factor (p = 0.41) (table 5).
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Table 5. Multivariate linear regression anaiysis predicting TAS-20 total and factor scores at follow-up from 
EuropASI severity scores, gender, age, time in treatment, intervention type and TAS-20 at baseline. Non- 
significant variables were removed until R-squared changed by more than 10%.
Factors P P R2 Fchange P
Total TAS-20 (n=140)
EuropASI .33 34.01 < 0.001
"Psychiatry"(FU) .22 0.002
TAS-20 at baseline .50 < 0.001
DIF(n=148)
EuropASI .34 18.00 <0.001




DIF at baseline .44 <0.001
DDF(n=151)
EuropASI .26 26.32 < 0.001
"Drugs"(Baseline) .20 0.007
DDF at baseline .47 < 0.001
EOT (n=142)
EuropASI .21 18.49 < 0.001
"legal"(FU) .19 0.01
EOT at baseline .41 <0.001
Note: TAS-20 = "Toronto Alexithymia Scale"; DIF = "Difficulty Identifying Feelings"; DDF = "Difficulty 
Describing Feelings"; EOT = "Externally Oriented Thinking"; FU = Follow-Up
Performing regression models with total TAS-20 and factors "change scores" as the dependent 
variables gender, type of intervention, time in treatment and all EuropASI "change scores" except 
the "psychiatry" and "drugs" domains did not have any predictive value. EuropASI "psychiatry" 
change score contributed small parts (p: 0.13 to 0.21) to the variance of the TAS-20 and factor 
"change scores" (table 6). Baseline alexithymia as a categorical variable explained larger parts of 
the variances (|3: 0.28 to 0.48). Age was negatively related to the change in the DIF factor and 
contributed minimally to the variance (p = -0.15). The "change score" of the EuropASI "drugs" 
domain was inversely related to the "change score" of the DDF-factor and explained a small part 
(P = -0.17) of the variance. For both the regression models no effect modification by treatment 
assignment was present.
Table 6. Multivariate linear regression analysis predicting TAS-20 "change" (baseline - follow-up) total and 
factor scores from EuropASI "change" scores (baseline - follow-up), gender, age, time in treatment, type of 
intervention and degree of alexithymia (low, moderate or high) at baseline. Non-significant variables were 
removed until R-squared changed by more than 10%.
Factors P P R2 Fchange P
Total TAS-20 (n=139)
EuropASI "change" .24 14.36 < 0.001
"Psychiatry" .21 0.007
Low vs. moderate alexithymia .25 0.005
Low vs. high alexithymia .48 <0.001
DIF (n=143)
EuropASI "change" .19 8.11 <0.001
"Psychiatry" .18 0.002
Age -.15 0.06
Lowvs. moderate alexithymia .20 0.02
Low vs. high alexithymia .38 < 0.001
DDF (n=145)
EuropASI "change" .16 6.74 < 0.001
"Drugs" -.17 0.04
"Psychiatry" .13 0.11
Low vs. moderate alexithymia .31 0.001













Note: TAS-20 = "Toronto Alexithymia Scale"; DIF = "Difficulty Identifying Feelings"; DDF = "Difficulty 
Describing Feelings"; EOT = "Externally Oriented Thinking"
Discussson
The baseline alexithymia mean score of 55.7 on the TAS-20 and the prevalence of "high" 
alexithymic patients of 37% is comparable to other reported homogeneous and heterogeneous 
SUD studies (de Timary et al., 2008; Dorard et al., 2008; Taylor et al., 1997). A higher score 
on the EuropASI "psychiatry" domain for alexithymic patients is in line with the higher scores 
on depression and anxiety in recently detoxified homogeneous AUD-patients (Haviland et al., 
1988; de Timary et al., 2008). However the EuropASI is not an optimal instrument for measuring 
depression and anxiety. More unemployment and less education match a larger score for "high" 
alexithymic patients on the EuropASI "work, education and income" domain, confirming previous 
epidemiological studies ( Saarijarvi et al., 1993; Mattila et al., 2006).
Unlike the study of Pinard et al (1996), but in accord with de Timary et al. (2008) we did not 
find absolute stability in total TAS-20 and factor scores. Pinard et al. (1996) found an insignificant 
increase in total TAS-20 and factor scores after 4-6 weeks of abstinence, but the study population
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was very small (n = 21). In the study of deTimary et al. the EOT factor, with no gender difference, 
and the DDF factor, only for men, showed absolute stability. The reduction reported by de Timary 
et al. (2008) in 14-18 days (difference score = 4.1, Cohen's d = 0.38) for the total TAS-20 was 
larger than the reduction we found (difference score = 2.1, Cohen's d =  0.19) in about half a year. 
A larger decrease in depression and anxiety during the detoxification process could be responsible 
for this difference. However the effect sizes (T1 - T3) for the reductions in BDI-scores (d = 0.89) 
and for STAI-scores (State-Trait Anxiety Inventory) (d = 0.95) in the de Timary et al (2008) study, 
were smaller than our effect size for the reduction in the EuropASI "psychiatry" domain (d = 
1.10).
Absolute changes in total TAS-20 scores vary for different populations and different 
interventions, but also regarding the different TAS-20 factors. We found mean level stability for 
the EOT factor and mean level changes for the total TAS and DIF and DDF scores, whereas others 
found mean level stability for DIF and EOT factors (Rufer et al., 2004), for DDF (only for men) and 
EOT factors (de Timary et al., 2008) or only for the DDF factor (Luminet et al., 2007).
However, our data demonstrated another prominent difference in mean level stability for the 
total TAS-20 and the factor scores between "low", "moderate" and "high" alexithymic patients. 
The most obvious change was a reduction for all TAS-scores in the "high" alexithymia group. 
In the "low" alexithymia group all the TAS scores increased. The "moderate" group showed 
a more ambivalent outcome with a reduction for the total TAS, DIF and DDF factors and an 
increase for the EOT factor. These results could not be explained by a related change in anxiety 
and/or depression, as measured by the EuropASI "psychiatry" domain. This phenomenon looks 
like a "regression toward the mean" and is to our knowledge not described in previous research 
on stability in alexithymia. Another study (Honkalampi et al., 2001) found, despite an absolute 
stability of TAS scores, a shift from categories of alexithymia at follow-up, but this could be 
explained by a related change of depression scores. Besides, the magnitude of change between 
the categories was difficult to interpret because of the borderline problems near the cut-off 
scores: a minimal change of scores near the cut-off points has more impact than a larger change 
of scores with more distance from the cut-off points. That is why we used numeric mean level 
scores for the analyses between the categories.
The results showed moderate levels of relative stability, with the lowest score for the EOT 
factor and the highest score for the total TAS-20. Unlike our results, the EOT factor appeared to 
be the factor with the highest relative stability in other studies (Honkalampi et al., 2001; Rufer 
et al.; 2004, Saarijarvi et al., 2006; Luminet et al., 2007; Speranza et al., 2007). The length of 
time between assessments has a known negative effect on relative stability, implying that larger 
changes occur as more time passes between assessments (Roberts et al., 2006). Relative stability 
in our patients after 6 months was lower than found in the general population after a period of 
a year (Honkalampi et al., 2001); 18 days of detoxification (de Timary et al., 2008); a 14-week 
intervention for depression (Luminet et al., 2001); a period of 6 months in patients with breast
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cancer (Luminet et al., 2007); 70-day or 6-year follow-up of multimodal cognitive behaviour 
therapy for obsessive-compulsive patients (Rufer et al., 2004; Rufer et al., 2006); 4-12 weeks 
of inpatient psychotherapy (Stingl et al., 2008). In a 5-year follow-up study of outpatients with 
major depression relative stability was lower, but not for the DDF and EOT factor (Saarijarvi et al., 
2006) and in a 3-year prospective study in patients with eating disorders (Speranza et al., 2007) 
relative stability, except for the EOT factor, had nearly the same magnitude. The differences in 
time are not, conforming to the prediction of Roberts et al. (2006), in a uniform way related to 
the degree of relative stability. However the difference in populations hampers making a clear 
comparison between these different groups, especially because the variety of interventions could 
have different impacts on the change in alexithymia (factors) and therefore also in their relative 
stability.
The differences in relative stability for baseline "low", "moderate" and "high" alexithymic 
patients hastoour knowledge not been described before. "Low" and "high" alexithymics showed 
low to moderate correlations and "moderate" alexithymics non-significant low correlations, 
except for the EOT factor. In spite of demonstrating the lowest ICC for the total sample, the 
EOT factor had the highest ICCs on categorical level in comparison with the total TAS and the 
two other factors. These findings plead against the alexithymia concept of a stable personality 
construct in this population.
The regression analyses showed that alexithymia at baseline was the best predictor of 
alexithymia at follow-up for total TAS-20 and factor scores, but explained at best a moderate part 
of the variance. Other variables, like age, the EuropASI domains "alcohol", "drugs", "legal" and 
even "psychiatry" contributed only minimally as predictors. In predicting alexithymia "change 
scores" changes in depression and anxiety, as measured with the EuropASI "psychiatry" domain, 
explained a minor part. When looking at change in alexithymia scores, a larger part of the change 
in alexithymia was explained by the baseline degree of alexithymia. Intervention-related variables 
as time in treatment or intervention type had no relation at all with the change of alexithymia 
scores.
In response to our questions and hypotheses, we found a mean level reduction of alexithymia 
and factor scores, however only for a small part related toa reduction in anxiety and/or depression, 
as measured with the EuropASI "psychiatry" domain. There were significant differences in change 
of alexithymia scores between baseline "low", "moderate" and "high" alexithymic patients, even 
when controlled for anxiety and depression. Relative stability for total TAS-20 and factor scores 
was moderate to high, but predominantly lower than described in previous research. However, 
relative stability showed remarkable differences for baseline "low", "moderate" and "high" 
alexithymic patients. In spite of a mean level reduction of alexithymia, for the greater part not 
related to anxiety and/or depression, we did not find a relationship with type of intervention. So 
we have insufficiënt arguments to attribute the difference in CBT-interventions to the reductions 
in alexithymia.
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In their meta-analysis Roberts et al. (2006) demonstrated that personality traits do not stop 
changing and their findings were most consistent with interactional models of personality 
development.
The interpretation of to what degree modifications of personality represent intrinsic 
maturational processes or reflect life experiences, perhaps facilitated by therapy or periods of 
abstinence, is currently under debate (Wilberg et al., 2009). Especially for SUD patients with 
a predominantly devastating lifestyle, it is conceivable that a 3-month inpatient therapy could 
be a catch-up period for normative change of personality traits. This process could be different 
for the individual patients and therefore be an explanation for the lower relative stability in 
comparison with other studies, where the treatments were perhaps less intensive or the variety 
in "normative change" possibilities between the patients was more limited. However, that 
does not explain the differences we found in stability between "low", "moderate" and "high" 
alexithymic SUD patients. Alexithymia could therefore in our patients partially be described as a 
state phenomenon, given the relation of the absolute stability of the TAS-20 with the changes 
in EuropASI-scores. However, the combination of the change in absolute stability not related 
to anxiety or depression, the differences in absolute stability between low, moderate and high 
alexithymic patients and especially the big differences of the relative stability between these three 
groups plead against alexithymia, measured with the TAS-20, as a stable autonomous personality 
trait in this population.
In future studies, especially in intervention studies, it would be interesting to compare the 
change of the alexithymia trait component with the change of other personality constructs, like 
the five-factor model. If changes in relative stability for alexithymia and these five factors are 
related, then that would be an argument for alexithymia as a stable personality trait. Because 
the differences between the low, moderate and high alexithymic patients in absolute and relative 
stability have not been reported in previous research, these results have to be replicated to be sure 
that this is not a chance finding. It would also be advisable to perform research on the stability 
concept of alexithymia with other alexithymia assessment instruments, like the Bermond Vorst 
Alexithymia Questionnaire, the Observer Alexithymia Scale and the Toronto Structured Interview 
for Alexithymia (Haviland et al., 2001; Vorst and Bermond, 2001; Bagby et al., 2006; Grabe et al., 
2009) and in a more homogeneous, such as a population only dependent alcohol.
Limitations of our study were the absence of systematic urine or blood samples to confirm 
abstinence and not measuring the change in depression and anxiety symptoms with more sensitive 
instruments, like the Hamilton Depression Rating Scale (Hamilton, 1967) or the BDI (Beek et al., 
1961). Next it would be better to perform multimethod alexithymia assessments with an observer 
scale included as the TAS-20 could be criticized for being a self-report scale and many researchers 
have questioned whether a self-report instrument can adequately assess alexithymia (Kooiman et 
al, 2002; Grabe et al. 2009). At least the heterogeneity in types of substance dependence of our 
sample could be criticized.
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Abstract
Previous research on substance use disorders (SUD) has yielded conflicting results concerning 
whether alexithymia is a state or trait, raising the question of how alexithymia should be 
addressed in the treatment of SUD patients. The absolute and relative stabilities of alexithymia 
were assessed using the Toronto Alexithymia Scale (TAS-20) and its subscales. In total, 101 
patients with SUD were assessed twice during a 3-week inpatient detoxification period while 
controlling for withdrawal symptoms and personality disorder traits. The relative stability of the 
total TAS-20 and subscales was moderate to high but showed remarkable differences between 
baseline low, moderate, and high alexithymic patients.
A small reduction in the mean levels of the total TAS-20 scores and those of one subscale 
revealed the absence of absolute stability. The levels of alexithymia were unrelated to changes 
in withdrawal, including anxiety- and depression-like symptoms. The differences between low, 
moderate, and high alexithymic patients in terms of the change in alexithymia scores between 
baseline and follow-up indicated a strong regression to the mean. The findings suggest that 
alexithymia in SUD-patients as measured using the TAS-20 is both a state and trait phenomenon 
and does not appear to be related to changes in anxiety- and depression-like symptoms.
Keywords: Alexithymia; substance use disorder; absolute stability; relative stability.
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Introduction
Alcohol misuse is an important public health problem that is related to mortality, reduced 
economic productivity, and other serious health-related issues (Ezzati et al., 2002; Smit et al.,
2006). The abuse of and addiction to substances, including alcohol and nicotine, cost the USA 
nearly 600 billion dollars a year in medical, economic, criminal, and social expenses (Harwood, 
2000; Office of National Drug Policy, 2004). Therefore, obtaining insight into the risk factors of 
substance use disorders (SUD) is important for developing novel methods to prevent and reduce 
substance-related harm.
Alexithymia may be a risk factor for SUD, particularly in the context of alcohol use disorders 
(AUD) (Taylor et al., 1997). Alexithymia is considered to be a deficit in emotion processing. 
More specifically, characteristics include difficulty identifying and describing feelings as well as 
discriminating between feelings and physical sensations. Individuals with alexithymia also show 
deficits in externally oriented thinking and are limited in their ability to fantasize or use their 
imagination (Sifneos, 1973). Overall, 45-67% of patients with SUD exhibit alexithymia (Taylor et 
al., 1997; Thorberg et al., 2009). There are indications that frontal lobe functioning is associated 
with alexithymia (Lyvers et al., 2011), and the association between alexithymia and alcohol use 
is mediated by anxious attachment (Thorberg et al., 2011a), alcohol expectancy (Thorberg et al., 
2011 b), and drinking motives (Bruce et al., 2012).
Early findings demonstrated a negative association between alexithymia and treatment-related 
outcomes, particularly in patients with AUD (Ziolkowski et al., 1995; Loas et al., 1997; Cleland et 
al., 2005). In 3 recent studies, alexithymia was unrelated to abstinence, attrition, or changes in 
AUD- or SUD-related problems following treatment (de Haan et al., 2011; de Haan et al., 2012b; 
Stasiewicz et al., 2012). However, alexithymia was associated with poor emotion regulation skills 
(Stasiewicz et al., 2012), which predict post-treatment levels of alcohol use (Berking et al., 2011) 
and may increase the risk for relapse (Bandura et al., 2003). Therefore, alexithymia remains a 
relevant problem in optimizing the treatment of SUD, particularly in patients with AUD.
An important clinical question is whether alexithymia is a mental state or a stable personality 
trait. In their review on alexithymia and SUD, Taylor et al. (1997) assumed that affective distress 
may contribute a state-dependent component to alexithymia. However, the high rates of 
alexithymia in SUD-patients in a stable phase of rehabilitation and with longlasting abstinence 
suggest an underlying trait structure as well (Taylor et al., 1997). In statistical terms, a stable 
personality trait is characterized by absolute and relative stability. Absolute stability refers 
to mean-level differences over time, which indicate whether and in which direction an entire 
sample or population is changing (Caspi et al., 2005; Roberts et al., 2006). However, individual 
differences in change reflect deviations from the overall mean level patterns. Relative stability, 
which is defined as the extent to which relative differences between subjects remain the same 
over time (Roberts and DelVecchio, 2006), is therefore an even more important indication of the 
stability of a trait. Relative stability is reflected in the strength of test-retest correlations.
Previous research revealed that alexithymia was not a stable personality trait in a sample of 
patients with SUD following inpatient treatment (de Haan et al., 2012a). A strong "regression to 
the mean" wasfound, indicating that low alexithymic patients with SUD at baseline scored higher 
at follow-up and high alexithymic patients at baseline scored lower at follow-up. The results 
also revealed large differences in relative stability between low, moderate, and high alexithymic 
patients with SUD. Both findings argue against alexithymia as a stable personality trait (de Haan 
et al., 2012a)
We discussed in a previous article that absolute and relative stability in total TAS-20 or TAS-20 
factor scores vary for different populations, including the general population and patients with 
diverse psychiatric disorders, which causes an extensive debate on the state versus trait concept 
of alexithymia in the literature (de Haan et al., 2012a).
Other alexithymia stability studies in SUD or AUD populations were conducted with detoxifying 
or recently detoxified patients and reported conflicting results. One study found a relative change 
of alexithymia in newly abstinent alcoholic inpatients, suggesting that alexithymia in SUD-patients 
is a state phenomenon (Haviland et al., 1988). In this study the change in alexithymia was not 
related to a change in depression-like symptoms, measured with the Beek Depression Inventory 
(BDI) (Beek and Steer, 1987) (Haviland et al., 1988). However, in a subsequent study, Haviland et al 
(1994) demonstrated with path analyses that a state of alexithymia in SUD-patients can result from 
severe anxiety- and depression-like symptoms, measured with the State-Trait Anxiety Inventory 
(STAI) (Spielberger, 1983) and the BDI. Another study (Pinard et al., 1996) reported no changes 
in the mean levels following detoxification and concluded that alexithymia is a stable trait. Only 
Haviland et al. (1988) investigated absolute and relative stability simultaneously. More recently, 
an absolute reduction in alexithymia was observed in patients with AUD during withdrawal, with 
high relative stability over a brief time period (de Timary et al., 2008). Alexithymia was defined in 
this previous study as a stable personality trait rather than a state-dependent phenomenon given 
the limited influence of anxiety- and depression-like symptoms and the observed high relative 
stability (de Timary et al., 2008). Anxiety- and depression-like symptoms were measured with the 
STAI and BDI. However, no data were available to examine differences in absolute and relative 
stability between low, moderate, and high alexithymic patients, rendering it impossible to detect 
a regression to the mean, in contrast to de Haan et al.'s (2012a) findings, which phenomenon 
was also suggested by Haviland et al. (1988).
In the aforementioned studies on alexithymia during or directly after detoxification, anxiety- 
and depression-like symptoms were probably SUD (including withdrawal) induced. However, no 
investigation had been reported if these anxiety- and depression-like symptoms derived partly 
from anxiety and depressive disorders independent from SUD. Neitherwas investigated, although 
suggested, if these anxiety- and depression-like symptoms were indeed part of or related to 
withdrawal symptoms.
During a detoxification period, withdrawal symptoms, including stress, anxiety-, and 
depression-like symptoms, change in severity and may affect the mental state of many patients 
with SUD. Therefore, a detoxification period appears to be a good opportunity to determine 
whether alexithymia is a state versus a trait in patients with SUD. A change in the absolute or 
mean level stability of alexithymia during detoxification indicates the sensitivity of alexithymia to 
a state, such as withdrawal, that affects the entire patiënt group. However, patients with SUD 
can be differentially affected by withdrawal symptoms during detoxification, a fact that can be 
captured by measures of relative stability. A strong personality characteristic or stable trait, which 
is best reflected in a high degree of relative stability, should be relatively independent of state 
factors.
A strong relationship with state factors, such as anxiety- or depression-like symptoms, and 
a low relative stability of alexithymia would support a more state-dependent phenomenon and 
argue against alexithymia as an autonomous trait-like SUD vulnerability factor (de Timary et al., 
2008). This means that addressing alexithymia in the treatment of patients with SUD would not 
be as necessary if alexithymia were defined primarily as a state-dependent phenomenon that 
occurs in response to stress, anxiety-, or depression-like symptoms. The treatment could then be 
focused specifically on the stress, anxiety, and depression components. In case alexithymia is a 
state-dependent phenomenon independent from other symptoms or disorders, information on 
the temporary character could be provided to patients to help them to overcome this period. 
However, if alexithymia is an independent, stable personality trait, it would be important to adjust 
our cognitive behavioral treatment (CBT) interventions to alexithymic patients with SUD with 
better treatment results as an expected outcome. In CBT, patients are expected to differentiate, 
name, and describe difficult experiences, such as cravings, withdrawal symptoms, anxiety, and 
mood states, which is difficult for patients with alexithymia.
Given the different results regarding the stability of alexithymia in detoxifying or recently 
detoxified SUD populations (Haviland et al., 1988; Pinard et al., 1996; de Timary et al., 2008), 
as well as the absence of a description of the differences between low, moderate, and high 
alexithymic patients, we conducted a prospective study of the stability of alexithymia to examine 
the stability of alexithymia during detoxification while controlling for withdrawal symptoms 
and personality disorder traits. These Controls were included given that withdrawal symptoms 
are supposed and personality disorder traits have been related to alexithymia in patients with 
alcoholism (De Rick & Vanheule, 2007; de Timary et al., 2008).
To address our hypothesis that alexithymia is primarily a stable trait in patients with SUD, 
we formed the following sub-hypotheses: 1) High relative stability of alexithymia scores would 
be found using the Toronto Alexithymia Scale (TAS-20). 2) Only slight differences in the degree 
of relative stability would be observed between low, moderate, and high alexithymic patients. 
This hypothesis was added because of previous findings regarding the differences between 
these 3 groups (de Haan et al., 2012a). 3) No change in the mean level of alexithymia scores
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would be observed (indicating absolute stability). 4) Few differences would be found between 
low, moderate, and high alexithymic patients with respect to pre-post changes in the mean 
level of alexithymia scores, indicating a limited regression to the mean. Additionally, to address 
our hypothesis of high relative and absolute stabilities, we expected to find that 5) baseline 
alexithymia, rather than state conditions, such as withdrawal symptoms (which are associated 
with anxiety- and depression-like symptoms), would predict the variance in follow-up alexithymia 
levels.
With respect to our alternative hypothesis that alexithymia is (partially) a state phenomenon, 
we predicted that 6) the change in alexithymia scores would be related to a change in withdrawal 
symptoms, including anxiety- and/or depression-like symptoms.
Methods
Participants
Between June and September 2004, 131 inpatients with SUD who were hospitalized for 
detoxification from alcohol and/or other substances for 3 or 4 weeks were recruited from 3 
addiction treatment centers in the Netherlands. During the detoxification process 30 patients 
dropped out too early and did not participate in the follow-up part of the study. The exclusion 
criteria included being under the age of 18, having insufficiënt knowledge of the Dutch language, 
having severe psychiatric co-morbidity (psychotic and severe mood disorders), undergoing a recent 
change in medication (except for detoxification), and providing no signed informed consent. All 
patients were diagnosed according to the DSM-IV as having 1 or more SUD and were abusing 
substances until the day of admission. Alcohol was the preferred substance of 41 %  of patients, 
6% preferred cocaine or other stimulants, 43% were poly-substance users, and 10% preferred 
other substances.
Procedure
During hospitalization, patients with SUD were detoxified with benzodiazepines and/or 
methadone. The maximum time span of the detoxification was 21 days. The treatment consisted 
of medical and nursing support aimed at completing the detoxification period without a 
psychotherapeutical intervention. Patients' urine was routinely analyzed twice per week and if 
alcohol or drug use was suspected.
During the research period, the patients were assessed twice (baseline and follow-up) using 
the TAS-20 and Subjective Withdrawal Scale (SWS) at a maximum interval (mean in days = 
14.1, SD = 3.3) of 3 weeks to obtain the highest difference in withdrawal symptoms. A baseline 
assessment that included the Assessment of DSM-IV Personality Disorders (ADP-IV) Questionnaire 
(Schotte et al., 1998) was conducted within 3 days following hospitalization for detoxification.
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The patients participated voluntarily after providing written informed consent. A student with 
a master's degree in medicine performed the interviews.
Instruments
Alexithymia was assessed using the Dutch version of the TAS-20 (Kooiman et al., 2002). The TAS- 
20 is the most frequently used assessment instrument for alexithymia and includes 3 factors: (1) 
difficulty in identifying feelings (DIF), (2) difficulty in describing feelings (DDF), and (3) externally 
oriented thinking (EOT) (Bagby et al., 1994). Each scale item is measured on a 5-point Likert 
scale that ranges from "completely disagree" to "completely agree". The TAS-20 demonstrated 
good test-retest reliability (r = 0.77) over a 3-week interval (Bagby et al., 1994). The TAS-20 
can be analyzed in its entirety or separately using these 3 components. Alexithymia may be 
conceptualized as a continuous (Parker et al., 2008) or categorical variable. Taylor et al. (1997) 
suggested that a total score of 61 and above indicates alexithymia and that a score of 51 and 
below indicates low or an absence of alexithymia. A score between 52 and 60 represents a 
moderate degree of alexithymia. The internal consistency of the total Dutch TAS-20, DIF, and 
DDF in students and psychiatric outpatients varied between a  = 0.67 and a = 0.85; however, the 
internal consistency of the EOT in psychiatric patiënt and general population samples was lower 
(a = 0.52 - 0.66). The test-retest reliability in psychiatric outpatients over a 3-month interval was 
satisfactory for the total TAS-20 (r= 0.74) and DIF-factor (r= 0.71) but was less so for the DDF- (r 
= 0.68) and EOT-factors (r= 0.66) (Kooiman et al., 2002).
The type of SUD was assessed using the Composite International Diagnostic Interview, 
Substance Abuse Module (CIDI-SAM) at baseline (Compton et al., 1996). The CIDI-SAM is an 
expanded and more detailed version of the substance use sections of the CIDI. The interview 
questions address the diagnostic criteria of DSM-IV-TR and ICD-10 psychoactive SUD.
Based on the European Addiction Severity Index (Hendriks et al., 1989), a general information 
questionnaire was developed to assess patiënt baseline sociodemographic characteristics and 
substance use.
The SWS (SOS in Dutch) has 33 items that are measured on a 5-point Likert scale to assess 
subjective withdrawal symptoms. The SWS was developed by combining different withdrawal 
symptoms for all substances covered by the DSM-IV. The Subjective Opiate Withdrawal Scale 
(SOWS), a component of the SWS, consists of 16 SWS items and has been validated in a Dutch 
sample of opioid dependent patients (Dijkstra et al., 2007). For the present study, we deleted 8 
items for which no significant differences were observed (paired sample t-tests) between the 2 
time points of assessment and therefore did not qualify as withdrawal symptoms. The remaining 
25 SWS items comprised all 16 of the SOWS items. We then conducted a principal component 
analysis on these 25 items using orthogonal rotation (varimax). The Kaiser-Meyer-Olkin (KMO) 
measure for sampling adequacy was 0.86, and all of the KMO values for individual items were > 
0.77 using Bartlett's test of sphericity (x2 (300) = 171 1.93, P < 0.0001). The 6 components had
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eigenvaluesgreaterthan Kaiser'scriterion of 1 andtogetherexplained 65.1 %  of the variance; thus, 
these components were retained in the final analysis. One component represented a depression 
factor (i.e., "feeling depressed", "being inert", "being listless or drowsy", and "being tired"), 
and another component represented an anxiety factor (i.e., "feeling anxious", "feeling restless", 
"having insomnia", and "having to keep moving"). Altogether, these 2 factors explained 14.3% 
of the variance and were particularly notable given their relationships with alexithymia (Haviland 
et al., 1988, 1994). An oblique rotation indicated identical factors. We referred to these factors 
as the SWS-depression and SWS-anxiety factors. The reliability scores were good to excellent, and 
the Cronbach's a values were 0.92, 0.73, and 0.74 for the SWS-total, SWS-depression, and SWS- 
anxiety factors, respectively. No multicollinearity was observed for the 25 items of the SWS-total, 
SWS-depression, or SWS-anxiety factors. The SWS-total and SWS-anxiety components exhibited 
the highest correlation (r = 0.74, P < 0.001). The SWS-depression factor demonstrated a high 
correlation with the SWS-total (r =  0.65, P < 0.001) and a moderate correlation with the SWS- 
anxiety factor (r = 0.37, P < 0.001).
The ADP-IV is a Dutch self-report instrument of DSM-IV personality disorders (Axis II). This 
instrument includes 94 items that are measured on a 7-point Likert scale that ranges from 
"completely disagree" to "completely agree". For each DSM-IV criterion, the ADP-IV assesses its 
typicality and the accompanying distress and impairment. The item format allows for dimensional 
and categorical diagnostic evaluations of the 10 DSM-IV personality disorders and an additional 
depressive personality disorder. In the present study, the total (composite) dimensional score for 
all of the personality disorder items, dimensional scores for the items of the DSM-IV clusters A, 
B, and C, and the depressive personality subscale were used. The ADP-IV and its subscales have 
been shown to have good internal consistency and concurrent validity in previous research that 
was conducted with patiënt and general population samples (Schotte et al., 1998, 2004).
Statistical analysis
Socio-demographic, substance use, and personality characteristics were associated with the TAS- 
20 and TAS-20 factors as continuous and categorical variables. To address hypotheses 1 and 2, 
intraclass correlations were used to assess the relative stability of TAS-20 and TAS-20 factor scores 
between baseline and follow-up for both the total sample and separate levels of alexithymia. This 
was performed using 95% confidence intervals for low, moderate, and high alexithymic patients.
With regard to hypothesis 3, differences in the absolute stability of the TAS-20 and TAS- 
20 factor scores between baseline and follow-up were tested using paired t-tests. Changes in 
baseline and follow-up SWS-total, SWS-anxiety, and SWS-depression scores were also examined 
using the same procedure. Cohen's d = (p1 - p2) / cr1 was calculated to determine the effect 
sizes for significant variables. To address hypothesis 4 and assess regression to the mean, pre-post 
differences in absolute stability between low, moderate, and high alexithymic patients were tested 
by comparing the different scores using analysis of variance (ANOVA) and post-hoc analyses.
To further assess relative stability, especially the influence of personality and state conditions, 
such as withdrawal symptoms (hypothesis 5), multivariate linear regression analyses were 
performed using the TAS-20 and TAS-20 factor scores at follow-up as the dependent variables. 
The predictor variables, which were based partially on previous research (Haviland et al., 1988, 
1994; Rosenblum et al., 2005; Mattila et al., 2006; De Rick & Vanheule, 2007), were age, gender, 
SWS-total, SWS-anxiety, SWS-depression, ADP-IV-total, ADP-IV-depression, and total baseline 
TAS-20 or TAS-20 factor scores. The variables with a P<  0.2 in the univariate analyses (correlations 
between predictors and the different dependent variables) were entered into a full multivariate 
model. Subsequently, the non-significant variables were sequentially removed until the R-squared 
value changed by more than 10% when compared with the previous analysis that included the 
last removed variable. We have used this same procedure in previous research (de Haan et al., 
2012a).
To assess the extent to which significant changes in the total TAS-20 or TAS-factor scores 
could be accounted for by withdrawal-related variables, multivariate linear regression models 
were performed using the relevant TAS-20 "change scores" (baseline minus follow-up scores) 
as the dependent variable (hypothesis 6). For these analyses, the predictor variables were age, 
gender, ADP-IV-total, ADP-IV-depression, the "change scores" of SWS-total, SWS-depression, 
SWS-anxiety, and the total baseline TAS-20 or TAS-20 factor scores. The variables with a P < 0.2 in 
the univariate analyses were entered into a full multivariate model. Subsequently, non-significant 
variables were removed sequentially removed until the R-squared value changed by more than 
10%.
All of the statistical tests were conducted using SPSS for Windows (release 16.0). All of the 
analyses were 2-sided, with a P value < 0.05 indicating statistical significance.
Resuits
Baseline characteristics (Table 1)
TAS-20 baseline data were available for 130 patients. Fifty-five patients (42.3%) were highly 
alexithymic, 35 (26.9%) were moderately alexithymic, and 40 (30.8%) scored low on alexithymia. 
The mean baseline TAS-20 score for all of the patients was 57.9 (SD = 12.9), with no significant 
difference between men (mean = 57.7, SD = 13.6) and women (mean = 58.5, SD = 10.1). High 
alexithymic patients did not differ from low or moderate alexithymic patients in terms of gender, 
age, country of birth, relationship status, employment, education, or the type of substance 
dependence, according to DSM IV. No correlation was observed between age and alexithymia 
(total TAS-20) when measured as a continuous variable (r = -0.01, P = 0.88). High alexithymic 
patients exhibited on the EuropASI a higher preference for poly-substance use compared with 
moderate and low alexithymic patients [x2(6) =14.55, P= 0.02], High alexithymic patients scored 
higher on the total SWS-scale and the SWS-anxiety and SWS-depression components compared
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with moderate and low alexithymic patients. This result is consistent with the correlations between 
these scales and the TAS-20 measured as a continuous variable (SWS: r = 0.40; SWS-anxiety: r 
= 0.40: SWS-depression: r = 0.31, all P < 0.001). For all of the ADP-IV dimensional personality 
disorder measures, high alexithymic patients scored higher compared with low alexithymic 
patients, and the total TAS-20 score was also related to these measures (ADP-IV total: r = 0.44; 
cluster A: r = 0.42; cluster B: r = 0.38; cluster C: r = 0.38, all P < 0.001; depressive personality: r 
= .27, P =  0.007).
Follow-up data
TAS-20 data were available for 101 patients 2-3 weeks after follow-up. The dropout rate bc2(2) = 
4.68, P =  0.10] did not differ between the baseline low, moderate, and high alexithymic patients.
Relative stability (hypotheses 1 and 2)
The ICC (Intraclass Correlation Coëfficiënt) between baseline and follow-up was 0.64 for the total 
TAS-20, 0.59 for DIF, 0.57 for DDF, and 0.44 for EOT (all P < 0.001). The ICCs for the total TAS- 
20 and factor scores differed for patients with low, moderate, or high alexithymia, although the 
95% confidence intervals overlapped. The highest ICC was observed for low alexithymic patients 
(range: 0.31 - 0.55; all P < 0.05). Moderate alexithymic patients had non-significant ICC values 
(range: -0.09 - 0.28), and high alexithymic patients had significant (except for the total TAS-20) 
ICCs (range: 0.25 - 0.34) (Table 2).
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42 3%  (n = 55)
Moderate
alexithymic
(51 < TAS <61) 




30 8%  (n = 40)
X2 F P
Gender %  (n) 0.85 0.65
Male 40.6(41) 26.7(27) 32.7(33)
Female 48.3(14) 27.6(8) 24.1(7)
Age (years) M(SD) 39.0(11.6) 39.5(11.7) 39.5(10.7) 0.03 0.97
Country of birth %  (n) 5.82 0.21
Netherlands 38.8(45) 28.4(33) 32.8(38)
Other 62.9(9) 15.4(2) 15.4(2)
Relationship %  (n) 0.92 0.92
Married 47.1(16) 23.5(8) 29.4(10)
Divorced/widowed 43.2(16) 24.3(9) 32.4(12)
Never married 39.0(23) 30.5(18) 30.5(18)
Employment %  (ri) 2.24 0.33
Employed 44.0(11) 16.0(4) 40.0(10)
Unemployed 42.4(43) 29.4(30) 28.4(29)
Education %  (n) 5.14 0.27
Low/primary 47.5(29) 29.5(18) 23.0(14)
Middle/secondary 41.7(20) 25.0(12) 33.3(16)
High 27.8(5) 22.4(4) 50.0(9)
Type of substance dependence %{n) 10.39 0.11
Not dependent 28.6(2) 28.6(2) 42.9(3)
Only alcohol-dependent 29.8(14) 23.4(11) 46.8(22)
Only drug-dependent 31.8(7) 36.4(8) 31.8(7)
Alcohol- and drug-dependent 55.2(16) 31.0(9) 13.8(4)
Years of alcohol use > 5 U M(SD) (n=98) 13.7(9.2) 13.2(9.3) 13.8(9.9) 0.03 0.97
Years of drug use M(SD) (n=98) 8.4(5.1) 8.1(5.5) 6.8(4.8) 0.87 0.42
Substance of preference %  (n) 14.55 0.02
Alcohol 33.3(17) 25.5(13) 41.2(21)
Cocaine/stimulants 25.0(2) 50.0(4) 25.0(2)
Poly-substance 58.5(31) 22.6(12) 18.9(10)
Other 16.7(2) 33.4(4) 50.0(6)
SWS M(SD)
Total1 60.0(20.2) 49.3(13.5) 44.9(17.4) 9.05 <0.001
SWS-depression1 11.5(3.5) 9.4(3.5) 8.6(4.7) 6.84 0.002
SWS-anxiety1 11.8(4.2) 9.0(3.4) 8.1(3.6) 12.30 <0.001
ADP-IV M(SD) n=39 n=28 n=35
Total2 275.8(73.5) 248.3(57.3) 208.5(66.9) 9.32 <0.001
Cluster A2 78.7(24.6) 69.0(15.6) 58.7(20.6) 8.33 <0.001
Cluster B2 121.0(34.7) 108.8(29.4) 89.9(32.8) 8.44 <0.001
Cluster C2 76.1(25.4) 70.4(21.6) 59.9(19.8) 4.83 0.01
Depressive Personality2 23.9(9.7) 23.0(9.3) 18.8(8.8) 3.04 0.05
Notes: M = Mean; SD = Standard Deviation; SWS = Subjective Withdrawal Symptoms; ADP-IV = Assessment 
of DSM-IV Personality Disorders Questionnaire; 1 post-hoc comparisons: Tukey's HSD: high alexithymics > 
moderate and low alexithymics
2 post-hoc comparisons: Tukey's HSD: high alexithymics > low alexithymics.
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Table 2. Intradass correlations (ICC) for total TAS-20 and TAS-20 components between baseline and follow- 
up for low, moderate and high baseline alexithymic patients.
ICC low alexithymia* moderate alexithymia* high alexithymia*
(n=35) (n=28) (n=38)
Total TAS-20 .31 (-.02/.58) (0.03) .16 (-.21 / .50) (0.20) .25 (-.07 / .53) (0.06)
DIF .55 (.27 / .74) (< 0.001) -.09 (-.44/.29) (0.68) .28 (-.04/.55) (0.04)
DDF .46 (.16/.69) (0.002) .28 (-.09/.59) (0.07) .34 (.03/.59) (0.02)
EOT .35 (.03/.61) (0.02) .12 (-.26/.46) (0.27) .32 (.01 / .58) (0.02)
Note: TAS-20 = Toronto Alexithymia Scale; DIF = Difficulty Identifying Feelings; DDF = Difficulty Describing 
Feelings; EOT = Externally Oriented Thinking; ICC = Intradass Correlation; * = (95% Cl) (p)
Absolute stability and regression to the mean (hypotheses 3 and 4)
We observed reductions in the total TAS-20 and DIF scores between baseline and follow-up, with 
small effect sizes; the DDF and EOT scores did not change (Table 3). For the SWS variables, the 
reductions at follow-up were all significant, and the effect sizes varied from moderate (d = 0.63 
for SWS-depression and d = 0.50 for SWS-anxiety) to large (d = 0.80 for SWS-total) (Table 3).




Baseline Follow-up r P d (Cohen)
Characteristics
TAS-20 57.3 (13.2) 55.2 (12.1) 1.99 0.05 0.16
DIF 20.7 (6.7) 18.7(6.2) 3.65 <0.001 0.30
DDF 15.4(4.7) 15.1 (4.3) 0.64 0.53 0.06
EOT 21.2 (5.3) 21.4(4.8) -0.35 0.73 -0.04
SWS-total 51.9(19.3) 36.4(10.7) 8.39 <0.001 0.80
SWS-depression 9.6 (4.2) 7.0 (3.0) 6.10 <0.001 0.63
SWS-anxiety 9.4 (4.0) 7.4 (3.4) 4.75 <0.001 0.50
Note: TAS-20 = "Toronto Alexithymia Scale"; DIF = "Difficulty Identifying Feelings"; DDF = "Difficulty 
Describing Feelings"; EOT = "Externally Oriented Thinking"; SWS = Subjective Withdrawal Scale.
Highly significant differences emerged between low, moderate, and high alexithymic patients 
in the mean change scores for the TAS-20 and TAS-factors (Table 4). Post-hoc analyses indicated 
that the high alexithymic patients differed from the low alexithymic patients in their change scores 
for all of the TAS-20 variables and from the moderate alexithymic patients in the change scores 
for the EOT-factor. Low alexithymic patients differed from the moderate alexithymic patients in 
the total TAS-20 and DDF-factor scores.
The total TAS-20, DDF, and EOT scores for low alexithymic patients increased at follow-up, 
whereas a significant reduction was observed only for the DIF-factor in the moderate alexithymic 
patients and no significant change was found for the total TAS-20, DDF and EOT scores. Flowever, 
all of the TAS-variables for the high alexithymic patients decreased at follow-up.
Table 4. ANOVA on mean difference scores for TAS-20 total and factor scores, SWS total and factor scores (ba: 
moderate (51 < TAS-20 <61) and high (TAS-20 > 60) alexithymic patients (at baseline). Total TAS-20 and factor l 
a better overview of the changes.









M (SD) (95% Cl)* (n=35)
-4.8 (9.1) (-7.8/-1,8) (43.2 / 47.9) 
-0.3 (4.7) (-1,9/1,3) (14.6 / 14.9) 
-1.8 (3.7) (-3,Q/-0,6) (11.1 / 12.9) 




M (SD) (95% Cl)* (n=28)
2.8 (8.2) (-0,2/5,8) (56.4 / 53.6) 
2.3 (5.4) (0,3/4,3) (20.2/ 17.9)
1.2 (4.5) (-0,5/2,9) (16.1 / 14.9) 




M (SD) (95% Cl)* (n=3 
7.9 (10.0) (4,7/11,1) (7i 
4.0 (5.8) (2,2/5,8) (26.7 
1.5 (3.8) (0,3/2,7) (18.E 




Note: TAS-20 = Toronto Alexithymia Scale; DIF = Difficulty Identifying Feelings; DDF = Difficulty Describing Feel 
= Subjective Withdrawal Scale; SWS-D = Subjective Withdrawal Scale - Depression; SWS-A = Subjective Withdr 
M TAS-20 follow-up)
The results of an ANOVA examining the mean change scores of the SWS variables indicated 
that the scores of high alexithymic patients changed more than the scores of moderate alexithymic 
patients; high alexithymic patients changed more than low alexithymic patients only on the SWS- 
total scale. All of the SWS variables were significantly reduced from baseline to follow-up, except 
for the SWS-anxiety score in moderate alexithymic patients (Table 4).
Estimating the relative and absolute stability of alexithymia while controlling for 
confounders (hypothesis 5)
The SWS-depression score at follow-up (r = 0.24) contributed less to the TAS-20 at follow-up 
than to the TAS-20 at baseline (r = 0.64). The DIF (baseline) score contributed more (r = 0.50) to 
the variance in the DIF-factor at follow-up compared with SWS-depression (follow-up) (r=  0.21) 
or the ADP-IV total score (r= 0.31). The ADP-IV contributed less to the variance in the DDF-factor 
at follow-up (r = 0.26) compared with the baseline DDF score (r = 0.48). The total SWS score at 
baseline (r = 0.20) contributed less to the variance in the EOT-factor score at follow-up than to 
the EOT-factor at baseline (r = 0.39) (Table 5).
Table 5. Multivariate linear regression analysis predicting the TAS-20 total and factor scores at follow-up (FU) 
from the SWS-total, SWS-depression, and SWS-anxiety at baseline and follow-up, gender, age, ADP-IV-total, 
and ADP-IV-depression and TAS-20 at baseline. Non-significant variables were removed until the R-squared 
changed by more than 10% (n=101).
Factors P (=r) P R2 F change P
Total TAS-20
.48 45.64 <0.001
SWS-depression at FU .24 0.001
TAS-20 at Baseline .64 <0.001
DIF
.55 39.27 <0.001
SWS-depression at FU .21 0.004
ADP-IV-total .31 <0.001




DDF at Baseline .48 <0.001
EOT
.23 14.98 <0.001
SWS-total at Baseline .20 0.03
EOT at Baseline .39 <0.001
Note: TAS-20 = Toronto Alexithymia Scale; DIF = Difficulty Identifying Feelings; DDF = Difficulty Describing 
Feelings; EOT = Externally Oriented Thinking; SWS = Subjective Withdrawal Scale; ADP-IV = Assessment of 
DSM-IV Personality Disorders Questionnaire.
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Relation between the change in alexithymia and withdrawal-related variables 
(hypothesis 6)
The change score (i.e., from baseline to follow-up) of the total TAS-20 was related to the change 
in the SWS-depression (r = 0.24, P = 0.02) but not the SWS-total (r = 0.13, P = 0.21) or SWS- 
anxiety (r = 0.15, P = 0.13) scores. The DIF-factor change score was correlated with changes in 
the SWS-depression (r=  0.22, P=  0.02) and SWS-anxiety (r = 0.21, P=  0.03) scores but not the 
SWS-total (r = 0.19, P = 0.06) score.
In the regression models that used the total TAS-20 and DIF-factor "change scores" as the 
dependent variables, the ADP-IV total score contributed to the variance in the DIF "change score" 
(r = -0.40). The baseline total TAS-20 and DIF-factor explained large portions of the variance (r 
= 0.51 for the total TAS-20 and 0.66 for DIF) in the changes of the total TAS-20 and DIF-factor 
scores (Table 6).
Table 6. Multivariate linear regression analysis predicting the TAS-20 "change" (baseline -  follow-up) total 
and DIF-factor scores for patients from the SWS-total, SWS-depression, and SWS-anxiety “change scores" 
(baseline - follow-up) and gender, age, ADP-IV-total, and ADP-IV-depression and TAS-20 at baseline. Non- 
significant variables were removed until the R-squared changed by more than 10% (n=101).
Factors P (=r) P R2 F  change P
Total TAS-20 









Note: TAS-20 = Toronto Alexithymia Scale; DIF = Difficulty Identifying Feelings; SWS = Subjective Withdrawal 
Scale; ADP-IV = Assessment of DSM-IV Personality Disorders Questionnaire.
Discussion
In the present study, we observed moderate to high relative stability of the total TAS-20 and 
factor scores, with the lowest relative stability for the EOT-factor (hypothesis 1). Although large 
differences were observed in the relative stability of the baseline scores for low, moderate, and 
high alexithymic patients, these differences were not found to be significant (hypothesis 2). A 
mean reduction was observed in the total TAS-20 and DIF-factor scores indicating no absolute 
stability (hypothesis 3). Large differences between baseline low, moderate, and high alexithymic 
patients in alexithymia score changes also indicated no absolute stability and a strong regression 
to the mean (hypothesis 4). Baseline alexithymia scores were better predictors of follow- 
up alexithymia scores than withdrawal-related variables, including anxiety- and depression- 
like symptoms (hypothesis 5); however, changes in alexithymia were unrelated to withdrawal 
symptoms (hypothesis 6).
Relative stability
The results indicated high relative stability of the TAS-20 total and DIF- and DDF-factor scores 
but a moderate relative stability of the EOT-factor score, de Timary et al. (2008) reported slightly 
higher correlations in their 2-week alcohol detoxification study and also reported the lower score 
for the EOT-factor. These results are perhaps due to the low reliability of the EOT-factor, as was 
demonstrated in earlier studies (Kooiman et al., 2002). To our knowledge, no clear definition 
is provided in the literature as to what constitutes a high rate of relative stability, particularly in 
relation to the time between the assessment points. Compared with the test-retest reliability of 
r = 0.77 (Bagby et al., 1994) as a theoretical maximum and in accordance with most studies on 
this topic (de Haan et al., 2012a), an ICC or Pearson correlation moment of 0.6 is considered to 
be high. However, whether this is sufficiently high for a stable personality construct over a time 
period of 2 - 3 weeks is debatable, because only 36% of the variance of the score after 2-3 weeks 
is explained by the baseline score.
The length of time between assessments has a known negative effect on relative stability, 
implying that larger changes occur as more time passes between assessments (Caspi et al., 
2005). However, we argued previously (de Haan et al., 2012a) that differences in relative stability 
between the total TAS-20 and TAS-factors varied for different populations and did not exhibit a 
consistent relationship with the time between assessments. In addition to the alexithymia baseline 
scores, both state factors such as withdrawal symptoms (including anxiety- and depression-like 
symptoms) and trait-related ADP-IV-variables contributed little to the variance in the alexithymia 
scores at follow-up. Clearly, unidentified variables affect the change in and relative stability of 
alexithymia scores as measured using the TAS-20 instrument.
The differences in relative stability among the baseline low, moderate, and high alexithymic 
patients are consistent with our previous research using the TAS-20 in a detoxified SUD population 
with a much longer (6-month) time interval (de Haan et al., 2012a). In our present study, we 
observed that the DDF-factor had the lowest ICC for the total sample but the highest ICC at 
categorical levels in comparison with the total TAS, DIF, and EOT. In our previous study, we observed 
this result for the EOT rather than for the DDF-factor. We do not have a satisfactory explanation 
for these differences. We believe that these results argue against a stable personality construct 
of alexithymia in SUD populations. However, because the differences were not significant, the 
results are inconclusive. To our knowledge, no other studies have investigated the relative stability 
of these 3 levels of alexithymia.
Absolute stability
We observed the absolute stability of the DDF- (no gender differences) and EOT-factors but not 
the total TAS-20 and DIF-factors; however, the observed reduction was small, based on the low 
effect sizes, and the clinical relevance of these changes could therefore be questioned. This result 
contradicts the study of Pinard et al. (1996), who observed overall stability in a small sample (n =
98 I
21). In the study by de Timary et al. (2008), the EOT- and DDF-factors exhibited absolute stability, 
but only for men in the latter scores. De Timary et al. (2008) also reported a greater reduction 
in the total TAS-20 after 14-18 days (difference score = 4.1, Cohen's d = 0.38) compared with 
the reduction that we observed (difference score = 2.1, Cohen's d = 0.16) in 14-21 days. A 
larger decrease in depression- and anxiety-like symptoms was not responsible for this difference 
given that in both de Timary et al.’s (2008) and our study, depression- and anxiety-like symptoms 
did not contribute to the change in alexithymia when tested in multivariate models. The total 
ADP-IV score related negatively to changes in the DIF score. A greater number of personality 
disorder traits appear to hinder a reduction in the DIF-factor. The baseline degree of alexithymia 
predominantly explained the change in alexithymia scores.
Regression toward the mean
Our results demonstrated a clear difference between low, moderate, and high alexithymic 
patients in terms of the absolute stability of the total TAS-20 and TAS-20 component scores. The 
TAS-20 scores were strongly reduced in the high alexithymic patients. In low alexithymic patients, 
all of the TAS-20 scores increased, except for the DIF-factor. In the moderate patiënt group, the 
total TAS-20 and DIF- and DDF-factors exhibited a greater reduction compared with the low 
alexithymic patients. However, regarding the change between baseline and follow-up, only the 
DIF-factor was reduced sianificantly. A related change in stress, anxiety, and/or depression, as 
measured using the SWS-total and SWS-factors, could not explain these results. These results 
indicate that the apparent degree of absolute stability for the entire group is inconsistent with 
the clear lack of absolute stability that was observed when the group was subdivided into 3 
degrees of alexithymia. This phenomenon appears to represent a "regression toward the mean", 
which we also observed in our previous study (de Haan et al., 2012a). Haviland et al. (1988) 
and Honkalampi et al. (2001) illustrated a shift from the categories of alexithymia at follow-up, 
combined with an absolute stability of TAS or TAS-20 scores. However, in the study of Honkolampi 
et al. (2001) this result may be explained by a related change in depression scores and Haviland 
et al. (1998) used the TAS, a less reliable previous version of the TAS-20. To our knowledge, no 
other studies of this topic have described such a phenomenon.
Roberts et al. (2006) demonstrated that personality traits do not stop changing over the 
course of an individual's life, a conclusion that is generally consistent with interactional models 
of personality development. Whether and how modifications in personality, which are perhaps 
facilitated by therapy or periods of abstinence, represent intrinsic maturational processes or reflect 
life experiences is debated (Wilberg et al., 2009). Patients with SUD often have lifestyles that are 
devastating to their physical and mental health and continuous fluctuations of intoxication and 
withdrawal from various substances. This instability may influence personality traits. One can 
therefore not exclude the possibility that a brief period of abstinence could serve as a catch-up 
period for certain normative changes in personality traits. Individual patients could react to this
process differently, which may be a tentative explanation for the difference in relative and absolute 
stability in patients with SUD compared with different subpopulations. However, the differences 
in stability that we observed between low, moderate, and high alexithymic patients with SUD are 
difficult to explain. This also applies to the differences that were found in stability between the 3 
TAS-20 factors. Except for the change in the DIF-factor, that was related to personality disorder 
traits, no other variables, that were related to changes of the TAS-20 factors, could be detected.
The limitations of our study included measuring the change in depression- and anxiety-like 
symptoms with the SWS-depression and SWS-anxiety factor scales rather than with instruments 
that are more sensitive, such as the Beek Depression Inventory (BDI) and the State Trait Anxiety 
Inventory (STAI). However, when using the BDI and STAI in patients with SUD who are detoxifying 
(de Timary et al., 2008), associations were not found between these measures and a change 
in alexithymia when controlling for anxiety- and depression-like symptoms. Subsequently, the 
TAS-20 may be criticized for being a self-report instrument, and it is questionable whether a self- 
report instrument can adequately assess alexithymia (Kooiman et al., 2002; Grabe et al., 2009).
Although we did not observe a correlation between changes in withdrawal, anxiety-, or 
depression-like symptoms and the mean level change of alexithymia, a reduction over such a 
brief time period suggests that alexithymia in patients with SUD can be viewed partially as a 
state phenomenon. This result is supported by the much greater mean level changes that were 
observed within and between the subgroups of low and high alexithymic patients. However, it is 
difficult to understand the clinical relevance of this finding given that we do not know to what 
degree the TAS-20 score (or of one of its subscales) must change before the patients themselves 
or their environment (family or counselors) would notice any effect on affect regulation. Clearly, 
more research on this topic must be performed.
We observed a moderate to high relative stability for the entire patiënt sample. This is an 
argument for alexithymia as a trait phenomenon in SUD-patients. However, the differences 
in absolute and, although not significant, relative stability among low, moderate, and high 
alexithymic patients argue against alexithymia, as measured using the TAS-20, as a stable 
autonomous personality trait in SUD populations. This replication of our previous study in a 
different population (de Haan et al., 2012a) contributes to the external validity of these findings. 
To determine the extent to which these findings are due to the use of the TAS-20 as a measure 
for alexithymia, we propose that further research into the stability concept of alexithymia be 
performed with other instruments, such as the Bermond Vorst Alexithymia Questionnaire (Vorst & 
Bermond, 2001), the Observer Alexithymia Scale (Haviland et al., 2001), or the Toronto Structured 
Interview for Alexithymia (Bagby et al., 2006, Caretti et al., 2011).
To better understand the concept of stability in alexithymia, it would also be interesting 
to replicate these findings in non-SUD patiënt populations and compare observed changes in 
alexithymia with those of other personality constructs, such as the 5-factor model or temperament 
and character personality model (Cloninger, 1994). As alexithymia did not relate to abstinence,
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attrition, or change in AUD- or SUD-related problems following treatment in the most recent 
studies (de Haan et ai., 2011, 2012b; Stasiewicz et al., 2012) and given that attrition was also 
unrelated to alexithymia in this study, the clinical relevance of measuring alexithymia with the 
TAS-20 in detoxifying patients with SUDs remains difficult to determine. However, as a state 
and trait phenomenon during a detoxification period, alexithymia may be partly an addiction- 
related temporary.but for the other part a long-lasting disruption of emotion-oriented brain 
functions. Both possibilities should be considered, and it should be noted in clinical practice 
that many patients with SUD may have a reduced capacity to identify and describe feelings 
during detoxification. Psycho-education, especially on the (partly) temporary or state character of 
alexithymia could perhaps help SUD-patients to overcome this period and help to keep them in 
treatment during detoxification.
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Abstract
Objectives: Previous research identified alexithymia as a potential risk factor for substance use 
disorders (SUD). More insight into the relation between alexithymia and SUD is needed in order 
to treat SUD effectively. Therefore, we investigated whether a familial vulnerability to alcoholism 
relates to the presence and severity of alexithymia in SUD patients.
Method: Hospitalized, abstinent SUD-patients (n = 187), were assessed with the Toronto 
Alexithymia Scale (TAS-20) and Addiction Severity Index (EuropASI). A maternal, paternal, and 
total continuous measure of the Family History of Alcohol (FHA) was developed. Kruskal-Wallis 
tests and Spearman correlations were used to relate the composite scores of FHA to alexithymia 
as a categorical and continuous measure. Multivariate regression models were performed to 
control for the effects of confounders on the relation between FHA and alexithymia.
Results: Compared to moderate (33%) and low (17%) alexithymic SUD-patients, high 
alexithymic (50%) patients were more likely to have fathers with alcohol problems (P = 0.004). 
Such a difference was not found for mothers with alcohol problems. The composite FHA-score 
was significantly associated with alexithymia (Rs = .19, P = 0.01). However, only a paternal FHA, 
independent from disturbed family functioning, related to the degree of alexithymia (p =.13, P 
= 0.06), especially to the Difficulty Identifying Feelings as measured by the TAS-20 (p =.16, P =
0 .02).
Condusions: The relation between a paternal FHA and a higher degree of alexithymia in SUD- 
patients suggests that alexithymia could mediate the familiality of alcoholism or SUD in the 
paternal line.
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Introduction
Sifneos first described the notion of alexithymia in 1973 [1] as the inability to express emotions 
or feelings'. Alexithymia is mostly seen as a personality construct characterized as a deficit in the 
ability to cognitively process and regulate emotions [2], Whereas the prevalence of alexithymia 
in population-based studies varies between 8 %  and 15% [3], rates of up to 67% have been 
reported in patients with alcohol use disorders (AUD) [4] and up to 50% in patients with other 
substance use disorders (SUD) [5,6]. In socio-demographicstudies, alexithymia has been associated 
with older age, low educational level, low socio-economic status, poor perceived health, and 
depression, although not all of these associations have been consistently observed in all studies 
[7-9]. Additionally, in SUD, alexithymia was related to state-anxiety and depression [10]. As 
alexithymia has been described as a potential risk factor for SUD, and in some studies, it has been 
related to negative treatment outcomes, improving the understanding of the relation between 
alexithymia and SUD could be of importance in the treatment of SUD and the optimization of 
treatment interventions [4, 11, 12].
In the context of further research into the relationship between alexithymia and AUD, in 
particular in view of the potential role of alexithymic traits in the etiology of AUD, three previous 
studies looked at the effect of a family history of alcoholism (FHA) on alexithymia [13-15]. One 
study found strong alexithymic features in non-alcoholic sons with an extensive generational 
paternal history of alcoholism, but not in non-alcoholic sons without any family history or with 
alcoholic fathers without an extensive family history [13]. In the second study consisting of 
100 male patients with alcohol dependence, no relation between a FHA and alexithymia was 
found [14], However, both studies assessed alexithymia using the Sifneos-Schalling Personality 
Scale (SSPS), which lacks sufficiënt validity and internal reliability [2]. The most recent study 
conducted with a non-clinical population found an association between the Toronto Alexithymia 
Scale (TAS-20) and being the offspring of an alcoholic parent, as defined by the Children of 
Alcoholics Screening Test (CAST) [15]. This population comprised 314 volunteers (54% female 
and 53% university students) aged 18-45 years, all of whom reported at least occasional alcohol 
consumption and 6 %  using an illicit drug more than once per month. Unfortunately, the results 
were limited in specificity because the CAST does not allow differentiation between mothers or 
fathers with alcohol problems.
A substantial genetic influence of alexithymia has been demonstrated in a small and 
extensive twin pair study. This was replicated in a study that controlled for depressive symptoms 
[16-18], Results from the first, small study [16] indicated that familial influences contributed 
to all 3 subscales of the TAS-20, i.e. Difficulty Identifying Feelings (DIF), Difficulty Describing 
Feelings (DDF) and Externally Oriented Thinking (EOT). The results also suggested that DIF and 
DDF were primarily influenced by nongenetic shared family environmental factors and EOT by 
genetic factors. However, because of the very small sample ( 77 twin pairs) and the way of
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recruiting, the different results could be due to selection bias [17]. Therefore the authors are 
not very confident concerning the distribution of the genetic and shared family environmental 
factors to the subscales of the TAS-20 [16]. The two other, larger studies (8,785 [17] and 729 
[18] twin pairs) found no differences between the subscales of the TAS-20. The Danish study [17] 
found nonshared environmental effects of 50-56%, heritabilities of 30-33% and 12-20% of the 
variance of the alexithymia scores being explained by shared environmental effects. In the Italian 
study [18] nonshared environmental factors accounted also for most of the variation in the TAS- 
20 and its subscales. When corrected for depression and gender a heritability factor of 33% was 
found for the total TAS-20, with no significant differences between the subscales. No significant 
contribution of shared environmental influences on alexithymia was found [18].
Based on this genetic and familial influence, a higher percentage of alexithymia is expected 
in parents and other family members of alexithymic patients. As alexithymia and alcohol use 
disorders are related, this could be a reason for more alcohol problems in the relatives of 
alexithymic patients [4, 15], However, in alexithymic patients with SUD or AUD, other genetic, 
environmental or familial mechanisms could of course have an important role in the alcohol 
problems of their relatives [19],
As part of an often shared environmental or familial mechanism, problems with alcohol 
in parents could result in neglecting their child's emotional states, leading to emotional self- 
regulation deficits, such as alexithymia. The latter has been shown in a recent meta-analysis on 
parental bonding and alexithymia [20]. A lack of maternal care, but also maternal and paternal 
overprotection, related to alexithymia [20], In line with this, a disturbed family functioning has 
been found to relate to the development of alexithymic characteristics [21], Similar finding was 
observed for a history of neglect or sexual abuse, regardless of whether it occurred within the 
family [22 - 24],
In this study, our aim was to test the hypothesis that the presence of a FHA would be related 
to higher levels of alexithymia in SUD-patients while controlling for disturbed family functioning 
and other variables, representing a combination of shared and unshared environmental issues.
Method
Subjects
Participants were SUD inpatients from three addiction treatment centres in the East and 
South part of the Netherlands. The study sample participated in a randomized controlled trial 
investigating a Shared Decision Making Intervention (SDMI) in addiction health care that was 
carried out between January 2005 and December 2006 and published in 2009 [25], Overall, 
187 of the 212 participants (88%) in the RCT were willing to participate in the alexithymia 
study and were assessed accordingly. No distinction was made for the kind of substance(s) used. 
Exclusion criteria were being younger than 18 years of age, insufficiënt knowledge of the Dutch
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language, severe psychiatric co-morbidity precluding their participation in the SDM-intervention, 
or no signed informed consent.
All patients have been diagnosed according to DSM-IV-TR as having one or more substance 
related disorders. The Dutch Ethical Assessment Committee for Experimental Investigations on 
People (No. 4.108) approved the study, and all participants gave written informed consent.
Instruments
For the assessment of alexithymia, the Dutch version of the TAS-20 was used [26-28]. It comprises 
three factors, DIF, DDF, and EOT. The TAS-20 demonstrated good internal consistency (a = .81) 
and test-retest reliability over a three-week interval (r = .77). The TAS-20 further has a three 
factor structure congruent with the alexithymia construct [26, 27], Each item was measured on 
a five-point Likert scale ranging from "completely disagree" to "completely agree". We used 
the total score and the 3 factor scores of the TAS-20 as dependent measures. The TAS-20 total 
scores can be categorized according to the empirically derived cut-off points suggested by Taylor 
et al. [2]. A total score of 61 and above indicates a high alexithymia score, scores between 52 and 
60 represent a moderate degree, and scores of 51 and below indicate a low alexithymia score. 
The internal consistency of the total Dutch TAS-20, DIF, and DDF in psychiatric outpatients and 
students varied between a = .67 and a = .85. The internal consistency of the EOT in general 
population and psychiatric patiënt samples was lower (a = .52 - .66). The test-retest reliability 
in psychiatric outpatients over a three-month interval was satisfactory for the total TAS-20 
(r = .74) and DIF-factor (r = .71) but was less so for the DDF- (r = .68) and EOT-factors (r = .66) 
[28],
Type of substance use disorder was assessed by using the Composite International Diagnostic 
Interview, Substance Abuse Module (CIDI-SAM) [29], The CIDI-SAM is an expanded and more 
detailed version of the substance use sections of the CIDI. The interview questions address the 
diagnostic criteria of DSM-IV-TR and ICD-10 psychoactive SUD.
Severity of substance use at baseline was measured using the European Addiction Severity 
Index (EuropASI) [30, 31]. The EuropASI isa clinical research interview designed to assess problem 
severity in 7 areas of functioning: physical health, employment, alcohol and/or drug use, legal, 
family/social, and psychiatric. Seven severity domains with scores that could range from 0 (no 
problem) to 9 (extremely serious problem) were derived from this interview. The family/social 
domain of the EuropASI represents an estimate of family and social problems and includes 
items assessing patients' history of trauma (physical or sexual). It is a combination of shared and 
unshared environmental issues.
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Data analysis
Because alexithymia is better conceptualized as a continuous rather than a categorical variable 
[32], we especially examined associations with alexithymia as a continuous variable. However, 
to gain more insight on our patiënt sample from a clinical point of view, we also examined 
some associations with alexithymia as a categorical variable with low, intermediate, and high 
levels. Chi-square tests were used to analyse dichotomous or categorical data and ANOVA or the 
Kruskal-Wallis test were used to analyse continuous data.
To assess the degree of FHA, we created a maternal, paternal, and total FHA variable by 
multiplying 151 family degree by a factor 3, 2nd degree by a factor 2, and 3^ degree by a factor
1, and then adding these scores up to a total maternal and paternal FHA-variable. We did use 
a genealogical classification of the different degrees of family relatedness: 15t family degree was 
represented by the biological parents (score range: 0 - 2: 0 = no parent with alcoholism; 1 
= one parent with alcoholism etc.), 2nd degree by grandparents (score range: 0 - 4), brothers 
and sisters (score range; 0 - 4 )  and 3rd degree by aunts and uncles (score range: 0 - 4), Other 
(biological) family members were not assessed by the EuropASI and therefore not available. In 
case of unfamiliarity or doubt about the FHA or absence of specific family members, values were 
scored as negative for alcoholism. To check the validity of these variables, we related them to 
a well-known typology of alcohol dependence, namely Early (EOA) (< 25 years) or Late Onset 
Alcoholism (LOA) (> 25 years) with more evidence of familial alcoholism for EOA [33]. EOA or 
LOA was based on the EuropASI-question that inquired about the age at which patients started 
to drink 5 or more units of alcohol per occasion.
Multivariate linear regression models were conducted with total TAS-20 and factor scores as 
the dependent variables. The predictor variables, mostly based on previous research, were total 
maternal and paternal FHA, age, gender, and EuropASI "family/social relations" and "psychiatric" 
domains [7, 11, 24, 25], Variables with a p < 0.2 in univariate analyses were entered in a full 
multivariate model. Subsequently, non-significant variables were removed, one by one, until 
/?-squared changed by more than 10%.
All statistical tests were 2-sided, considered significant at a p value < 0.05, and conducted 
using SPSS for Windows (release 16.0).
Results
Patiënt characteristics
According to the cut-off score, 37% (n = 69) had a high degree of alexithymia, 30% (n = 56) 
had a moderate degree of alexithymia, and 33% (n = 62) had low alexithymia. The mean TAS-20 
score was 55.7 (SD = 11.3). Forty-seven (25%) patients were female. Mean age was 40.7 years 
(SD = 10.9) and 94% was born in the Netherlands. Seventeen percent was married, 39% was 
divorced or widowed, and 44% had never been married. Forty-four percent was unemployed and
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mean years of education was 11.4 (SD = 3.0). Most, 54%, preferred alcohol as the substance 
of preference, 29% polydrugs, 11 %  cocaine or other stimulants, 4 %  cannabis, and 2%  other 
substances, with no gender differences. Alexithymia was measured as a continuous variable 
related to years of education (r = -.19, P = 0.01) and the EuropASI "psychiatry" domain (r = 
.31, P < 0.001), but unrelated to gender, age, country of birth, kind of relationship, degree of 
employment, years of alcohol or drug use, type of substance dependence, substance preference, 
and other EuropASI domains.
Relation between FHA and early (EOA) or late-onset alcoholism (LOA)
No significant differences were found between the maternal FHA in EOA (n = 82) [Mdn =0.0 (IQR 
= 0.0 - 2.2)] and in LOA (n = 53) [Mdn =0.0 (IQR = 0.0-1.0)] (U = 1845.0, z = -1.7, P = 0.09) and 
between the paternal FHA (n = 82) in EOA [Mdn =0.0 (IQR = 0.0 - 3.0)] and in LOA (n = 53) [Mdn 
=0.0 (IQR = 0.0- 3.0)] U=  1969.5, z= -1.0, P=  0.31). However, a difference was found between 
EOA (n = 81) [Mdn =3.0 (IQR = 0.0 - 6.0)] and LOA (n = 53) [Mdn = 2.0 (IQR = 0.0 - 4.0)] (U =
1714.0, z  = -2.0, P = 0.05) for the total FHA-variable.
Relation between FHA and alexithymia
High alexithymic patients were more likely to have alcoholic fathers but not mothers compared 
to moderate and low alexithymic patients (Table 1). When comparing patients with none, one, 
or two alcoholic parents, we found that high alexithymic patients were more likely to have two 
alcoholic parents compared to moderate and low alexithymic patients. Looking at the paternal, 
maternal, and total FHA, high alexithymic patients obtained higher scores on the total, paternal, 
and maternal FHA compared to low alexithymic patients.
Mean (SD) of the total TAS-20 for patients with non-alcoholic mothers did not differ from the 
mean obtained by patients with alcoholic mothers [M = 55.3 (11.4); M = 58.1 (11.4); f (181) = 
1.2, P = 0.23]. These patients did not differ in the DIF [M = 18.8 (6.4); M = 20.9 (6.7); f (181) =
1.6, P = 0.11 ], DDF [M = 16.3 (4.3); M = 16.4 (3.8); t (181) = 0.7, P = 0.91 ] and EOT [M = 20.3 
(4.2); M = 20.9 (4.1); t (181) = 0.7, P =  0.47]. However, differences were found for patients with 
non-alcoholic versus alcoholic fathers on the TAS-20 [M = 53.9 (11.7); M = 59.1(9.8); f (177) =
3.0, P =  0.003], the DIF-factor [M = 17.9 (6.5); M =21.2 (5.5); t (177) = 3.3, P =  0.001] and the 
DDF-factor [M = 15.8 (4.4); M = 17.1 (3.9); t (177) = 2.0, P = 0.05], but not on the EOT-factor [M 
= 20.2 (4.1); M = 20.8 (4.2); t (177) = 1.0, P =  0.32],
When comparing patients with none, one, or two alcoholic parents, the total TAS-20 [M = 
53.9 (12.0); M = 57.9 (9.3); M = 60.1 (11.3); F (2, 173) = 3.5, P =  0.03] and the DIF-factor [M =
18.0 (6.6); M = 20.1 (5.5); M = 22.3 (6.3); F (2, 173) = 4.5, P =  0.01] differed, but not the DDF 
and EOT-factors. Post hoc tests (Tukey HSD) showed a significant difference between patients 
with none and two alcoholic parents in the DIF-factor only.
A fanlily history of alcoholism v  t alêxithymia in SUÖ patients [111
The results indicated significant correlations (Spearman) between maternal FHA and both 
the total TAS-20 (Rs = . 15, P = 0.04; n = 187) and the DIF-factor (Rs = .20, P =  0.006; n = 187), 
between paternal FHA and both the total TAS-20 (Rs= .19, P=  0.01; n = 187) and the DIF-factor 
(Rs = .24, P = 0.001; n = 187), and between total FHA and both the Tas-20 total (Rs = .19, P =
0.01; n = 186) and the DIF-factor (Rs = .28, P <0.001; n = 186).
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Estimating the relation between the FHA and alexithymia, controlling for gender, age, 
EuropASI "family/social relations" and "psychiatry" domains
When performing multivariate regression models with the total TAS-20 or TAS-20 factors as 
dependent variables, total FHA contributed a small part (p(r) = .16, P = 0.02) to the variance in 
the DIF-factor and although not significantly (p(r) = .13, P = 0.11) to the variance in the total 
TAS-20,, next to the "psychiatry" domain of the EuropASI and the years of education (Table 2).
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Table 2. Multivariate linear regression analyses predicting TAS-20 total and factors from gender, age, the 
"family/social" and "psychiatry" domains and total family history ofalcoholism (FHA). Non-significant variables 
were removed until R-squared changed by more than 10%.
B(r) P Rx Fchange P
TAS-20 total (n = 185) 14 9.39 <0.001
"Psychiatry" domain .28 <0.001
Years of education -.15 0.02
Total FHA .13 0.11
DIF-factor (n = 185) .22 24.93 <0.001
"Psychiatry" domain .40 <0.001
Total FHA .16 0.02
DDF-factor (n = 186) .05 9.22 0.003
"Psychiatry" domain .22 0.003
EOT-factor (n = 187) .09 8.70 <0.001
Gender -.15 0.03
Years of education -.26 <0.001
Regression models conducted separately for the maternal and paternal line indicated that only
paternal FHA contributed a small part to the variance in the total TAS-20 (p(r) = . 13, P = 0.06) and
the DIF-factor (p(r) = .16, P = 0.02) (Table 3).
Table 3. Multivariate linear regression analyses predicting TAS-20 total and factors from gender, age, the 
"family/social" and "psychiatry" domains and family history of alcoholism (HFA) of the maternal and paternal 
lines. Non-significant variables were removed until R-squared changed by more than 10%.
B(r) P R2 Fchange p
TAS-20 total (n = 186) 14 10.04 <0.001
"Psychiatry" domain .28 <0.001
Years of education -.16 0.06
Paternal FHA .13 0.06
DIF-factor (n = 186) .21 23.68 <0.001
"Psychiatry" domain .40 <0.001
Paternal FHA .16 0.02
DDF-factor (n = 186) .05 9.22 0.003
"Psychiatry" domain .22 0.003
EOT-factor (n = 187) .09 8.70 <0.001
Gender -.15 0.03
Years of education -.26 <0.001
'liistoryof aioj n isrii celatfis > alexithymia in SUD pa-tens [113
Discussion
In response to our research question, we found that high alexithymic SUD-patients were more 
likely to have fathers or both fathers and mothers, but not mothers only, with alcohol problems 
compared to low alexithymic SUD-patients. Next, we found that especially paternal FHA relates 
to the degree of alexithymia, independent of disturbed family functioning.
The high degree of alexithymia in our abstinent SUD sample is consistent with previous 
reports [4, 10, 34], Higher scores on the "psychiatry" severity EuropASI domain reflect symptoms 
of anxiety and depression [31], The relationship between alexithymia and these symptoms 
suggests that the high baseline alexithymia score can at least partially be interpreted as a state 
phenomenon [4, 34], That relationship is also the reason why we controlled for "psychiatry" 
severity while analysing the association between alexithymia and FHA. Alexithymia was related to 
years of education, as was found in previous studies of the general population [3, 8], but not in 
all [35]. Salminen et al. [3] argued that alexithymic persons are less likely to seek higher education 
reflecting the social status, values and emotional atmosphere in the family of origin and therefore 
yielding information about the individual's developmental background. In our study, years of 
education were related to the EOT-factor and not to the DIF- and DDF-factor. The aforementioned 
studies [3, 8] did not consider the relations between years of education and the TAS-20 factors. 
Further developmental and longitudinal studies of alexithymic persons are therefore needed to 
address the relation between years of education and alexithymia, in particular on factor level. 
However, we do agree with Salminen et al. [3] that a higher education often requires more 
psychological introspection and therefore could be less attractive for alexithymic individuals.
The results indicated no significant differences between patients with and without alcoholic 
mothers in total alexithymia as a dimensional variable or factor scores. We did find a relation 
between the maternal FHA and alexithymia as a categorical and dimensional variable (total TAS 
and DIF-factor). However, the effect sizes for alexithymia as a continuous variable were small and 
the relation disappeared when controlling for psychiatric problems, including anxiety, depression, 
and the paternal FHA. Therefore, no relation was found between mothers with an alcohol 
problem themselves or their families and alexithymia in their offspring.
For patients with alcoholic fathers, we found a higher degree of total alexithymia, DIF-, and 
DDF-factors compared with patients of non-alcoholic fathers, as supported by differences among 
high, moderate, and low alexithymic patients in percentage of alcoholic fathers. Although the 
relation between the paternal FHA and offspring alexithymia as a dimensional variable (total TAS 
and DIF-factor) had a small effect size, it remained significant after controlling for psychiatric 
problems and other possibly confounding factors like gender, age, and problems in the family or 
social relations. This indicates that a paternal FHA relates to alexithymia in SUD-patients and is in 
line with the study of Finn et al. [13], that demonstrated a relation between a paternal FHA and 
alexithymia, but unlike the study of Rybakowski et al. [14], in which no relation between FHA and
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alexithymia was found. In both studies, the FHA was defined as a categorical variable, unlike our 
continuous score. Next, these studies used an insufficiently valid and unreliable instrument, the 
SSPS, for assessing alexithymia and did not account for possible confounders [2,13, 14]. Because 
the SSPS has another factor structure that has not been validated [2], unlike the TAS-20 [26, 27], 
we could not make a comparison on alexithymia factor levels between our study and that of Finn 
et al. [13],
High alexithymic patients had a higher percentage of both parents with alcohol problems 
compared to moderate and low alexithymic patients. Further, patients who had both parents with 
alcohol problems scored higher on the DIF-factor compared to patients without alcohol abusing 
parents. However, without controlling for unshared environmental or psychological confounders, 
this is not a strong indication for a familial component in the relation between alcohol problems 
of the parents and a higher alexithymia score in their offspring. For the total FHA, we controlled 
for some shared (family domain of the EuropASI) and unshared (social relation domain of the 
EuropASI, age and gender) environmental and psychological confounders. We found that total 
FHA explained a small part of the variance in the total alexithymia and the DIF-factor. Because 
this part of the explained variance was just as large as for the paternal FHA, only the latter is of 
interest in explaining a part of the high prevalence of alexithymia in SUD-patients. We have no 
good explanation for only a paternal familial transmission. In familial transmission and inheritance 
studies of alexithymia, no gender differences were found [16-18], Although some evidence 
exist concerning sex differences in the inheritance of alcoholism [36] most research suggests an 
equivalent genetic load for alcohol dependence in both genders [37] and the absence of gender 
difference in familial transference [38]
Our measure of FHA reflects a combination of genetic and shared environmental aspects and 
it is impossible to discern the genetic (including gene-environment interaction) and the shared 
environmental part that contributed to the variance of the DIF-factor and the total TAS-20. In 
previous twin studies on alexithymia [16-18] no agreement was found in the contribution of the 
genetic and shared environmental parts on the subscales of the TAS-20. Without one or more 
replications of our finding it therefore makes little sense to look for explanations that only the 
DIF-factor and not the DDF- and EOT-factor were related to the FHA.
Our results should be interpreted in the context of some limitations. Our measures of 
depression, anxiety, and family functioning, especially the relation between parents and patients, 
were rather global and not specific enough to distinguish unshared and shared environmental 
issues. We constructed a new measure of total FHA, which was related to an EOA. However, 
our measure of paternal FHA was not, and familial alcoholism in EOA is especially seen in the 
paternal line [33], Finally, we used the family history approach and collected information on 
family members from our patients rather than from these family members themselves.
In conclusion, we did find a relation between a paternal FHA and a higher degree of alexithymia 
in SUD-patients, with an indication that this relation is partly based on a familial component. The
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clinical importance of this finding is that alexithymia could mediate the familiality of alcoholism 
or SUD in the paternal line, however, to a small extent, given the correlations of the paternal FHA 
with total TAS-20 (|3(r) = .13) and DIF-factor (p(r) = .16). In order to look for more causal models 
to explain this relationship, structural equation modelling should be performed on larger datasets 
of twins and extended family that would provide both data on substance use and alexithymia 
of all family members. Further, more directly, candidate genes may be considered to test for 
associations between genetic polymorphisms shown to be related to alexithymia and alcoholism 
[39, 40]. With more indications for alexithymia as an endophenotype that mediates familial risk 
for alcoholism, it would be interesting to develop evidence-based treatments for alexithymia, 
which to our knowledge do not exist.
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Chapter 7
Summary and general discussion

The aim of this thesis is to examine the prevalence, the stability, the familial-history correlates and 
the clinical implications (of high levels) of alexithymia in SUD (Substance Use Disorder) patients. 
The first topic covers the prevalence of alexithymia in different SUD populations, we are interested 
in replicating the high prevalence of alexithymia that was found in a previous study with a SUD 
population in the Netherlands (van Rossum, Laheij, de Doelder, de Jong & Jansen, 2004). The 
second theme addresses the influence of alexithymia on the outcome results of a mainstream 
therapy for SUD patients in the Netherlands, i.e., a combination of Cognitive Behavioral Therapy 
(CBT) and Motivational Interviewing (Ml). The third topic covers the stability of alexithymia in SUD 
patients to determine whether it is a state phenomenon that is related to other state conditions 
or if it is a stable personality trait. The last research question examines the influence of a Family 
History of Alcoholism (FHA) on the degree of alexithymia experienced by SUD patients.
Following a description of the concept of alexithymia, this chapter summarizes the major 
findings of this thesis. Thereafter, the strengths, limitations, clinical implications and suggestions 
for future research will be discussed.
Alexithymia is predominantly perceived as a personality construct associated with a deficit in 
the processing and regulation of emotions (Taylor, Bagby & Parker, 1997). Specifically, alexithymia 
involves having difficulty with identifying and describing feelings, distinguishing these feelings 
from the bodily sensations of emotional arousal, having constricted imaginative capacities and 
having an externally oriented cognitive style (Taylor & Bagby, 2004).
The Toronto Alexithymia Scale-20 (TAS-20) is the most frequently used assessment instrument 
for alexithymia and includes the following 3 factors: (1) difficulty with identifying feelings (DIF), 
(2) difficulty with describing feelings (DDF), and (3) having externally oriented thinking (EOT) 
(Bagby, Parker, & Taylor, 1994). Each scale item is measured on a 5-point Likert scale that ranges 
from "completely disagree" to "completely agree". The TAS-20 demonstrates good test-retest 
reliability (r = 0.77) over a three-week interval (Bagby et al., 1994) and can be analyzed in its 
entirety or separately according to the 3 components. Alexithymia may be conceptualized as a 
continuous (Parker, Keefer, Taylor, & Bagby, 2008) or as a categorical variable. Taylor et al. (1997) 
suggested that a total score of 61 or above indicates alexithymia and that a score of 51 or below 
indicates a low degree of or the absence of alexithymia. A score between 52 and 60 represents 
a moderate degree of alexithymia.
Key findings
Prevalence o f  alexithymia in patients with SUDs
As discussed at the start of this chapter, we were interested in replicating the finding that there 
was a high prevalence of alexithymia in SUD populations, as was found in a previous study in 
addiction centers in the Netherlands (van Rossum, Laheij, de Doelder, de Jong & Jansen, 2004). 
Van Rossum et al. (2004) reported that 54% of the AUD-patients from 4 inpatient detoxification
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units, which are affiliated with the NISPA (Nijmegen Institute for Scientist-Practitioners in 
Addiction), in the eastern and Southern parts of the Netherlands were alexithymic, according to 
the Toronto Alexithymia Scale (TAS-20). However, as described in our introduction, an unusual 
cut-off score for identifying alexithymia (> 55) was used in this study, given that the conventional 
cut-off score for alexithymia on the TAS-20 is higher (> 60) (Taylor et al., 1997). This unusual cut- 
off score may have resulted in overestimation of the number of alexithymic patients.
We measured the prevalence of alexithymia in 3 different inpatient SUD populations. In the 
first population, 187 heterogeneous SUD patients from 3 inpatient treatment units, which are 
affiliated with NISPA, were assessed at baseline. These patients were abstinent for at least 4 
weeks. The prevalence of alexithymia (TAS-20 > 60) was 37% (de Haan et al., 2011; chapter 2a/b). 
However, with a cut-off score of 56, the prevalence was 52% (table 1).The second population 
included 100 homogeneous alcohol dependent or alcohol/drug dependent inpatients from one 
of the previously mentioned inpatient treatment units. Patients were also abstinent for at least 
4 weeks, but measured at a different time compared with the previous study. The prevalence of 
alexithymia in this sample was 45% (TAS-20 > 60) and 58% with a cut-off score of 56 (de Haan 
et al., 2012b; chapter 3; table 1). The third population included patients from 4 of these inpatient 
detoxification units, which are affiliated with NISPA, as in the van Rossum et al. (2004) study. The 
TAS-20 baseline data were available for 130 heterogeneous SUD patients, of which 42% were 
alexithymic and 55% with a cut-off score on 56 (de Haan et al., 2014; chapter 5; table 1). When 
the different prevalence rates are compared with each other based on the cut-off score of 56, no 
significant differences were found [x2(3) = 1.01, p > 0.5].
In conclusion, the high prevalence rates reported by van Rossum et al. (2004) were replicated 
in 3 different SUD populations with the higher cut-off score taken into consideration. We 
found some preliminary evidence for a reduction in alexithymia, i.e., in the TAS-20 scores, after 
detoxification (de Haan et al., 2014; chapter 5) and after inpatient CBT treatment (de Haan et al., 
2012a; chapter 4). These reductions were not related to withdrawal symptoms (including anxiety 
and depression) after detoxification (de Haan et al., 2014; chapter 5)orto the type of intervention 
after CBT (with or without SDMI) (de Haan et al., 2012a; chapter 4). However, the reduction that 
was evident after CBT was partially related to a reduction in the patients' symptoms of anxiety 
and depression, as measured by the EuropASI (de Haan et al., 2012a; chapter 4).
Thus, we do not have an explanation for the small reduction in alexithymia scores found 
in our SUD populations over the course of time. In the previous literature, we found very few 
arguments for the high prevalence of alexithymia in SUD-populations, apart from a critical 
discussion regarding the measurement of alexithymia with a self-report instrument such as the 
TAS-20 (Grabe et al., 2009; Kooiman, Spinhoven & Trijsburg, 2002). One study reported that 
SUD patients may have inaccurate self-images and may perceive or report themselves as more 
alexithymic than they actually are (Lindsay & Ciarrochi, 2009).
Moreover, the consistently found high prevalence of alexithymia, as measured with the TAS- 
20 and described in this thesis, seems not to be consistent in quantity with the descriptions and 
characteristics of SUD patients in clinical practice. A part of the explanation for this gap could 
be the lack of familiarity with the concept of alexithymia. However, several years of research on 
alexithymia in an addiction care facility has shown no change in how often alexithymia has been 
observed or recorded in the medical files (personal observation).
Table 1. Prevalence of alexithymia (TAS-20 > 60) and the mean TAS-20 scores for the Dutch SUD-inpatients
Study Mean (SD)(N) Alexithymia (% ) Patiënt characteristics
Van Rossum et al., 2004 55.8 (26-80)*(84) 53.6** during detoxification,
mixed gender,
alcohol dependent,
with or without drug dependence
de Haan et al., 2011 55.7 (11.3X187) 36.9(51.9**) abstinent s 4 weeks, 
mixed gender,
alcohol and/or drug dependent
de Haan et al., 2012b 58.0 (10.7X100) 45.0(58.0**) abstinent > 4 weeks,
only men,
alcohol dependent,
with or without drug dependence
de Haan et al., 2014 57.9(12.9X130) 42.3 (54.6**) during detoxification, 
mixed gender,
alcohol and/or drug dependent
*Range, not SD; **TAS-20 > 55; TAS = Toronto Alexithymia Scale
The research question discussed in chapter 2(a/b) was, "Does alexithymia predict therapy- 
related outcomes in heterogeneous SUD patients after CBT, and is there a moderation of 
these results as a result of adding shared decision-making (SDM) as a structured therapeutic 
intervention?"
We hypothesized that alexithymia would be positively associated with SUD related problems 
and negatively associated with resulting outcomes. A total of 187 SUD patients were assessed 
at a baseline and at a 3-month follow-up (FU) with the Dutch version of the TAS-20 and the 
European Addiction Severity Index (EuropASI). The 3-month FU was following a typical 3-month 
inpatient CBT as usual (CBT-TAU) intervention or after CBT with a SDM (Shared Decision Making) 
intervention (CBT-SDMI), as part of a Randomized Controlled Trial (RCT) examining SDM.
We found that 37% of the patients were highly alexithymic (TAS-20 > 61) and that these 
patients showed greater severity-scores on the EuropASI with regard to the "work, education 
and income" and "psychiatric" severity domains. Highly alexithymic patients had fewer years of 
education and were more often unemployed than low-scoring alexithymics. In recently detoxified 
SUD patients, the incidence of symptoms of depression and anxiety was high, and given their
relationship with alexithymia, a part of this high baseline alexithymia score could be interpreted 
as alexithymia being partly a state phenomenon. Alexithymia did not predict abstinence at the 
follow-up. Differences between the baseline high- and low-scoring alexithymic patients were 
found for the "work, income and education" domain in the CBT-SDMI group and for the "family 
and social relations" and "drugs" domains in the CBT-TAU group in favor of the highly alexithymic 
patients. In the CBT-TAU group, patients' TAS-20 dimensional scores were negatively associated 
with changes in the "physical health" domain but were positively associated with changes in the 
"drugs", "family and social relations" and "psychiatry" domains.
Overall, highly alexithymic patients improved on the EuropASI change scores as much as 
or more than the low-scoring alexithymic patients, and alexithymia as a continuous score was 
predominantly positively associated with these change scores. However, these differences should 
be interpreted with caution given that a high number of tests were performed.
Reviewing our hypotheses, we can conclude that alexithymia is positively associated with 
SUDrelated problems but is not negatively associated with resulting outcomes for the 3-month 
CBT treatment intervention (de Haan, Joosten, Wijdeveld, Boswinkel, van der Palen & De Jong,
2011).
In chapter 3, the main research question was, "Does alexithymia predict therapy-related 
outcomes in more homogeneous Alcohol Use Disorder (AUD) patients after completing an 
inpatient treatment program based on CBT?"
A total of 101 alcohol-dependent inpatients (DSM IV) were assessed with the Mini International 
Neuropsychiatric Interview for psychiatric disorders, the TAS-20 and the EuropASI. Baseline 
alexithymia scores, as categorical and continuous variables, were used to compare or relate the 
baseline demographic and addiction characteristics, the time spent in treatment, abstinence, 
and the differences in addiction severity at a 1-year follow-up. Consistent with chapter 2, we 
hypothesized that highly alexithymic patients with AUD would benefit less from treatment 
compared with low-scoring alexithymic patients.
The prevalence of alexithymia was 45%  (TAS-20 > 61). The total TAS-20 score correlated 
negatively with the number of years of education and correlated positively with the "psychiatry" 
domain of the EuropASI. Alexithymia showed no relation to abstinence, to the time spent in 
treatment or to changes in the severity of alcohol-related problems according to the EuropASI. 
Within the patients with co-morbid drug abuse, the highly alexithymic patients improved more 
than the low-scoring alexithymic patients on the "drugs" domain. However, this result was based 
on a very small sample (n = 22) and should be interpreted with caution.
Unlike our hypothesis, but consistent with the previous chapter discussing the mixed alcohol 
and drug inpatient SUD population, our findings confirm, as in chapter 2, that inpatient (highly) 
alexithymic patients with AUD can benefit from a CBT-oriented treatment. Therefore, alexithymia, 
as measured by the TAS-20, does not seem to be a negative prognostic factor in the treatment of 
alcohol, drugs or combined alcohol-drug related disorders (de Haan, Schellekens, van der Palen, 
Verkes, Buitelaar, & De Jong, 2012b).
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Chapter 4 addressed the following research question: “Is alexithymia a state or trait 
phenomenon in heterogeneous SUDpatients, based on the absolute and relative stabilities of 
alexithymia after inpatient CBT treatment, when controlling for anxiety, depression and therapy- 
specific variables?"
Due to conflicting research results regarding alexithymia as a state or trait phenomenon, 
alexithymia as a vulnerability factor for SUDs remains under debate (Haviland, Macmurray, & 
Cummings, 1988; Pinard, Negrete, Annable, & Audet, 1996; de Timary, Luts, Hers, & Luminet, 
2008). Therefore, the absolute and relative stabilities of alexithymia were evaluated in a pre- 
post design that controlled for several covariates as part of the same RCT that was presented in 
chapter 2.
Absolute stability refers to mean level differences over time, which indicate whether and 
in which direction an entire sample or population is changing (Caspi, Roberts, & Shiner, 2005; 
Roberts, Walton, & Viechtbauer, 2006). However, individual differences in changes reflect 
deviations from overall mean level patterns. Thus, relative stability, which is defined as the 
extent to which relative differences between subjects remain unchanged over time (Roberts & 
DelVecchio, 2000), is an even more important indication of the stability of a trait. Relative stability 
is reflected in the strength of the test-retest correlation. Assessments were conducted with the 
TAS-20 and the EuropASI at baseline and follow-up 3 months after the inpatient CBT-intervention 
that was with or without an SDMI for the 187 SUD patients. Mean level reductions in the total 
TAS-20 and 2 of its subfactors, as shown by t-tests, demonstrated no absolute stability, but 
changes in alexithymia differed for low, moderate and highly alexithymic patients. The most 
obvious change was a reduction in all of the TAS-20 scores in the highly alexithymia group, 
whereas there were increases in all of the TAS-20 scores in the low alexithymia group. These 
results could not be explained by a related change in anxiety and/or depression, as measured by 
the EuropASI "psychiatry" domain.
This phenomenon looks like a regression toward the mean and has not been described in 
previous research examining the stability in alexithymia. The relative stability of alexithymia, 
according to intraclass correlations (ICC), was moderate to high for the total population. However, 
it differed for low, moderate and highly alexithymic patients. In multivariate linear regression 
models, the change in the EuropASI "psychiatry" domain, which covers anxiety and depression, 
was related to the change in alexithymia, whereas CBT-related variables were not.
Based on these results on the absolute and relative stability of alexithymia, we concluded 
that alexithymia is partly a state-dependent phenomenon, yet it is not a stable personality trait in 
this SUD-population (de Haan, Joosten, Wijdeveld, Boswinkel, van der Palen & De Jong, 2012a).
Elaborating on the topic of alexithymia as a trait or state phenomenon, chapter 5 examined the 
absolute and relative stabilities of alexithymia in SUD patients during the phase of detoxification. 
The corresponding research question was, "is alexithymia a state or trait phenomenon in 
heterogeneous SUD patients during detoxification, based on the absolute and relative stabilities
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of alexithymia in an SUD population, when controlling for withdrawal symptoms that include 
anxiety and depression?“
The absolute and relative stabilities of alexithymia were assessed with the TAS-20 and its 
subscales for 101 SUD patients at two time-points during a 3-week inpatient detoxification 
period. We controlled for withdrawal symptoms with the Subjective Withdrawal Scale (SWS) 
and for personality disorder traits with the Assessment of the DSM-IV Personality Disorders 
Questionnaire (ADP-IV).
The TAS-20 baseline data were available for 130 patients, of which 42% were highly 
alexithymic. Highly alexithymic patients did not differ from low or moderate alexithymic patients 
in terms of gender, age, country of birth, relationship status, employment, education or the type 
of substance dependence. Highly alexithymic patients exhibited a greater preference for poly- 
substance use compared with moderate and low alexithymic patients. Highly alexithymic patients 
scored higher on the total SWS-scale, the SWS-anxiety and the SWS-depression components 
compared with moderate and low alexithymic patients. Across all of the ADP-IV dimensional 
personality disorder measures, highly alexithymic patients scored higher compared with low 
alexithymic patients, and patients' total TAS-20 scores were also related to these measures (i.e., 
ADP-IV total, cluster A-, cluster B-, cluster C personality traits and depressive personality). The 
relative stabilities of the total TAS-20 and its subscales were moderate to high, and remarkable 
differences were evident, although not significant, between the baseline low, moderate, and 
highly alexithymic patients when taking into account 95% confidence intervals.
A small reduction in the mean levels of the total TAS-20 scores and those for one subscale 
revealed the absence of absolute stability. The levels of alexithymia were unrelated to changes in 
withdrawal symptoms, including anxiety and depression. The differences in the changes of the 
alexithymia scores between the low, moderate, and highly alexithymic patients from baseline to 
follow-up indicated, as in the previous chapter, a strong regression to the mean.
The findings in this chapter suggest that alexithymia in SUD-patients during detoxification, 
as measured by the TAS-20, is both a state and trait phenomenon, and it does not appear to be 
related to changes in anxiety and depression, in contrast to the results, presented in chapter 4 (de 
Haan, van der Palen, Wijdeveld, Buitelaar & De Jong, 2014).
In chapter 6, the final research question addressed was, "Does a family history of alcoholism 
(FHA) predict higher levels of alexithymia in SUD patients when controlling for disturbed family 
functioning?"
To gain more insight into the relation between alexithymia and SUDs, we investigated whether 
familial vulnerability to alcoholism relates to the presence and severity of alexithymia in SUD 
patients. Given that alexithymia may be a potential risk factor for SUDs, insight regarding this 
relation could aid the development of more effective treatments for SUDs. A maternal, paternal 
and total composite measure of FHA was developed for the inpatient SUD patients (n = 187) 
who were discussed in chapters 2 and 4. Compared to moderate and low alexithymic SUD-
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patients, highly alexithymic SUD patients were more likely to have fathers with alcohol problems, 
a finding that was not evident for mothers with alcohol problems. The patients' composite FHA- 
scores were significantly associated with alexithymia. However, only a paternal FHA, which is 
independent of disturbed family functioning, related to the degree of alexithymia, especially with 
regard to the DIF-factor, as measured by the TAS-20.
As a conclusion of the chapter we suggested that alexithymia could mediate the familiality 
of alcoholism or SUD in the paternal line, because of the relation we found between a paternal 
FHA and a higher degree of alexithymia in SUD patients (de Haan, Joosten, de Haan, Schellekens, 
Buitelaar, van der Palen & De Jong, 2013).
Strengths and limitations
Some strengths and innovative approaches of this thesis are noteworthy. First, we focused our 
study with 2 main hypotheses on different populations with very similar outcomes. An innovative 
addition of our study is that we, after dividing the whole population into 3 levels of alexithymia, 
as suggested by Taylor et al. (1997), compared these levels with regard to their absolute and 
relative stabilities.
Another innovation of our study is the use of a continuous score for the FHA in chapter 6, 
which, to our knowledge, is not often the case. A continuous score was calculated in Milne et al.'s 
(2009) study, based on Vandeleur et al.'s (2008) recommendations, such that each participant's 
family history of disorders was calculated according to the proportion of members in the family 
who had a positive history of disorders. Second degree relatives were counted as "half" of a 
family member for the purposes of calculating this proportion (Milne et al., 2009). Given that our 
family member data were from the EuropASI, which only had a limited number of family members 
involved, we chose to use a summation based on the genealogical classification of the patients' 
family members instead of a medical classification, which may have been more appropriate. An 
advantage to the genealogical approach is that the FHA of the parents has a greater influence 
than that of other first degree family members, which is consistent with a cognitive model of 
intergenerational transference of alcohol use behavior (Campbell & Oei, 2010).
However, the results of our studies should be interpreted in the context of some limitations 
as well, including the absence of systematic urine or blood samples to confirm abstinence, 
particularly with regard to the studies presented in chapters 2, 3 and 4. Additionally, we did not 
measure depression and anxiety or the change in depression and anxiety symptoms with sensitive 
Instruments such as the Hamilton Depression Rating Scale (Hamilton, 1967), the BDI (Beek et al., 
1961) or the State Trait Anxiety Inventory (STAI) (Spielberger et al., 1983).
Chapters 2,3 and 4 discussed our treatment interventions, which were primarily group-based. 
We did not check how much time patients' spent on individual interventions and coaching, 
and we did not record the differences in outpatient (after inpatient) treatments. As a result.
the possibility that highly alexithymic SUD patients received more individual attention than low 
alexithymics cannot be ruled out, which could have biased our results.
Although the TAS-20 is the most widely used measurement for alexithymia, it can be 
criticized for being a self-report scale and for its psychometric shortcomings with regard to 
alcohol dependent populations (Thorberg et al., 2010). A number of researchers have questioned 
whether a self-report instrument can adequately assess deficits that alexithymic patients are not 
aware of (Grabe et al., 2009; Kooiman, Spinhoven & Trijsburg, 2002). It is therefore advisable to 
perform multimethod alexithymia assessments with an observer scale (Dorard et al., 2008).
In chapter 6, family and social functioning, as measured by the EuropASI, with a particular 
focus on the relation between parents and patients, were not specific enough to distinguish 
unshared and shared environmental issues, as they were rather global. In the same chapter, 
we developed a new measure of total FHA that was related to the Early Onset of Alcoholism 
(EOA), which is unlike our measure of paternal FHA. Familial alcoholism with regard to the EOA 
is typically evident in the paternal line (Leggio, Kenna, Fenton, Bonenfant & Swift, 2009). Next, 
we used a family history approach to collect information regarding family members from our 
patients, rather than from the family members themselves.
Clinical impSications
Lumley et al. (2007) showed that alexithymia is generally related to negative treatment outcomes 
but that sometimes alexithymia does not interfere with the outcome results (Rufer et al., 2004; 
Spek, Nyklicek, Cuijpers & Pop, 2008). In 3 studies, alexithymia was associated with positive 
results when very structured forms of therapy or externally focused interventions (Lumley et al.,
2007) were used.
Our results confirm that highly alexithymic SUD patients can benefit from structured CBT. They 
may benefit even more when structured motivational aspects in the form of SDM are added (de 
Haan et al, 2011; chapter 2). The addition of a structured motivational intervention, such as SDM, 
improves the outcome results for highly alexithymic SUD patients. However, this improvement 
is, to a slightly lesser extent, also observed in the low or non-alexithymic SUD patients. Highly 
alexithymic SUD patients benefit from regular CBT at least as much as non-alexithymic SUD 
patients (de Haan et al, 2011; de Haan et al. 2012b; chapter 2 and 3).
The predictive value of measuring SUD patients' baseline alexithymia with the TAS-20 before 
they participate in inpatient treatment is of very little clinical or therapeutical importance. Previous 
studies have questioned the validity of the TAS-20 with SUD populations due to problematic 
factorial models, particularly with regard to the EOT-factor (Cleland et al., 2005; Kooiman et al., 
2002; Thorberg et al., 2010). Our results, including the regression to the mean phenomenon 
found in the 2 stability studies (de Haan et al., 2012a; de Haan et al., 2014; chapters 4 and 5), 
corroborate these concerns about the validity of the TAS-20 within SUD populations.
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In condusion, according to our results, there is no need to assess SUD patients' alexithymia 
with the TAS-20 at baseline before they participate in an inpatient CBT-intervention or to make 
therapeutic adjustments for highly alexithymic SUD patients based on the TAS-20. When a choice 
is available, a more structured form of intervention is recommended for highly alexithymic SUD 
patients. However, this approach is also preferred for low or non-alexithymic patients so that all 
SUD patients can benefit from this form of intervention.
Based on our results as described in Chapter 2 to 6, the importance of the concept of 
alexithymia for SUD patients and addiction could be doubted and I will briefly discuss this issue.
First of all, alexithymia has its origin in patients with psychosomatic disorders (Sifneos, 1973) 
and has as such also a face validity in the addiction field. A part of the SUD patients do show 
alexithymic characteristics. However, the consistently found high prevalence of alexithymia, as 
measured with the TAS-20 and described in this thesis, seems, as indicated in this summary, 
not to be consistent in quantity with the descriptions and characteristics of SUD patients in 
clinical practice. Next, as also mentoned before, we do not have satisfactory explanations for the 
changes in alexithymia scores in our SUD populations over the course of time.
As alexithymia, measured with the TAS-20, did not have major clinical implications, i.e. is 
not related to treatment outcome and did not show optimal stability as a personality trait, it is 
justified to seriously doubt the validity of the concept of alexithymia or the TAS-20 as a measure 
for alexithymia in SUD patients. Our findings have sufficiently demonstrated that measuring 
alexithymia or affect dysregulation in SUD patients only with the TAS-20 is inadvisable. However, 
as we did measure alexithymia only with the TAS-20, it is too early to reject alexithymia as a 
concept in understanding affect dysregulation in SUD patients. In the next paragraph I will try 
to systematically describe which recommendations for future research are advised to further 
examine the validity of alexithymia in SUD patients.
Recommendations for future research
Given that the validity of the TAS-20 in SUD populations is questionable (Cleland et al., 2005; 
Kooiman et al., 2002; Thorberg et al., 2010; de Haan et al., 2012a; de Haan et al., 2014; chapters
4 and 5), research on alexithymia in SUD-populations with other measurement instruments, such 
as multimethod assessments that include an observer scale, is strongly advised (Dorard et al.,
2008).
Other available instruments that serve this purpose are the Bermond Vorst Alexithymia 
Questionnaire (BVAQ) (Vorst & Bermond, 2001), which is another self-report scale; the Toronto 
Structured Interview for Alexithymia (TSIA) (Bagby, Taylor, Parker & Dickens, 2006); and the 
Observer Alexithymia Scale (OAS) (Haviland, Warren, Riggs & Gallacher, 2001). The characteristic 
features of alexithymia have been operationalized differently according to these instruments. 
Therefore, research using a combination of these instruments is needed with SUD populations to
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compare whether they are consistent with regard to the original features of alexithymia, as defined 
by Sineos (1973). In addition, research examining the construct validity of these instruments is 
recommended, in particular when measuring a limited fantasy life and the inclination toward an 
externally oriented way of thinking, as the TAS-20 fails to adequately cover these components 
(Kooiman et al., 2002; Thorberg et al., 2010).
Another interesting research direction with regard to the construct validity of these 
instruments and the concept of alexithymia would be to develop a more qualitative research 
project examining the changes of alexithymia scores. An investigation into the clinical relevance 
of small and large changes in the measurement of alexithymia could clarify the meanings of 
these changes for patients, relatives and counselors. To our knowledge, no research has been 
conducted with SUD-populations on this topic. It is not clear how changes in affect regulation 
in relation to alexithymia are experienced by patients, relatives and counselors, nor is it clear 
how much change is necessary before it is noticed by the different alexithymia instruments. This 
information could also be helpful for clarifying the differences in the state and trait debate for 
alexithymia. How do patients, their relatives and their treatment providers notice changes in 
alexithymia during times of (extreme) stress, anxiety or depression compared with experiencing a 
more stable alexithymic personality trait?
Within the context of absolute and relative stabilities, it would be interesting to compare 
the changes in alexithymia, particularly with regard to the regression to the mean phenomenon, 
with changes in other personality constructs such as the five-factor model of personality (Costa & 
McCrae, 1992). If changes in the stability of alexithymia and one or more of these five factors are 
related, this would support the argument that alexithymia is a personality trait.
To determine the extent to which our specific findings regarding the absolute and relative 
stabilities of alexithymia are due to the use of the TAS-20, we propose the need to perform 
future research examining the stability concept with the aforementioned instruments, such as the 
Bermond Vorst Alexithymia Questionnaire (Vorst & Bermond, 2001), the Observer Alexithymia 
Scale (Haviland et al., 2001), and the Toronto Structured Interview for Alexithymia (Bagby et al., 
2006).
Given that direct or mediating involvement of several brain structures, such as the corpus 
callosum, cingulate cortex, amygdala, orbitofrontal cortex and insula, in alexithymia has been 
demonstrated by neuroimaging (Wingbermühle, Theunissen, Verhoeven, Kessels & Egger, 2012), 
the combination of qualitative and instrument studies is highly recommended for studying 
the stability of alexithymia with neuroimaging in combination with neuropsychological or 
neurobiological tests, directed to the above-mentioned brain structures. This kind of research 
also could support investigations into the aspects of alexithymia that overlap with other disorders 
than SUDs. Alexithymia is not only common in SUDs, but also in anxiety-, autism spectrum-, 
eating-, mood-, personality- and somatoform disorders (Taylor et al, 1997). An example is 
research that elaborates on the similarities and differences of patients with autism spectrum
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disorders and different degrees of alexithymia ( Bird et al., 2010; Bird & Cook, 2013). Differences 
and similarities in alexithymia and its sub-factors between psychiatric disorders, as measured with 
the different alexithymia instruments in combination with the neurobiological and -psychological 
oriented tests, can help to establish the construct validity of alexithymia. Because of the overlap 
of alexithymia between psychiatric disorders it is also interesting to investigate if the alexithymia 
construct could be an endophenotype, i.e. intermediate between genotype and phenotype, like 
other constructs as impulsivity, and have, as such, a place in the reorganization of psychiatric 
nosology.
To validate our finding (chapter 6) that alexithymia may mediate the familiality of alcoholism or 
SUDs in the paternal line, structural equation modeling should be performed with larger datasets 
that include twins and extended family. This approach would provide data on substance use and 
alexithymia for all of the patients' family members to further investigate more causal models 
that could explain this relationship. Furthermore, this approach may aid in testing the candidate 
genes for associations between genetic polymorphisms that have been shown to be related to 
alexithymia and alcoholism (Ham et al., 2005; Walter, Montag, Markett & Reuter, 2011).
In conclusion, these recommendationsforfuture research highlightthat alexithymia, as aform 
of disturbed affect regulation in SUD, is still a challenging topic to study. However, the outcome 
of these future studies is difficult to predict in the sense of gaining a better understanding of 
SUDs or in determining whether alexithymia is a relevant risk factor for SUDs. To date, alexithymia 
has yielded too littie results regarding these two purposes. Alexithymia will only prove to be an 
important clinical concept in SUDs, if the above-mentioned multi-method measurement yields 
that alexithymia is affecting the acquisition, severity or treatment outcomes, such as the relapse 
risk, in SUDs. However, given that the study of alexithymia may help us better understand affect 
regulation and, in this way, may optimize treatment in SUD patients, it is still a topic that matters.
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Nederlandse samenvatting
Dit proefschrift heeft als doel om de prevalentie, de stabiliteit, de relatie met een familiaire 
belasting voor alcoholproblemen en de klinische gevolgen van (een hoge mate) van alexithymie bij 
verslaafde patienten te onderzoeken. Allereerst wordt ingegaan op de prevalentie van alexithymie 
in verschillende verslaafde populaties. We waren benieuwd of we de hoge prevalentie, die in 
een eerdere studie bij een verslaafde populatie in Nederland werd gevonden, konden repliceren 
(van Rossum, Laheij, de Doelder, de Jong & Jansen, 2004). Het tweede onderwerp gaat over de 
invloed van alexithymie op de behandelresultaten van de meest gebruikte vorm van therapie voor 
verslaafde patienten in Nederland, namelijk een combinatie van cognitieve gedragstherapie (CGT) 
en motiverende gespeksvoering. Het derde onderwerp behandelt de stabiliteit van alexithymie bij 
verslaafde patienten. De vraag is of het om een tijdelijk toestandsbeeld ("state") gaat, gerelateerd 
aan andere tijdelijke toestandsbeelden of dat het een stabiel persoonlijkheidskenmerk ("trait") 
betreft. Met de laatste onderzoeksvraag wordt de invloed van een familiaire belasting voor 
alcoholproblemen op de mate van alexithymie bij verslaafde patienten bestudeerd.
Na een beschrijving van het begrip alexithymie, vat dit hoofdstuk de belangrijkste bevindingen 
van het proefschrift samen. Vervolgens worden de sterke kanten, beperkingen, de klinische 
implicaties en aanbevelingen voor verder onderzoek besproken.
Alexithymie wordt vooral gezien als een persoonlijkheidsconcept, namelijk een gebrek in het 
verwerken en reguleren van emoties (Taylor, Bagby & Parker, 1997). Meer specifiek omschreven, 
kenmerkt alexithymie zich door moeite met het identificeren en beschrijven van gevoelens, 
het moeilijk gevoelens van lichamelijke gewaarwordingen (bij arousal) kunnen onderscheiden, 
een beperking in het imaginaire vermogen en de aanwezigheid van een extern georiënteerde 
cognitieve stijl (Taylor & Bagby, 2004).
De Toronto Alexithymia Scale-20 (TAS-20) is het meest gebruikte meetintrument voor 
alexithymie en bestaat uit drie factoren: (1) moeite met het identificeren van gevoelens (DIF), 
(2) moeite met het beschrijven van gevoelens (DDF), en (3) een extern georiënteerde wijze van 
denken (EOT) (Bagby, Parker, & Taylor, 1994). Elk item wordt met behulp van een 5-punts schaal 
gemeten, variërend van "volledig niet mee eens" tot "volledig mee eens". De TAS-20 heeft een 
goede test-hertest betrouwbaarheid (r = 0.77) over een tijdsbestek van drie weken (Bagby et 
al., 1994) en kan in zijn geheel geanalyseerd worden of apart, overeenkomstig de drie factoren. 
Alexithymie kan als een continue of categorale variabele worden geconceptualiseerd (Parker, 
Keefer, Taylor, & Bagby, 2008). Taylor e.a. (1997) hebben gesuggereerd dat een score van 61 of 
hoger op (een hoge mate van) alexithymie duidt en een score van 51 of lager op een lage mate 




Prevalentie van alexithymie bij verslaafde patiënten
Zoals aan het begin van dit hoofdstuk is aangegeven, waren we benieuwd of we de hoge 
prevalentie, die in een eerdere studie bij verslaafde patiënten in Nederland werd gevonden 
(van Rossum, Laheij, de Doelder, de Jong & Jansen, 2004), konden repliceren. Van Rossum e.a. 
beschreven dat 54% van de alcoholafhankelijke patiënten afkomstig uitvier klinische detoxificatie 
afdelingen, verbonden aan het NISPA (Nijmegen Institute for Scientist-Practitioners in Addiction), 
volgens de TAS-20 alexithym was. In deze studie werd echter, zoals in de introductie beschreven, 
een ongebruikelijke cut-off score gebruikt voor (hoge) alexithymie (> 55) in plaats van de 
gebruikelijke score om met de TAS-20 alexithymie vast te stellen (>60) (Taylor et al., 1997). Deze 
ongebruikelijke cut-off score kan in een overschatting van het aantal (hoog) alexithyme patiënten 
hebben geresulteerd.
We hebben de prevalentie van alexithymie in drie verschillende verslaafde populaties 
gemeten. Allereerst werden 187 (qua middelen) heterogeen verslaafde patiënten afkomstig 
uit drie klinische behandelafdelingen, verbonden aan het NISPA, bij de start van een klinische 
behandeling beoordeeld. Deze patiënten waren tenminste vier weken abstinent. De prevalentie 
van alexithymie (TAS-20 > 60) was 37% (de Haan e.a., 2011; hoofdstuk 2a/b). Bij een cut-off 
score van 56, was de prevalentie echter 52% (tabel 1). De tweede populatie bestond uit 100 
alcoholafhankelijke patiënten, al dan niet in combinatie met andere middelen, afkomstig uit één 
van de bovengenoemde afdelingen. Deze patiënten waren ook tenminste vier weken abstinent. 
Het gaat hier om andere patiënten dan uit de eerste studie. De prevalentie van alexithymie in 
deze studie was 45% (TAS-20 > 60) en 58% bij een cut-off score van 56 (de Haan e.a., 2012b; 
Hoofdstuk 3; tabel 1). De derde populatie bestond uit patiënten uit vier klinische detoxificatie 
afdelingen, verbonden aan het NISPA, dezelfde als beschreven in de van Rossum e.a. (2004) 
studie. TAS-20 gegevens waren voorhanden van 130 (qua middelen) heterogeen verslaafde 
patiënten, van wie 42% alexithym was (TAS-20 > 60) en 55% bij een cut-off score van 56 
(de Haan e.a., 2014; Hoofdstuk 5; tabel 1). Bij het onderling vergelijken van de verschillende 
prevalentie percentages, gebaseerd op een cut-off score van 56, werden geen significante 
verschillen gevonden. [x2(3) = 1.01, p > 0.5].].
Als conclusie kunnen we vaststellen dat de hoge prevalentie van alexithymie, zoals gevonden 
door van Rossum e.a. (2004) werd gerepliceerd in drie verschillende verslaafde populaties. 
Vervolgens vonden we voorlopige aanwijzingen voor een daling van alexithymie, dat wil zeggen 
de TAS-20 scores, na detoxificatie (de Haan e.a., 2014; hoofdstuk 5) en na een klinische CGT 
georiënteerde behandeling (de Haan e.a., 2012a; hoofdstuk 4). Deze reducties waren bij 
detoxificatie niet gerelateerd aan onthoudingsverschijnselen (inclusief angst- en depressieve 
symptomen) (de Haan e. a., 2014; hoofdstuk 5) of, gedurende een klinische behandeling, aan het 
wel of niet combineren van CGT met een gestructureerde interventie als Shared Decision Making
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(SDM) (de Haan e.a., 2012a; hoofdstuk 4). De vermindering in alexithymie na een klinische CGT- 
behandeling was deels wel gerelateerd aan een daling van angst- en depressieve symptomen, 
gemeten met de EuropASI (de Haan e. a„ 2012a; hoofdstuk 4).
We hebben geen goede verklaring voor de geringe vermindering van alexithymie scores, die 
we na verloop van tijd bij onze verslaafde populaties vonden. In de literatuur zijn ook weinig 
argumenten gevonden voor de hoge prevalentie van alexithymie in verslaafde populaties, 
los van de kritische discussie over het adequaat meten van alexithymie met behulp van een 
zelfbeoordelingsinstrument (Grabe e.a., 2009; Kooiman, Spinhoven & Trijsburg, 2002). In één 
studie wordt beschreven dat verslaafde patiënten een onjuist zelfbeeld kunnen hebben en zichzelf 
als meer alexithym beschouwen of beschrijven dan ze werkelijk zijn (Lindsay & Ciarrochi, 2009).
Bovendien lijkt de consequent gevonden hoge prevalentie van alexithymie, gemeten met 
de TAS-20, en beschreven in dit proefschift, niet qua kwantiteit in overeenstemming met de 
beschrijvingen en karakteristieken van verslaafde patiënten in de praktijk. Een deel van dit verschil 
zou verklaard kunnen worden door de onbekendheid met het concept alexithymie. Aan de andere 
kant blijkt dat vele jaren onderzoek naar alexithymie in een instelling voor verslavingszorg geen of 
nauwelijks verandering laat zien in hoe vaak alexithymie in de patiëntendossiers is vastgesteld of 
beschreven (persoonlijke observatie).
Tabel 1. Prevalentie van alexithymie (TAS-20 > 60) en de gemiddelde TAS-20 scores voor verslaafde patiënt­
en uit Nederland
Studie Gemiddelde (SD)(N) Alexithymie (% ) Patiënt kenmerken
Van Rossum e.a., 2004 55.8 (26-80)*(84) 53.6** tijdens detoxificatie, 
gemengd qua geslacht, 
alcoholafhankelijk, met of zonder 
drugafhankelijkheid
de Haan e.a. , 2011 55.7(11.3X187) 36.9(51.9**) abstinent > 4 weeks, 
gemengd qua geslacht, 
alcohol- en/of drugafhankelijk
de Haan e.a. , 2012b 58.0(10.7X100) 45.0 (58.0**) abstinent > 4 weeks, 
alleen mannen,
alcoholafhankelijk, met of zonder 
drugafhankelijkheid
de Haan e.a. , 2014 57.9 (12.9)(130) 42.3 (54.6**) tijdens detoxificatie, 
gemengd qua geslacht, 
alcohol- en/of drugafhankelijk
* Range, geen SD; **TAS-20 > 55; TAS = Toronto Alexithymia Scale
De onderzoeksvraag, die in hoofdstuk 2(a/b) behandeld wordt, is: "voorspelt alexithymie 
therapie-gerelateerde behandeluitkomsten na een CGT behandeling bij (qua middelen) 
heterogeen verslaafde patiënten en worden deze resultaten beïnvloed door het toevoegen van 
SDM als een gestructureerde therapeutische interventie?"
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We veronderstelden dat alexithymie positief geassocieerd zou zijn met verslavinggerelateerde 
problemen en negatief geassocieerd met behandeluitkomsten. Hiervoor werden 187 verslaafde 
patiënten beoordeeld bij de start van een klinische behandeling en bij follow-up met de 
Nederlandse versie van de TAS-20 en de European Addiction Severity Index (EuropASI). De follow- 
up na drie maanden volgde op een klinische CGT-interventie met een SDM-interventie (CBT-SDM) 
of zonder deze interventie (CBT-TAU), als onderdeel van een Randomized Controlled Trial (RCT) 
naar SDM.
We vonden dat 37% van de patiënten hoog alexithym was (TAS-20 > 60) en deze patiënten 
scoorden hoger op de EuropASI onderdelen "werk, opleiding en inkomen" en "psychisch- 
emotionele klachten". Hoog alexithyme patiënten hadden minder jaren opleiding genoten en 
waren vaker werkloos dan laag alexithyme patiënten. In recent gedetoxificeerde verslaafde 
patiënten zijn er vaak angst- en depressieve klachten, en vanwege de mogelijke relatie 
hiervan met alexithymie, zou een deel van de hoge baseline alexithymie score als een "state" 
geïnterpreteerd kunnen worden. Alexithymie was geen voorspeller van abstinentie bij follow-up. 
Verschillen tussen de op baseline hoog of laag scorende alexithyme patiënten werden gevonden 
voor de onderdelen "werk, opleiding en inkomen" in de CGT-SDM groep en voor de onderdelen 
"familie en sociale relaties" en "drugs" in de CGT-TAU groep ten gunste van de hoog alexithyme 
patiënten. In de CGT-TAU groep waren de (dimensionele) TAS-20 scores negatief geassocieerd 
met verbeteringen op het onderdeel "lichamelijke gezondheid", maar positief geassocieerd met 
verbeteringen op de onderdelen "drugs, "familie en sociale relaties" en "psychisch-emotionele 
klachten".
Globaal bekeken verbeterden hoog alexithyme patiënten op de EuropASI scores dus even 
goed of zelfs beter dan de laag alexithyme patiënten. Alexithymie was ook als een continue 
score grotendeels positief geassocieerd met deze verbeterscores. Deze verschillen moeten echter 
voorzichtig geïnterpreteerd worden, gezien het grote aantal testen dat werd verricht.
In overeenstemming met onze hypothesen, kunnen we concluderen dat alexithymie inderdaad 
positief geassocieerd is met de ernst van verslavinggerelateerde problemen, maar, tegen de 
verwachting in, niet negatief geassocieerd met de behandeluitkomsten na drie maanden klinische 
CGT-behandeling (de Haan, Joosten, Wijdeveld, Boswinkel, van der Palen & De Jong, 2011).
In hoofdstuk 3 is de hoofdonderzoeksvraag: "voorspelt alexithymie behandelgerelateerde 
uitkomsten bij alcoholafhankelijke patiënten na een klinische CGTbehandeling?"
In totaal werden 101 alcohol afhankelijke patiënten beoordeeld met de Mini International 
Neuropsychiatric Interview (MINI) voor psychiatrische stoornissen, de TAS-20 en de EuropASI. 
Baseline demografische en verslavingskenmerken, de duur van de behandeling, abstinentie en de 
ernst in verslavingsernst na één jaar follow-up werden gebruikt om met baseline alexithymie scores, 
zowel categorale als continue variabelen, te vergelijken of te correleren. In overeenstemming met 
hoofdstuk 2, hadden we als hypothese dat hoog alexithyme patiënten met alcoholafhankelijkheid 
minder zouden profiteren van de behandeling dan laag alexithyme patiënten.
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De prevalentie van (hoge) alexithymie was 45% (TAS-20 > 60). De TAS-20 score correleerde 
negatief met het aantal jaren opleiding en positief met de "psychisch-emotionele klachten" 
sectie van de EuropASI. Alexithymie was niet gerelateerd aan abstinentie, de tijd doorgebracht 
in behandeling of veranderingen in ernst van alcohol gerelateerde problemen (EuropASI). Van 
de alcohol afhankelijke patiënten met co-morbide drugsproblematiek, verbeterden de hoog 
alexithyme patiënten op de sectie "drugs" meer dan de laag alexithyme patiënten. Dit resultaat 
was echter gebaseerd op een erg kleine onderzoeksgroep (n = 22) en moet daarom met enig 
voorbehoud worden geïnterpreteerd.
In tegenstelling tot onze hypothese, maar in overeenstemming met de bevindingen uit 
het vorige hoofdstuk, bevestigen onze bevindingen dat hoog alexithyme alcoholafhankelijke 
patiënten kunnen profiteren van een klinische CGT-georiënteerde behandeling. Alexithymie, 
gemeten met de TAS-20, lijkt daarom geen negatief voorspellende factor te zijn voor de 
behandeling van alcohol-, drugs- of gecombineerde alcohol-drugs gerelateerde stoornissen ( de 
Haan, Schellekens, van der Palen, Verkes, Buitelaar & De Jong, 2012b).
Hoofdstuk 4 behandelt de volgende onderzoeksvraag: "is alexithymie een "state"of "trait" 
fenomeen bij (qua middelen) heterogene, verslaafde patiënten, gebaseerd op de absolute en 
relatieve stabiliteit van alexithymie na een klinische CGT-behandeling, gecontroleerd voor angst­
en depressieve klachten en therapie-specifieke variabelen?"
Vanwege tegenstriidige onderzoeksresultaten ten aanzien van alexithymie als een "state" of 
"trait" fenomeen, blijft er discussie over alexithymie als een mogelijke kwetsbaarheidsfactor voor 
verslaving (Haviland, Macmurray, & Cummings, 1988; Pinard, Negrete, Annable, & Audet, 1996; 
de Timary, Luts, Hers, & Luminet, 2008). Daarom werden de absolute en relatieve stabiliteit van 
alexithymie geëvalueerd in een pre-post design met controle op verschillende co-variaten. Deze 
studie is een onderdeel van dezelfde RCT, zoals gepresenteerd in hoofdstuk 2.
Absolute stabiliteit verwijst naar het (groeps)gemiddelde verschil over tijd, waarmee wordt 
aangegeven of en in welke richting een populatie verandert (Caspi, Roberts, & Shiner, 2005; Roberts, 
Walton, & Viechtbauer, 2006). Individuele verschillen in veranderingen kunnen echter wijzen op 
afwijkingen van deze (groeps) gemiddelde patronen. Relatieve stabiliteit wordt gedefinieerd als 
de mate waarin veranderingen tussen de personen onderling over een tijdsperiode onveranderd 
blijven (Roberts & DelVecchio, 2000). Dit is een nog belangrijkere indicatie voor de stabiliteit van 
een persoonlijkheidskenmerk dan de absolute stabiliteit. De mate van relatieve stabiliteit wordt 
gekenmerkt door de sterkte van de test-hertest correlatie. De TAS-20 en de EuropASI werden op 
de baseline en bij follow-up, drie maanden na een klinische CGT-behandeling met of zonder een 
SDM-interventie, afgenomen bij 187 verslaafde patiënten. Gemiddelde reducties van de totale 
TAS-20 en twee van de (sub)factoren lieten op groepsniveau zien, aangetoond m.b.v. t-testen, 
dat er geen absolute stabiliteit was. Ook bleek dat veranderingen in de mate van alexithymie 
verschilden voor laag, beperkt en hoog alexithyme patiënten. De meest opvallende verandering 
was een vermindering van alle TAS-20 scores in de hoog alexithyme groep, terwijl er daarentegen 
een toename van alle TAS-20 scores was in de laag alexithyme groep. Deze resultaten konden
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niet worden verklaard door een daaraan gerelateerde verandering in angst- of depressieve 
symptomen, gemeten met de sectie "psychische en emotionele klachten" van de EuropASI.
Dit fenomeen lijkt op een regressie naar het gemiddelde en is op deze manier nog niet eerder 
beschreven in voorgaand onderzoek naar de stabiliteit van alexithymie. De relatieve stabiliteit 
van alexithymie, op basis van de intra class correlaties (ICC), was gematigd tot hoog voor de 
totale populatie. Echter de relatieve stabiliteit verschilde voor laag, beperkt en hoog alexithyme 
patiënten. In multivariate, lineaire regressie modellen was de verandering in de sectie "psychische 
en emotionele klachten" van de EuropASI, gerelateerd aan de verandering in alexithymie. Dit 
gold niet voor de behandelgerelateerde variabelen.
Gebaseerd op deze resultaten met betrekking tot de absolute en relatieve stabiliteit, 
concluderen we dat alexithymie in deze populatie van verslaafde patiënten deels een "state"- 
afhankelijk fenomeen is, maar geen stabiel persoonlijkheidskenmerk of "trait" (de Haan, Joosten, 
Wijdeveld, Boswinkel, van der Palen & De Jong, 2012a).
Voortbordurend op het onderwerp "state" of "trait" fenomeen, wordt in hoofdstuk
5 de absolute en relatieve stabiliteit van alexithymie bij verslaafde patiënten gedurende de 
detoxificatie-fase onder de loep genomen. De daarmee corresponderende onderzoeksvraag 
was: "is alexithymie gedurende detoxificatie een “state" of "trait" fenomeen bij ( qua middelen) 
heterogeen verslaafde patiënten, gebaseerd op de absolute en relatieve stabiliteit van alexithymie, 
gecontroleerd voor onthoudingsymptomen, inclusief angst- en depressieve klachten?"
De absolute en relatieve stabiliteit van alexithymie werden beoordeeld met behulp van de 
TAS-20 en haar subschalen bij 101 verslaafde patiënten op twee momenten gedurende een 
drie-weekse klinische detoxificatieperiode. Er werd gecontroleerd voor onthoudingsymptomen 
met behulp van de de Subjectieve Ontwenning Schaal (SOS) en voor kenmerken van 
persoonlijkheidstoornissen met de Assessment of the DSM-IV Personality Disorders Questionnaire 
(ADP-IV).
TAS-20 baseline data waren beschikbaar van 130 patiënten, van wie 42% hoog alexithym 
was. Hoog alexithyme patiënten verschilden niet van laag of beperkt alexithyme patiënten 
wat betreft geslacht, leeftijd, geboorteland, burgerlijke staat, werk, opleiding of type 
middelenafhankelijkheid. Hoog alexithyme patiënten lieten wel een grotere voorkeur voor 
polydruggebruik zien, vergeleken met beperkt en laag alexithyme patiënten. Hoog alexithyme 
patiënten scoorden hoger op de (totale) SOS-schaal, de SOS-angst en SOS-depressie onderdelen, 
in vergelijking met beperkt en laag alexithyme patiënten. Op alle ADP-IV onderdelen, lieten 
hoog alexithyme patiënten een hogere score zien dan laag alexithyme patiënten. De TAS-20 
scores lieten ook een significante correlatie met deze onderdelen zien ( ADP-IV totaal, cluster A-, 
cluster B-, cluster C kenmerken en de depressieve persoonlijkheid). De relatieve stabiliteit van de 
(gehele) TAS-20 en de subschalen was gematigd tot hoog en opmerkelijke verschillen, hoewel 
niet significant, waren aanwezig tussen op baseline laag, beperkt en hoog alexithyme patiënten, 
gebaseerd op de 95% betrouwbaarheidsintervallen.
Een geringe reductie van de (groeps)gemiddelden van de TAS-20 en één subschaal, toonden 
de afwezigheid van absolute stabiliteit. De alexithymie scores waren niet gerelateerd aan 
veranderingen in onthoudingssymptomen, inclusief angst-en depressieve klachten. De verschillen 
in verandering van alexithymie scores tussen laag, beperkt en hoog alexithyme patiënten van 
baseline tot follow-up, lieten, net als in het vorige hoofdstuk, een sterke regressie naar het 
gemiddelde zien.
De resultaten van dit hoofdstuk suggereren dat alexithymie, gemeten met de TAS-20, 
bij verslaafde patiënten gedurende detoxificatie, zowel "state" als "trait" eigenschappen 
bezit. Daarnaast blijkt er nu geen verband te zijn met veranderingen in angst- en depressieve 
symptomen, in tegenstelling tot de reultaten uit hoofdstuk 4 (de Haan, van der Palen, Wijdeveld, 
Buitelaar & De Jong, 2014).
In hoofdstuk 6 werd de laatste onderzoeksvraag gesteld, namelijk: "voorspelt een familiaire 
belasting voor alcohol problematiek (FBA) een hogere mate van alexithymie bij verslaafde 
patiënten, wanneer er wordt gecontroleerd voor een verstoord functioneren in de familie, c.q. 
het gezin?"
Om meer inzicht te krijgen in de relatie tussen alexithymie en verslaving, onderzochten we of 
een familiaire kwetsbaarheid voor alcoholproblematiek samenhing met de ernst van alexithymie 
bij verslaafde patiënten. Gezien het feit dat alexithymie een mogelijke risicofactor vormt voor 
verslaving, zou meer inzicht in deze relatie de ontwikkeling van effectieve behandelingen voor 
verslaving kunnen ondersteunen. Maternale, paternale en samengestelde maten voor FBA 
werden ontwikkeld voor klinisch opgenomen verslaafde patiënten (n = 187), welke populatie 
al eerder in hoofdstuk 2 en 4 werd besproken. In vergelijking tot beperkt en laag alexithyme 
verslaafde patiënten, hadden hoog alexithyme patiënten vaker vaders met alcoholproblemen, in 
tegenstelling tot wat werd gevonden voor moeders met alcoholproblemen. De samengestelde 
FBA scores waren significant geassocieerd met de mate van alexithymie. Uiteindelijk bleek echter 
alleen de paternale FBA, onafhankelijk van een verstoord gezins functioneren, gerelateerd aan de 
mate van alexithymie. Dit gold met name voor de DIF-factor, gemeten met de TAS-20.
Als conclusie van dit hoofdstuk opperen we daarom dat alexithymie via een paternale lijn 
zou kunnen mediëren in de familiaire overdracht van verslaving aan alcohol of andere middelen, 
vanwege de relatie die we vonden tussen de paternale FBA en een hogere mate van alexithymie 
bij verslaafde patiënten (de Haan, Joosten, de Haan, Schellekens, Buitelaar, van der Palen & De 
Jong, 2013).
Sterke kanten en beperkingen van dit proefschrift
Een aantal sterke en vernieuwende onderdelen van dit proefschrift zijn het vermelden waard. 
Allereerst focusten we voor twee van de belangrijkste hypothesen, namelijk de relatie tussen 
alexithymie en behandeluitkomsten en de stabiliteit van alexithymie, op verschillende populaties 
en vonden vrijwel dezelfde uitkomsten. Een vernieuwend aspect van onze studie is dat we, na het 
verdelen van de gehele populatie in drie niveaus van alexithymie, zoals voorgesteld door Taylor 
e.a. (1997), deze niveaus vergeleken met betrekking tot hun absolute en relatieve stabiliteit. 
Een andere innovatie in dit proefschrift is het gebruik van een continue score voor de FBA in 
hoofdstuk 6, waarvan voor zover ons bekend, weinig gebruik wordt gemaakt. Een continue score 
werd berekend in de studie van Milne e.a. (2009), gebaseerd op de aanbevelingen van Vandeleur 
e.a. (2008). De FBA van elke deelnemer werd berekend op basis van het deel van de familieleden 
dat met de betreffende stoornissen bekend was. Eerste graads familieleden werden als een 
geheel en tweede graads familieleden werden als "half" familielid berekend (Milne e.a., 2008). 
Omdat onze familiegegevens uit de EuropASI kwamen, waarin gegevens worden uitgevraagd 
van een beperkt deel van de familieleden, hebben we gekozen voor een optelsom gebaseerd op 
de genealogische in plaats van de meer gebruikelijke medische classificatie. Een voordeel van de 
genealogische classificatie is dat de ouders meer invloed hebben op de totale som dan de andere 
eerste graads familieleden. Dit genealogische model is ook meer in overeenstemming met een 
cognitief model van intergenerationele overdracht van alcoholproblematiek (Campbell & Oei, 
2010).
De resultaten van onze studies moeten echter ook beoordeeld worden in de context van een 
aantal beperkingen, inclusief de afwezigheid van systematisch urine- en/of bloedonderzoek om 
abstinentie aan te tonen. Dit geldt in het bijzonder de studies, die in de hoofdstukken 2,3 en 4 
gepresenteerd zijn. Daarnaast hebben we angst- en depressieve klachten of de veranderingen 
daarin niet gemeten met meer sensitieve instrumenten als de Hamilton Depression Rating Scale 
(Hamilton, 1967), the BDI (Beek et al., 1961) of the State Trait Anxiety Inventory (STAI) (Spielberger 
et al., 1983).
In de hoofdstukken 2,3 en 4 worden behandelinterventies besproken, die vooral gebaseerd 
zijn op het behandelen in groepen. We hebben niet gecontroleerd hoeveel tijd er besteed 
werd aan interventies en coaching van individuele patienten. Ook hebben we de verschillen in 
ambulante behandeling (na de klinische opname) niet gemeten. Ten gevolge hiervan kunnen 
we de mogelijkheid niet uitsluiten dat hoog alexithyme verslaafde patiënten meer individuele 
aandacht hebben gekregen dan laag alexithyme patiënten, wat onze resultaten zou kunnen 
hebben beïnvloed.
Hoewel de TAS-20 het meest gebruikte meetinstrument is voor alexithymie, is er kritiek op 
het feit dat het een zelfbeoordelingsinstrument is en zijn er mogelijk psychometrische (factor- 
analytische) tekortkomingen in alcoholafhankelijke populaties (Thorberg e.a., 2010). Een
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aantal onderzoekers hebben de vraag gesteld of een zelfbeoordelingsinstrument wel adequaat 
tekortkomingen kan vaststellen, die alexithyme patiënten zichzelf misschien niet bewust zijn 
(Grabe et al., 2009; Kooiman, Spinhoven & Trijsburg, 2002). Daarom wordt er geadviseerd om 
alexithymie vast te stellen met behulp van meerdere methoden van onderzoek, inclusief een 
observatieschaal (Dorard et al., 2008).
In hoofdstuk 6, zijn het sociale en familiaire c.q. gezinsfunctioneren, zoals vastgesteld met 
behulp van de EuropASI, met het focus op de relatie tussen ouders en patiënten, eigenlijk 
niet specifiek genoeg om ongedeelde en gedeelde omgevingskenmerken goed te kunnen 
onderscheiden, daar deze onderdelen nogal globaal worden uitgevraagd. In hetzelfde hoofdstuk 
ontwikkelden we een nieuwe maat voor de totale FBA, die was gerelateerd aan de Early Onset of 
Alcoholisme (EOA), maar dat was niet het geval voor onze maat van de paternale FBA. Familiaire 
alcoholproblematiek met betrekking tot EOA is daarentegen juist kenmerkend voor de paternale 
lijn (Leggio, Kenna, Fenton, Bonenfant & Swift, 2009). Daarnaast maakten we in het kader van 
de familiaire belasting gebruik van gegevens, die we verkregen van onze patiënten en niet van 
de familieleden zelf.
Klinische implicaties
Lumley e.a. (2007) toonden aan dat alexithymie in het algemeen samenhangt met negatieve 
behandelresultaten, maar dat dit niet altijd het geval is (Rufer e.a., 2004; Spek, Nyklicek, Cuijpers
& Pop, 2008). In drie studies, met zeer gestructureerde vormen van behandeling of op externe 
doelen gerichte interventies, was alexithymie geassocieerd met positieve behandeluitkomsten 
(Lumley e.a., 2007).
Onze resultaten bevestigen dat hoog alexithyme verslaafde patiënten kunnen profiteren 
van gestructureerde CGT. Deze patiënten profiteren mogelijk zelfs nog wat meer, indien een 
structurerende, motiverende aanpak zoals SDM wordt toegevoegd (de Haan e.a., 2011; hoofdstuk 
2). Anders gezegd, de toevoeging van een dergelijke aanpak lijkt de behandelresultaten voor 
hoog alexithyme verslaafde patiënten te verbeteren. Deze verbetering is echter in iets mindere 
mate ook aanwezig bij laag of niet-alexithyme patiënten. Hoog alexithyme verslaafde patiënten 
profiteren dus van reguliere CGT op zijn minst zo goed als laag of niet-alexithyme verslaafde 
patiënten (de Haan e.a., 2011; de Haan e.a. 2012b; hoofdstuk 2 en 3).
De voorspellende waarde van de mate van alexithymie bij verslaafde patiënten, gemeten 
met de TAS-20, voor de start van een klinische behandeling is daarom van weinig klinisch of 
therapeutisch belang. Eerdere studies betwijfelden de validiteit van de TAS-20 binnen verslaafde 
populaties vanwege problematische factor analyses, in het bijzonder wat betreft de EOT-factor 
(Cleland e.a., 2005; Kooiman e.a., 2002; Thorberg e.a., 2010). Onze resultaten, inclusief het 
fenomeen van regressie naar het gemiddelde, gevonden in twee studies naar stabiliteit, (de Haan 
e.a., 2012a; de Haan e.a., 2014; hoofdstukken 4 en 5), bevestigen de zorgen over de validiteit 
van de TAS-20 in verslaafde populaties.
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Concluderend blijkt het het weinig zin te hebben om de mate van alexithymie met de 
TAS-20 bij verslaafde patiënten in het kader van een klinische CGT-interventie te meten of om 
therapeutische aanpassingen te maken voor hoog alexithyme patiënten, gebaseerd op de uitslag 
van de TAS-20. Als er een keuze mogelijk is, dan wordt bij hoog alexithyme verslaafde patiënten 
een meer gestructureerde vorm van behandelen, aanbevolen. Deze aanpak heeft echter ook de 
voorkeur bij laag of niet-alexithyme patiënten, anders gezegd, alle verslaafde patiënten profiteren 
van een dergelijke behandeling.
Op basis van onze resultaten, zoals beschreven in hoofdstuk 2 tot en met 6, kan het belang 
van alexithymie concept bij verslaafde patiënten en verslaving betwijfeld worden en ik zal hierop 
kort ingaan.
In de eerste plaats heeft alexithymie als concept zijn oorsprong in het werken met patiënten 
met psychosomatische stoornissen (Sifneos, 1973) en vooralsnog vooral een face-validiteit op 
het terrein van verslaving. Een deel van de verslaafde patiënten vertoont (hoog) alexithyme 
kenmerken. Maar de consistent gevonden hoge prevalentie van alexithymie, gemeten met de 
TAS-20 en beschreven in dit proefschrift, komt in kwantiteit niet overeen met de beschrijving en 
karakterisering van verslaafde patiënten in de praktijk. Bovendien hebben we geen bevredigende 
verklaringen voor de veranderingen in alexithymie scores na verloop van tijd.
Alexithymie, gemeten met de TAS-20, heeft geen belangrijke klinische implicaties, hangt niet 
samen met behandelresultaten en vertoont geen optimale stabiliteit. Dit betekent dat de validiteit 
van het alexithymie concept of de TAS-20 als maat voor alexithymie bij verslaafde patiënten kan 
worden betwijfeld. Op basis van onze bevindingen kunnen we afraden om alexithymie of affect 
disregulatie bij verslaafde patiënten alleen met behulp van de TAS-20 te meten. Het is het echter 
te vroeg om alexithymie als concept voor het begrijpen van affect disregulatie bij verslaafde 
patiënten volledig te verwerpen, omdat we alexithymie alleen met de TAS-20 hebben gemeten. 
In de volgende paragraaf zal ik vervolgonderzoek aanbevelen om de validiteit van alexithymie bij 
verslaafde patiënten beter te kunnen beoordelen.
Aanbevelingen voor verder onderzoek
Vanwege de dubieuze validiteit van de TAS-20 in verslaafde populaties (Cleland e.a., 2005; 
Kooiman e.a., 2002; Thorberg e.a., 2010; de Haan e.a., 2012a; hoofdstukken 4 en 5), bevelen 
we met klem aan om onderzoek naar alexithymie in verslaafde populaties te verrichten met 
meerdere instrumenten, inclusief een observatieschaal (Dorard e.a., 2008).
Andere beschikbare instrumenten, die voor dit doel kunnen worden gebruikt, zijn de 
Bermond Vorst Alexithymia Questionnaire (BVAQ) (Vorst & Bermond, 2001), een andere 
zelfbeoordelingsschaal; de Toronto Structured Interview for Alexithymia (TSIA) (Bagby, Taylor, 
Parker & Dickens, 2006); en de Observer Alexithymia Scale (OAS) (Haviland, Warren, Riggs & 
Gallacher, 2001). De karakteristieke kenmerken van alexithymie zijn in deze instrumenten
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verschillend geoperationaliseerd. Daarom is onderzoek meteen combinatie van deze instrumenten 
in verslaafde populaties geïndiceerd om te kunnen beoordelen in hoeverre ze overeenkomen met 
de originele kenmerken van alexithymie, zoals gedefinieerd door Sifneos (1973). Bovendien is 
onderzoek nodig naar de constructvaliditeit van deze instrumenten, vooral naar de onderdelen 
die een beperkt fantasieleven en een extern georiënteerde denkwijze meten, omdat de TAS-20 
hierin te kort schiet (Kooiman e.a., 2002; Thorberg e.a., 2010).
Een andere interessante optie met het oog op de constructvaliditeit van deze instrumenten 
en het alexithymie concept is het opzetten van kwalitatief onderzoek, gericht op het bestuderen 
van de veranderingen in alexithymie scores. Een onderzoek naar de klinische relevantie van 
veranderingen bij het meten van alexithymie kan de betekenis hiervan voor patiënten, familie, 
maar ook behandelaren verhelderen. Voor zover ons bekend heeft er bij verslaafde populaties 
geen onderzoek op deze manier plaatsgevonden. Het is niet duidelijk hoe veranderingen in affect 
regulatie in relatie tot alexithymie worden ervaren door patiënten, familie en behandelaren. Ook 
is niet duidelijk hoe groot die (subjectieve) veranderingen moeten zijn om door de verschillende 
alexithymie instrumenten gemeten te worden. Deze informatie kan ook helpen om de verschillen 
te verhelderen in het "state" en "trait" debat. Hoe bemerken patiënten, hun familieleden en 
behandelaren veranderingen in alexithymie gedurende periodes van (extreme) stress, angst of 
depressie in vergelijking met de ervaring van een meer stabiel, alexithym persoonlijkheidskenmerk?
Binnen de context van de absolute en relatieve stabiliteit zou het interessant zijn om 
veranderingen in alexithymie, ook wat betreft het fenomeen van regressie naar het gemiddelde, 
te vergelijken met veranderingen in andere persoonlijkheidsmodellen zoals de big five of five- 
factor model (Costa & McCrae, 1992). Als de veranderingen in de stabiliteit van alexithymie en 
één of meer van deze vijf factoren sterk aan elkaar gerelateerd zijn, pleit dat voor alexithymie als 
een 'trait'.
Om te bepalen in hoeverre onze bevindingen met betrekking tot de absolute en relatieve 
stabiliteit van alexithymie toegeschreven kunnen worden aan het gebruik van de TAS-20, stellen 
we voor om in de toekomst onderzoek naar het stabilitieitsconcept te doen met de eerder 
genoemde instrumenten, zoals de Bermond Vorst Alexithymia Questionnaire (Vorst & Bermond, 
2001), de Observer Alexithymia Scale (Haviland et al., 2001), en de Toronto Structured Interview 
for Alexithymia (Bagby et al., 2006).
Doordat voor alexithymie de betrokkenheid van verscheidene hersendelen, zoals het corpus 
callosum, de cortex cinguli, amygdala, orbitofrontale cortex en insula, in directe of mediërende 
zin met neuroimaging is aangetoond (Wingbermühle, Theunissen, Verhoeven, Kessels & Egger,
2012), bevelen we aan om de studies naar de stabiliteit van alexithymie te combineren met 
neuroimaging en neuropsychologische of neurobiologische testen, gericht op de bovengenoemde 
hersendelen. Dit kan ook het onderzoek stimuleren naar aspecten van alexithymie, die 
overlappen met andere stoornissen dan verslaving. Alexithymie is niet alleen bij verslaving 
vaak aanwezig, maar ook bij angst-, autisme spectrum-, eet-, stemming-, persoonlijkheid- en
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somatoforme stoornissen (Taylor e.a., 1997). Een voorbeeld hiervan is onderzoek dat gericht is 
op de overeenkomsten en verschillen van patiënten met autisme spectrum stoornissen en (de 
mate van) alexithymie (Bird et al., 2010; Bird & Cook, 2013). Verschillen en overeenkomsten 
in alexithymie tussen psychiatrische stoornissen, gemeten met de verschillende alexithymie 
instrumenten en gecombineerd met neurobiologische en -psychologische testen, kunnen helpen 
om de constructvaliditeit van alexithymie te beoordelen c.q. verbeteren. Vanwege de overlap in 
de mate van alexithymie bij psychiatrische stoornissen, is het ook interessant om naar alexithymie 
te kijken als een endofenotype. Dit laatste verwijst naar een mediërend concept tussen genotype 
en fenotype, zoals bijvoorbeeld het begrip impulsiviteit. Mogelijk krijgen endofenotypes een 
plaats in de reorganisatie van de psychiatrische nosologie.
Om onze bevinding uit hoofdstuk 6 dat alexithymie de familiaire overdracht van 
alcoholproblematiek of andere verslavingen zou kunnen mediëren te valideren, zou strucutural 
equation modeling toegepast moeten worden op grotere datasets, die ook tweelingen en zo 
veel mogelijk familieleden bevatten. Deze benadering zou gegevens op moeten leveren over het 
middelengebruiken de mate van alexithymie van alle familieleden, waarmee meer causale modellen 
kunnen worden onderzocht, die de relatie tussen middelengebruik en alexithymie verklaren. 
Bovendien zou deze aanpak kunnen helpen om kandidaat-genen te testen voor associaties tussen 
genetische polymorfismen, die gerelateerd zijn aan alexithymie en verslavingsproblematiek (Ham 
e.a., 2005; Walter, Montag, Markett & Reuter, 2011).
Deze aanbevelingen voor toekomstig onderzoek geven aan dat alexithymie, als een vorm van 
verstoorde affectregulatie bij verslaving, nog steeds een uitdagend onderwerp voor onderzoek 
is. De uitkomsten van toekomstige studies, zoals meer inzicht in verslaving of aanwijzingen voor 
alexithymie als een relevante risicofactor voor verslaving, is echter moeilijk te voorspellen. Tot op 
heden heeft het alexithymie concept ten aanzien van deze twee aspecten te weinig resultaten 
laten zien. Alexithymie zal alleen een belangrijk klinisch concept bij verslaving blijken te zijn, als 
de hierboven vermelde, op meerdere methodieken gebaseerde, wijze van meten oplevert dat 
alexithymie het ontstaan, de ernst en/of de behandeluitkomsten, zoals de kans op terugval, van 
verslaving beïnvloedt. Er van uitgaande dat het onderzoek naar alexithymie gaat helpen om 
affectregulatie beter te begrijpen, en op die manier de behandeling van verslaafde patiënten kan 
verbeteren, blijft het een onderwerp dat van belang is.
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Rama, Marion, Maarten, Chris, Laura, Cor, Harmen, Maureen, Lucas, Carolien, Thomas, Juul, 
Serge, Judith, Wiebren en alle anderen uit het verleden.
Mijn intervisieclub, Anja, Jitske, Patricia, Jéröme en Luuk, ben ik dankbaar voor de vele 
woensdagavonden, waarop we de afgelopen jaren psychiater-, instelling-, onderzoek-, 
proefschrift- en ander genot, maar ook frustraties en leed hebben gedeeld en hopelijk gaan we 
hier nog vele jaren mee door.
Vriend en collega dokter ("grote") Maarten. Wat is het geweldig om met iemand, die je al zo 
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te veel om allemaal op te noemen, dat gaat me niet lukken en daarom beperk ik me tot hen, die 
er het meest direct bij betrokken waren. Piet, Peter en Jeroen, die me vervingen tijdens diensten 
als dat voor het werken aan dit proefschrift nodig was en Geert, die me als plaatsvervanger de 
mogelijkheid heeft gegeven om me gedurende een paar maanden terug te trekken en de basis 
voor dit proefschrift te leggen. Ook het secretariaat, Rina, Anouck en zeker bij de laatste loodjes 
Marijke, die me de afgelopen jaren op allerlei manieren hebben gesteund. Dyane, voor haar hulp 
bij het drukken van het proefschrift en het organiseren van het feest. En dan natuurlijk, John en 
Ruud. Ik ben erg blij met de samenwerking van ons als bestuur-directie van Tactus en de ruimte, 
die jullie me hebben gegeven om aan dit proefschrift te werken. Ik hoop dat we, ondanks de
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lastige periode waar we als zorg mee te maken hebben, de komende jaren onze samenwerking 
op dezelfde manier kunnen voortzetten.
Lydia, je hebt een prachtige voorkant gemaakt, dank je wel daarvoor en het doet me erg goed 
dat we elkaar in het onderzoek en schrijven de laatste jaren zo hebben gevonden. Gelukkig dat 
je mij voor liet gaan en dat je eerst nog als mijn paranimf wilt optreden, voordat je zelf aan de 
beurt bent.
Maarten, ook met jou als paranimf ben ik heel blij. Je was bij het onderzoek betrokken en het 
steunt me erg dat jij en Lydia je vader, intellectueel en fysiek (hoop niet dat het nodig is!) terzijde 
staan. Het echte fysieke werk op de fiets is er de laatste tijd weinig van gekomen. Ik pak het graag 
weer met je op.
Laura, in gedachten ben je mijn derde paranimf. Super, dat jij andere taken in de organisatie van 
het feest op je hebt genomen. Ik ga meer tijd vrijmaken voor muziek en hoop dat het ons lukt 
om daar samen nog meer van te maken dan we nu al af en toe doen en vroeger hebben gedaan.
Marianne, als ik je zo noem, dan is er altijd iets speciaals. Ik heb onze relatie erg op de proef 
gesteld met mijn gestress van de afgelopen jaren. Een van mijn vroegere (dokter)bazen heeft me 
eens verteld dat bij dokters het werk voor het meisje gaat. Ik dacht toen nog "wat een traditionele 
onzin". Inmiddels begrijp ik heel goed dat ik veel heb goed te maken. Ik ga mijn best doen. Heel 
veel dank voor je steun en liefde, zonder dat was dit niet gelukt en een heleboel meer niet.
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Stellingen behorende bij het proefschrift
Alexithymia in patients with substance use disorders
Hein de Haan, 13 juni 2014, Radboud Universiteit Nijmegen
1. Alexithymie, gemeten met de Toronto Alexithymia Scale-20 (TAS-20) komt vaak voor 
bij verslaafde patiënten (dit proefschrift).
2. De mate van alexithymie, gemeten met de TAS-20, heeft bij verslaafde patiënten 
geen invloed op de resultaten van een cogn'itief-gedragstherapeutische 
verslavingsbehandeling (dit proefschrift).
3. Alexithymie heeft bij verslaafde patiënten zowel "state" als "trait" kenmerken (dit 
proefschrift).
4. Bij het bepalen van deabsoluteen relatieve stabiliteit van een persoonlijkheidskenmerk 
is het aan te bevelen om dit kenmerk in gradaties, bijvoorbeeld hoog, midden en 
laag, in te delen en de stabiliteit tussen deze gradaties te vergelijken. Dit kan onder 
andere een regressie naar het gemiddelde opleveren, die anders wordt gemist (dit 
proefschrift).
5. Alexithymie, gemeten met de TAS-20, is geen stabiel persoonlijkheidskenmerk bij 
verslaafde patiënten (dit proefschrift).
6. Het meten van alexithymie met alleen de TAS-20 in het kader van een behandeling 
voor verslaving heeft weinig zin (dit proefschrift).
7. Alexithymie kan via een paternale lijn mediëren in de familiaire overdracht van 
verslaving aan alcohol of andere middelen (dit proefschrift).
8. Alexithymie kan als valide concept bij verslaving worden betwijfeld, maar dient eerst 
met andere instrumenten dan de TAS-20 te worden onderzocht, voordat het in meer 
definitieve zin wordt ontkracht (dit proefschrift).
9. Promoveren moet je zo snel mogelijk na een doctoraal of master studie doen en er 
niet te lang mee wachten.
10. De verslavingsarts KNMG moet in de verslavingszorg en bij het behandelen van 
verslaving zo snel mogelijk door alle partijen als hoofdbehandelaar worden erkend en 
zeker door de Nederlandse Vereniging voor Psychiatrie (NVvP).
11. Als er destijds (zeventiger en tachtiger jaren van de vorige eeuw) vanuit de officiële 
psychiatrie meer toenadering was gezocht naar de anti-psychiatrische beweging 
dan had dat geholpen bij het begrip voor en maatschappelijke acceptatie van de 
(biologische) psychiatrie.
12. Het is onterecht dat de Kinks niet dezelfde waardering krijgen en hebben gekregen als 
de Beatles en de Stones. Hun invloed op de ontwikkeling van allerlei muziekstijlen is 
minstens even groot en hun teksten waren stukken beter.

